UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
|
| | |
þ | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| | For the Fiscal Year Ended September 30, 2016 |
OR |
o | | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| | For the transition period from to |
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934________________
FOR THE FISCAL YEAR ENDED September 30, 2019
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM ___________ TO___________
Commission file number 1-16671
AMERISOURCEBERGEN CORPORATIONCORPORATION
(Exact name of registrant as specified in its charter)
|
| | | | |
Commission
File Number
| | Registrant, State of Incorporation
Address and Telephone Number
| | I.R.S. Employer
Identification Number
|
1-16671 | | AmerisourceBergen CorporationDelaware | | 23-3079390 |
| (State or other jurisdiction of | | (a Delaware Corporation) 1300 Morris Drive
Chesterbrook, PA 19087-5594
610-727-7000
I.R.S. Employer |
| incorporation or organization) | | Identification No.) |
| | | | |
| 1300 Morris Drive | Chesterbrook, | PA | | 19087-5594 |
| (Address of principal executive offices) | | (Zip Code) |
(610) 727-7000
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Common Stock, $0.01 par value per share Registered on New York Stock ExchangeSecurities Registered Pursuant to Section 12(g) of the Act: |
| | | |
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
| Common stock | ABC | New York Stock Exchange | (NYSE) |
None
_____________________________
Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yesþ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes oNoþ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yesþ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yesþ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (Section 229.405 of this chapter) is not contained herein, and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):Act:
Large accelerated filerþ Accelerated filer o Non-accelerated filer o Smaller reporting company ☐ |
| | | | | | |
Large accelerated filer þ
| | Accelerated filer o
| | Non-accelerated filer o
(Do not check if a smaller reporting company)
| | Smaller reporting company o
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes o☐ No þ
The aggregate market value of voting stock held by non-affiliates of the registrant on March 31, 20162019 based upon the closing price of such stock on the New York Stock Exchange on March 31, 20162019 was $13,618,229,743.$9,817,515,026.
The number of shares of common stock of AmerisourceBergen Corporation outstanding as of October 31, 20162019 was 220,100,206.205,922,186.
Documents Incorporated by Reference
Portions of the following document are incorporated by reference in the Part of this report indicated below:
Part III — Registrant's Proxy Statement for the 20172020 Annual Meeting of Stockholders.
TABLE OF CONTENTS
PART I
ITEM 1. BUSINESS
As used herein, the terms "Company," "AmerisourceBergen," "we," "us," or "our" refer to AmerisourceBergen Corporation, a Delaware corporation.
AmerisourceBergen Corporation is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers located in the United States and select global markets, including chain retail and independent pharmacies, mail order pharmacies, acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, long-term care and other alternate site pharmacies, veterinarians, and other customers. We also provide pharmacy services to certain specialty drug patients. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services, niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and pharmacy management.packaging solutions.
Industry Overview
Pharmaceutical sales in the United States, as recently estimated by IMS Healthcare, Inc.,IQVIA, an independent third partythird-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximately 7.1%4.2% from 20152018 through 2020,2023, and the growth rate is dependent, in part, on pharmaceutical manufacturer price increases.
In addition to general economic conditions, factors that impact the growth of the pharmaceutical industry in the United States and other industry trends include:
Aging Population. The number of individuals age 65 and over in the United States is expected to exceed 5561 million by 20202023 and is the most rapidly growing segment of the population. This age group suffers from more chronic illnesses and disabilities than the rest of the population and accounts for a substantial portion of total healthcare expenditures in the United States.
Introduction of New Pharmaceuticals. Traditional research and development, as well as the advent of new research, production, and delivery methods, such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases. We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry. In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business.
Increased Use of Generic Pharmaceuticals. A number of patents for widely used brand-name pharmaceutical products will continue to expire during the next several years. In addition, increased emphasis by managed care and other third partythird-party payors on utilization of generics has accelerated their growth. We consider the increase in generic usage a favorable trend because generic pharmaceuticals have historically provided us with a greater gross profit margin opportunity than brand-name products, although their lower prices reduce revenue growth. Generic pharmaceuticals currently account for approximately 89%90% of the prescription volume in the United States.
Increased Use of Drug Therapies. In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that encourage the use of efficient drug therapies to prevent or treat diseases. While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays. Pharmaceuticals currently account for approximately 12%11% of overall healthcare costs. Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.
Legislative Developments. In recent years, regulation of the healthcare industry has changed significantly in an effort to increase drug utilization and reduce costs. In March 2010, the federal government enacted major health reform legislation designed to expand access to health insurance, which increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs. The health reform law provides for sweeping changes to Medicare and Medicaid policies (including drug reimbursement policies), expanded disclosure requirements regarding financial arrangements within the healthcare industry, enhanced enforcement authority to prevent fraud and abuse, and new taxes and fees on pharmaceutical and medical device manufacturers. These policies and other legislative developments (including potential revisions to or repeal of any portions of the health reform legislation) may affect our businesses directly and/or indirectly (see Government Regulation on page 6 for further details).
Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A. Risk Factors on page 9)8).
The Company
We currently serve our customers (healthcare providers and pharmaceutical and biotech manufacturers, and certain specialty drug patients)manufacturers) through a geographically diverse network of distribution service centers and other operations in the United States and selectedselect global markets. In our pharmaceutical distribution business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers. We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.
Strategy
Our business strategy is focused on the global pharmaceutical supply channel where we provide value-added distribution and service solutionsglobal commercialization services to healthcare providers (primarily pharmacies, health systems, medical and dialysis clinics, physicians, and veterinarians) and pharmaceutical manufacturers that increaseimprove channel efficiencies and improve patient outcomes. Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well-positioned to continuewell positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:
Optimize and Grow Our Pharmaceutical Distribution and Service Businesses. We believe we are well-positioned in size and market breadth to continue to grow our distribution business | |
| • | Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses. We believe we are well positioned in size and market breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies. Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value-added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients. |
We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products. We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products. We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the pharmaceutical supply channel, as we provide superior distribution services and deliver value-added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.
near future.With the rapidcontinued growth of generic pharmaceuticals in the U.S. market, we have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland. We source generics globally, offer a value-added generic formulary program to our healthcare provider customers, and monitor our customers' compliance with our generics program. We also provide data and other valuable services to our manufacturingmanufacturer customers, which includes the current expansion of our international presence intoin Switzerland where we lead our global manufacturer relations and commercialization strategy.
We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes. Services for manufacturers include: assistance with rapid new product launches, promotional and marketing services to accelerate product sales, product data reporting, and logistical support.
Our provider solutions include: our Good Neighbor Pharmacy® program, which enables independent community pharmacies to compete more effectively through pharmaceutical benefit and merchandising programs; Elevate Provider Network®, our managed care network, which connects our retail pharmacy customers to payor plans throughout the country and is one of the largest in the U.S.;United States; generic product purchasing and private label services; hospital pharmacy consulting designed to improve operational efficiencies; and packaging solutions for institutional and retail healthcare providers.
We believe we have one of the lowest operating cost operating structures among all pharmaceutical distributors. AmerisourceBergen Drug Corporation ("ABDC") has aOur robust distribution facility network totaling 26 distribution facilities in the United States. This network includes a national distribution center in Columbus, OH, which offers pharmaceutical
manufacturers a single shipping destination. We continue to seek opportunities to achieve increased productivity and operating income gains as we invest in and continue to implement warehouse automation technology, adopt "best practices" in warehousing activities, and increase operating leverage by increasing volume per full-service distribution facility.
In March 2013, we and Walgreens Boots Alliance, Inc. ("WBA") entered into various agreements and arrangements, including a ten-year pharmaceutical distribution agreement between WBA and us pursuant to which we distribute branded and generic pharmaceutical products to WBA and an agreement that provides us the ability to access generics and related pharmaceutical products through a global sourcing arrangement with Walgreens Boots Alliance Development GmbH ("WBAD"). In May 2016, our distribution agreement with WBA and our global sourcing arrangement with WBAD were extended to now expire in 2026. The increased volume associated with the distribution agreement improved our distribution center efficiency and our access to WBAD continues to improve our purchasing power.
In an effort to supplement our organic growth, we continue to utilize a disciplined approach to seek acquisitions that will assist us with our strategic growth plans.
In November 2015, we acquired PharMEDium Healthcare Holdings, Inc. ("PharMEDium"), the leading national provider of outsourced compounded sterile preparations ("CSPs") to acute care hospitals in the United States. PharMEDium is the premier provider of customized outsourced CSPs that meet specific hospital and physician clinical needs and quality standards in formulations that are not otherwise commercially available. PharMEDium delivers "sterile to sterile" CSPs in a ready to use form with enhanced safety, labeling, sterility assurance, and extended expiration dating supported by appropriate studies that often exceeds what hospital pharmacies can accomplish on their own. The CSPs are prepared in state-of-the-art, FDA and state board of pharmacy inspected facilities, using only FDA-approved or allowed drugs in finished dosage form and FDA-approved diluents and FDA-cleared containers (see Risk Factor — Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability). PharMEDium maintains four Section 503B outsourcing facilities, provides a broad range of 2,000 SKUs, and serves over 3,000 hospital customers across all 50 states. The acquisition of PharMEDium strengthened our core business and meaningfully expanded our innovative service offerings to our health systems customers.
Optimize and Grow Our Specialty Distribution and Service Businesses. Our specialty pharmaceuticals business has a significant presence in this growing part of the pharmaceutical supply channel. With distribution and value-added services to physicians and other healthcare providers, including hospitals and dialysis clinics, our specialty pharmaceuticals business is a well-developed platform for growth. We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products. We also distribute plasma and other blood products, injectible pharmaceuticals, and vaccines. Additionally, we are well-positioned to service and support many of the new biotechnology therapies that will be coming to market in the near future. We continue to seek opportunities to expand our offerings in specialty distribution and services.
In fiscal 2014, we expanded globally by acquiring a minority ownership in Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), a leading pharmaceutical wholesaler in Brazil. In addition, we launched a joint venture with Profarma to provide enhanced specialty distribution and services to the Brazilian marketplace.
Optimize and Grow Our Manufacturer Services Businesses. Our consulting service businesses help global pharmaceutical and biotechnology manufacturers commercialize their products in the channel. We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs. We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies. World Courier Group, Inc. ("World Courier"), is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. World Courier further strengthens our service offerings to global pharmaceutical manufacturers and provides an established platform for the introduction of our specialty services outside North America. We continue to seek opportunities to expand our offerings in consulting and other services.
Optimize and Grow Our Animal HealthPharmaceutical Distribution and Service Business. In February 2015, we acquired MWI Veterinary Supply, Inc. ("MWI"), a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. MWI also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI. We continue to seek opportunities to expand our offerings in animal health distribution and services.
Strategic Global Sourcing businesses.
| |
| • | Optimize and Grow Our Global Commercialization Services and Animal Health Businesses. Our consulting service businesses help global pharmaceutical and biotechnology manufacturers commercialize their products. We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs. We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies. World Courier is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. World Courier further strengthens our service offerings to global pharmaceutical manufacturers and provides an established platform for the introduction of our specialty services outside North America. MWI Animal Health (“MWI”) sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. MWI also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI. We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses. |
Divestitures. In order to allow us to concentrate on our strategic focus areas of pharmaceutical distribution and related services and specialty pharmaceutical distribution and related services, we have divested certain non-core businesses and may, from time to time, consider additional divestitures.
| |
| • | Acquisitions. In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments. |
| |
| • | Divestitures. In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time, consider additional divestitures. |
Operations
Operating Structure. We are organized based upon the products and services we provide to our customers. Our operations as of September 30, 20162019 are comprised of the Pharmaceutical Distribution Services reportable segment and Other. See Note 17 of the Notesother operating segments that are not significant enough to Consolidated Financial Statements forrequire separate reportable segment information.disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.
Pharmaceutical Distribution Services Segment
The Pharmaceutical Distribution reportable segment is comprised of two operating segments, which include the operations of ABDC and AmerisourceBergen Specialty Group ("ABSG"). Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution Services segment's operations provide drug distribution, strategic global sourcing, and related services designed to reduce healthcare costs and improve patient outcomes.
ABDCThe Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced CSPs,compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.
ABSG, throughThrough a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSGthe Pharmaceutical Distribution Services reportable segment provides third party logistics,data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers.
Our use The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of the terms "specialty"retail and "specialty pharmaceutical products" referinstitutional healthcare providers. Additionally, it delivers packaging solutions to drugs used to treat complex diseases, such as cancer, diabetes,institutional and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms "specialty" and "specialty pharmaceutical products" are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.
Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially all of ABSG sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.retail healthcare providers.
Other
Other consists of theoperating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS") operating segment, the, World Courier, operating segment, and the MWI operating segment. The results of operations of these operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in "Other" for the purpose of our reportable segment presentation.MWI.
ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers.support. World Courier, which operates in over more than
50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.
Sales and Marketing. The majority of ABDC'sPharmaceutical Distribution Services’ sales force is led nationally, with geographic focus and specialized by either healthcare provider type or size. Customer service representatives are centralized in order to respond to customer needs in a timely and effective manner. ABDCPharmaceutical Distribution Services also has support professionals focused on its various technologies and service offerings. ABDC's marketing organization designs and develops business management solutions for AmerisourceBergen healthcare provider customers. Tailored to specific groups, these programs can be further customized at the business unit or distribution facility level to adapt to local market conditions. ABDC'sPharmaceutical Distribution Services’ sales teams and marketing organization also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their
needs. Our other operating segments each have independent sales forces and marketing organizations that specialize in their respective product and service offerings. In addition, we have a corporatean enterprise-wide marketing group that coordinates branding and all other marketing activities across the Company.
Customers. We have a diverse customer base that includes institutional and retail healthcare providers as well as pharmaceutical manufacturers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies, and providers of pharmacy services to such facilities, physicians, and physician group practices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. We are typically the primary source of supply for our healthcare provider customers. Our manufacturingmanufacturer customers include branded, generic, and biotechnology manufacturers of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers. In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.
Our two largest customers, WBAWalgreens Boots Alliance, Inc. ("WBA") and Express Scripts, Inc. ("Express Scripts"), accounted for 30%approximately 34% and 16%approximately 13%, respectively, of ourrevenue in the fiscal 2016 revenue.year ended September 30, 2019. Our top 10 customers, including governmental agencies and group purchasing organizations ("GPOs"GPO"), represented approximately 65%64% of revenue in the fiscal 2016 revenue.year ended September 30, 2019. The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.
Suppliers. We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal 2016.year ended September 30, 2019. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers. We believe that our relationships with our suppliers are good.strong. The 10 largest suppliers in fiscal 2016year ended September 30, 2019 accounted for approximately 45% of our purchases.
Information Systems. The ABDCPharmaceutical Distribution Services operating segment operates its full-service wholesale pharmaceutical distribution facilities in the U.S.United States on a centralizedtwo primary enterprise resource planning ("ERP") systems. We are currently working to transition all of these facilities to a single primary ERP system. ABDC'sPharmaceutical Distribution Services’ ERP system providessystems provide for, among other things, electronic order entry by customers, invoice preparation and purchasing, and inventory tracking. All of our other operating segments operate the majority of their businesses on their own common centralized ERPoperating systems resulting in operating efficiencies as well as the ability to rapidly deploy new capabilities. We expect to makeare currently making significant investments over the next few years to enhance and upgrade the ERPoperating systems utilized by our other operating segments.
Additionally, over the next couple of years, we intend to improveare improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.
We will continue to invest in advanced information systems and automated warehouse technology. For example, in an effort to comply with future pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems.
In fiscal 2016, ABDC began to makePharmaceutical Distribution Services has made significant investments in its electronic ordering systems. These investments will continue into fiscal 2017. ABDC'sPharmaceutical Distribution Services’ systems are intended to strengthen customer relationships by allowing the customerhelping customers to lower itsreduce operating costs and by providing a platform for a number of the basic and value-added services offered to our customers, including product demand data, inventory replenishment, single-source billing, third partythird-party claims processing, real-time price and incentive updates, and price labels.
ABDC
Pharmaceutical Distribution Services processes a substantial portion of its purchase orders, invoices, and payments electronically. However,electronically, and it continues to make substantial investments to expand its electronic interface with its suppliers. ABDCPharmaceutical Distribution Services has a warehouse operating system,systems, which isare used to manage the majority of ABDC'sPharmaceutical Distribution Services’ transactional volume. The warehouse operating system hassystems have improved ABDC'sPharmaceutical Distribution Services’ productivity and operating leverage.
A significant portion of our information technology activities relating to ABDC and our corporate functions aredata center operations, which were previously outsourced to IBM Global Services and other third party service providers.third-party providers, is now insourced.
Competition
We face a highly competitive global environment in the distribution of pharmaceuticals and related healthcare services. Our largest competitors are McKesson Corporation ("McKesson") and, Cardinal Health, Inc. ("Cardinal"). ABDC, FFF Enterprises, Henry Schein, Inc., and UPS Logistics, among others. Pharmaceutical Distribution Services competes with both McKesson and Cardinal, as well as national generic distributors and regional distributors within pharmaceutical distribution. In addition, we compete with manufacturers who sell directly to customers, chain drugstores who manage their own warehousing, specialty distributors, and packaging and healthcare technology companies. The distribution and related service businesses in
which ABSG engages are also highly competitive. ABSG's operating businesses face competition from a variety of competitors, including McKesson, Cardinal, FFF Enterprises, Henry Schein, Inc., and UPS Logistics, among others. Our ABCS, World Courier, and MWI businesses also face competition from a variety of competitors.businesses. In all areas, competitive factors include price, product offerings, value-added service programs, service and delivery, credit terms, and customer support.
Intellectual Property
We use a number of trademarks and service marks. All of the principal trademarks and service marks used in the course of our business have been registered in the United States and, in some cases, in foreign jurisdictions or are the subject of pending applications for registration.
We have developed or acquired various proprietary products, processes, software, and other intellectual property that are used either to facilitate the conduct of our business or that are made available as products or services to customers. We generally seek to protect such intellectual property through a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections.
We hold patents and have patent applications pending that relate to certain of our products, particularly our automated pharmacy dispensing equipment, our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions. We seek patent protection for our proprietary intellectual property from time to time as appropriate.
Although we believe that our patents or other proprietary products and processes do not infringe upon the intellectual property rights of any third parties, third parties may assert infringement claims against us from time to time.
Employees
As of September 30, 2016,2019, we had approximately 19,00022,000 employees, of which approximately 18,00021,000 were full-time employees. Approximately 2% of our employees are covered by collective bargaining agreements. We believe that our relationship with our employees is good. If any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations, butoperations. However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.
Government Regulation
We are subject to extensive oversight by various federal and state governmental entities and we are subject to, and affected by, a variety of federal and state laws, regulations, and policies.
The U.S. Drug Enforcement Administration ("DEA"), the U.S. Food and Drug Administration ("FDA"), the U.S. Department of Justice ("DOJ"), and various other federal and state regulatory authorities regulate the compounding, purchase, storage, and/or distribution of pharmaceutical products, including controlled substances. Wholesale distributors of controlled substances and entities that compound pharmaceuticals that contain controlled substances must hold valid DEA licenses, meet various security and operating standards, and comply with regulations governing the sale, marketing, compounding, packaging, holding, and distribution of controlled substances. Our Section 503B outsourcing facilities must comply with current Good Manufacturing Practices ("GMPs"cGMPs") and are inspected by the FDA periodically to determine that we are complying with such GMPs. ThecGMPs. DEA, FDA, DOJ, and state regulatory authorities have broad enforcement powers, including the ability to suspend our distribution centers or Section 503B outsourcing facilities from distributing pharmaceutical products (including controlled substances,substances), seize or recall products, and impose significant criminal, civil, and administrative sanctions. We have all necessary licenses or other regulatory approvalsOn May 17, 2019, PharMEDium Healthcare Holdings, Inc. ("PharMEDium") reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and believethe Consumer Protection Branch of the Civil Division of the DOJ that we are inwas entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with all applicable pharmaceutical compoundingthe requirements of the Consent Decree. As required by the Consent Decree, we have completed audit inspections by an independent cGMP expert at the Dayton and wholesaleSugar Land facilities to confirm that the facilities are being operated in conformity with cGMP. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for four years. The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility, where we voluntarily suspended production activities in December 2017. We continue the ongoing compliance efforts of our subsidiary PharMEDium, including efforts to resume commercial distribution requirements needed to conduct our current operations.at the Memphis, Tennessee facility.
We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute.statute and False Claims Act. The anti-kickback statute prohibits persons from soliciting, offering, receiving, or paying any remuneration in order to induce the purchasing, leasing, or ordering, induce a referral to purchase, lease, or order, or arrange for or recommend purchasing, leasing, or ordering items or services that are in any way paid for by Medicare, Medicaid, or other federal healthcare programs. The False Claims Act prohibits knowingly submitting, or causing the submission, of false or fraudulent claims for payment to the government, and authorizes treble damages and substantial civil penalties in the case of violations. The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.
In recent years, some states have passed or proposed laws and regulations that are intended to protect the safety of the pharmaceutical supply channel. These laws and regulations are designed to prevent the introduction of counterfeit, diverted, adulterated, or mislabeled pharmaceuticals into the distribution system. At the federal level, Congress has enactedthe supply chain security legislation to regulateknown as the pharmaceutical distribution system by establishingDrug Quality and Security Act (“DQSA”) became law in 2013. The DQSA establishes federal pedigree trackingtraceability standards requiring drugs to be labeled and tracked at the lot level. This same legislationlevel, preempts state drug pedigree requirements, and will eventually require all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system. The DQSA also establishes new requirements for drug wholesale distributors and third partythird-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. We expect that the FDA, and calls for enhanced regulation of CSPs, including heightened compliance, reporting, labeling,eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and inspection
standards. The legislation also creates Sectionthird-party logistics providers. In addition, the DQSA created 503B outsourcing facilities as a new category for providers of CSPs,compounded sterile preparations ("CSPs"), allowing such facilities to voluntarily register with the FDA. Our CSP business locations have registered with the FDA as Section 503B outsourcing facilities and have implemented policies and procedures to achieve compliance with current legislativefederal and state requirements for such facilities. However, thereThere can be no assurance that we are fully compliant with the new DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our CSP facilitiesoperations into compliance. These and other requirements will continue to increase the cost of our operations.
FederalThe regulation of public and private health insurance and health care reform legislation known as the Affordable Care Act became law in March 2010. The Affordable Care Act is intended to expand health insurance, including coverage for at least a portion of drug costs, through a combination of insurance market reforms, an expansion of Medicaid, subsidies,benefit programs can also affect our business and health insurance mandates. The Affordable Care Act contains many provisions designed to generate the revenues necessary to fund the coverage expansions and reduce the costs of Medicare and Medicaid. Among other things, the Affordable Care Act changed the formula for Medicaid federal upper limits for multiple source drugs available for purchase by retail community pharmacies on a nationwide basis to no less than 175% of the weighted average manufacturer price. Further, recent regulations require state Medicaid programs to implement payment mechanisms for branded prescription drugs which are consistent with pharmacies' "actual acquisition costs" for drugs. These provisions could reduce prescription drug reimbursement levels under state Medicaid programs.
As a result of political, economic, and regulatory influences, scrutiny of the healthcare delivery systemand reimbursement systems in the United States can be expected to continue at both the state and federal levels. This process may result in additional legislation and/or regulation governing the production, delivery, or pricing of pharmaceutical products as well as additional changes to the structure of the presentand other healthcare delivery system.services. In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate our distribution centers or Section 503B outsourcing facilities, which may have a material adverse effect on our financial condition and results of operations.
Any future reductions in Medicare or Medicaid reimbursement rates could negatively impact our customers' businesses and their ability to continue to purchase drugs from us. We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.
We are subject to various federal, state, and local environmental laws, including with respect to the sale, transportion,transportation, storage, handling, and disposal of hazardous or potentially hazardous substances, as well as laws relating to safe working conditions and laboratory practices.
The costs, burdens, and/or impacts of complying with federal and state regulations could be significant and the failure to comply with any such legal requirements could have a significant impact on our results of operations and financial condition.
See "Risk Factors" belowbeginning on page 8 for a discussion of additional legal and regulatory developments, as well as enforcement actions or other litigation that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.
Health Information and Privacy Practices
The Health Information Portability and Accountability Act of 1996 ("HIPAA") and its implementing regulations set forth privacy and security standards designed to protect the privacy of and provide for the security of protected health information, as such term is defined under the HIPAA regulations. Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations. Our operations, depending on their location, may also be subject to state or foreign regulations affecting personal data protection and the manner in which information services or products are provided. Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws. We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.
The Health Information Technology for Economic and Clinical Health Act ("HITECH Act"), enacted as part of the 2009 American Recovery and Reinvestment Act ("ARRA"), strengthened federal privacy and security provisions governing protected health information. Among other things, the HITECH Act expanded certain aspects of the HIPAA privacy and security rules, imposed new notification requirements related to health data security breaches, broadened the rights of the U.S. Department of Health and Human Services ("HHS") to enforce HIPAA, and directed HHS to publish more specific security standards. On January 25, 2013, the Office for Civil Rights of HHS published the HIPAA omnibus final rule ("HIPAA Final Rule"), which amended certain aspects of the HIPAA privacy, security, and enforcement rules pursuant to the HITECH Act, extending certain HIPAA obligations to business associates and their subcontractors. Certain components of our business act as "business associates" within the meaning of HIPAA and are subject to these additional obligations under the HIPAA Final Rule.
Some of our businesses collect, maintain, and/or access other personal information (including sensitive personal informationinformation) that is subject to federal and state laws protecting such information, in addition to the requirements of HIPAA, the HITECH Act, and the implementing regulations. Security and disclosure of personalPersonally identifiable information is also highly regulated in many other countries in which we operate,
andoperate. As such regulations continue to evolve. Additionally,evolve, we need tomust comply with applicable privacy and security requirements of these countries, throughout the world in which we maintain operations, including but not limited to those in the European Union.
Most notably certain aspects of our business are subject to the European Union's General Data Protection Regulation ("GDPR") which became effective on May 25, 2018, and the recently enacted California Consumer Protection Act ("CCPA") which becomes effective on January 1, 2020 (with the promulgation of regulations due to be released on July 1, 2020). We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with GDPR, CCPA and other applicable privacy regulations. There can be no assurances that compliance with these requirements will not impose new costs on our business.
Available Information
For more information about us, visit our website at www.amerisourcebergen.com. The contents of the website are not part of this Form 10-K. Our electronic filings with the Securities and Exchange Commission (including all Forms 10-K, 10-Q, and 8-K, and any amendments to these reports) are available free of charge through the "Investor Relations" section of our website at investor.amerisourcebergen.com immediately after we electronically file with or furnish them to the Securities and Exchange Commission and may also be viewed using their website at www.sec.gov.
ITEM 1A. RISK FACTORS
The following discussion describes certain risk factors that we believe could affect our business and prospects. These risk factors are in addition to those set forth elsewhere in this report. Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material. The reader should not consider this list to be a complete statement of all risks and uncertainties.
Our results of operations arecould be adversely impacted by manufacturer pricing changes.
In fiscal 2019, we continued to experience unfavorable brand and generic pharmaceutical pricing trends, which negatively impacted our Pharmaceutical Distribution Services reportable segment profit and our consolidated operating earnings. We expect these trends to continue in fiscal 2020, which could have an adverse effect on our results of operations.
Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost ("WAC") as the reference price. We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price. If manufacturers change their pricing policies or practices with regard to WAC or if prices setcharged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the profitabilityvalue of future genericour services, our results of operations could be adversely affected. Additionally, there are a number of policy initiatives being considered which, if enacted, could directly or indirectly regulate or impact WAC list prices. If such initiatives are passed and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.
The pharmaceutical launches.
Certainproducts that we purchase are also subject to price inflation and deflation. Additionally, certain distribution service agreements that we have entered into with brandedbrand and generic pharmaceutical manufacturers continue to have an inflation-based compensationa price appreciation component to them. As a result, our gross profit from brand-name and generic manufacturerspharmaceuticals continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control. If the frequency or rate of brandedbrand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected. In addition, generic pharmaceuticals are also subject to price deflation. If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations couldwill be adversely affected. A decline in the number of generic pharmaceutical launches, or launches that are less profitable than those in the past, could also adversely impact our results of operations.greater.
In fiscal 2016, we experienced unfavorable trends in brand and generic pharmaceutical pricing. Those trends are expected to continue in fiscal 2017, and could have a material and adverse effect on our results of operations.
Competition and industry consolidation may erode our profit.
As described in greater detail in the “Competition”"Competition" section beginning on page 5, the industries in which we operate are highly competitive. In addition, in recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers.manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business. If we do not compete successfully, it could have a material and adverse effect on our business and results of operations. The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which maycould lead to greater pressure on us to reduce prices for our products and services.
Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability.
The healthcare industry in the United States is highly regulated at the federal and state levels. There have been increasing efforts by Congress and state and federal agencies, including state boards of pharmacy, departments of health, and the FDA, to regulate the pharmaceutical distribution system and pharmacy compounding activities. Regulation of pharmaceutical distribution is intended to prevent diversion and the introduction of counterfeit, adulterated, and/or mislabeled drugs into the pharmaceutical distribution system. Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies. In recent years, some states have passed or proposed laws and regulations that are intended to protect the safety and security of the supply channel but that also may substantially increase the costs and burden of pharmaceutical distribution and pharmaceutical compounding.
At the federal level, the DQSA establishes federal traceability standards requiring drugs to be labeled and tracked at the bottle level, preempts state drug pedigree requirements, and will require all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system by November 2023. The DQSA also established requirements for drug wholesale distributors and third-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. In addition, the DQSA established 503B outsourcing facilities as a category for providers of CSPs, allowing such facilities to voluntarily register with the FDA. Our CSP business locations have registered with the FDA as 503B
outsourcing facilities and have implemented policies and procedures to achieve compliance with current federal and state requirements for such facilities.
There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance. Moreover, we expect that the FDA will continue to issue draft and final guidance and to promulgate regulations in its efforts to implement the requirements in the DQSA, including those relating to current good manufacturing practices ("cGMPs") and other matters related to 503B outsourcing facilities, which may require changes to our business, some of which may be significant. Additional details on risks related to our 503B outsourcing facilities and implementation of cGMPs are described below.
As discussed in the risk factor below about public concern over the abuse of opioid medications, certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. In addition to conducting investigations and participating in litigation related to the misuse of prescription opioid medications, federal, state and local governmental and regulatory agencies are considering legislation and regulatory measures to limit opioid prescriptions and more closely monitor product distribution, prescribing, and dispensing of these drugs.
Complying with the DQSA requirements and other chain of custody and pharmaceutical distribution and compounding requirements, including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.
Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.
Both our business and our customers' businesses may be adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services, changing the methodology by which reimbursement levels are determined, or regulating pricing, contracting, and discounting practices with respect to medical products and services. Additionally, on occasion, price increases and pricing practices with respect to certain brand and generic pharmaceuticals have been the subject of U.S. Congressional inquiries, federal and state investigations and private litigation. Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations.
Federal insurance and healthcare reform legislation known as the Affordable Care Act ("ACA") became law in March 2010, and included numerous reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute. Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations. Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.
Subsequent legislation has made additional changes to federal drug payment policies, including the Bipartisan Budget Act of 2018, which increased the Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs. The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs. Any reduction in the Medicaid reimbursement rates to our customers may indirectly impact the prices that we can charge our customers for multiple source pharmaceuticals and cause corresponding declines in our profitability.
There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business. Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.
Our businesses also sell specialty and other drugs to physicians, hospitals, community oncology practices and other providers that are reimbursed under Part B of the Medicare program. The Centers of Medicare & Medicaid Services ("CMS") published a final rule on November 13, 2017 that reduces Medicare outpatient hospital reimbursement for separately payable drugs (other than vaccines) purchased through the 340B drug discount program from average sales price ("ASP") plus 6% to ASP minus 22.5% (with certain exceptions), effective January 1, 2018. On December 27, 2018, the United States District Court for the District of Columbia concluded that this policy exceeded CMS statutory authority (with regard to 2018 payments). While the appeals process is still underway, CMS solicited comments in the proposed calendar year 2020 Medicare outpatient prospective payment system rule on appropriate payment for such 340B-acquired drugs, potentially including a reduced rate of ASP plus 3%
for calendar years 2018 through 2020. Separately, on November 21, 2018, CMS published a final rule that reduces from 6% to 3% the “add-on” payment for new, separately-payable Part B drugs and biologicals that are paid based on WAC when ASP data during first quarter or sales is unavailable.
The federal government may adopt measures in the future that would further reduce Medicare and/or Medicaid spending or impose additional requirements on healthcare entities. Notably, the Trump Administration and members of Congress proposed numerous amendments to Part B drug distribution and payment models during 2018 and have continued to do so throughout 2019. Some of these proposals could have significant effects on our business, including a potential proposal to create an “International Pricing Index” payment model that would modify distribution methods for Part B drugs and tie reimbursement rates to international drug pricing metrics. Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers. At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.
Finally, federal and state governments may adopt policies affecting drug pricing and contracting practices outside of the context of federal programs such as Medicare and Medicaid, which may adversely affect our business. For example, several states have adopted laws that require drug manufacturers to provide advance notice of certain price increases and to report information relating to those price increases, while others have taken legislative or administrative action to establish prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. On July 31, 2019, the Department of Health and Human Services announced a “Safe Importation Action Plan” that outlines two potential pathways to allow importation of certain drugs from foreign markets. There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.
If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.
We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse. The federal government continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs. Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs. Legislative provisions relating to healthcare fraud and abuse give federal enforcement personnel substantially increased funding, powers and remedies to pursue suspected fraud and abuse, and these enforcement authorities were further expanded by the ACA. While we believe that we are in compliance with applicable laws and regulations, many of the regulations applicable to us, including those relating to marketing incentives offered in connection with pharmaceutical sales, are vague or indefinite, and have not been interpreted by the courts. They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations. If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.
Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.
Certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. Federal, state and local governmental and regulatory agencies are conducting investigations of us and others in the supply chain, including pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications. In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain. The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims, that we failed to provide effective controls and procedures to guard against the diversion of controlled substances, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations. Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future. We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence
and ongoing monitoring of customers. While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.
We are currently engaged in discussions with the objective of reaching potential terms for a global resolution of the multi-district opioid litigation and other related state court litigation described in Note 13 of the Notes to Consolidated Financial Statements. Given the large number of parties involved, the complexity and difficulty of the underlying issues, and the resulting uncertainty of achieving a potential global resolution, we continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation as well as in state courts where lawsuits have been filed, and intend to continue to vigorously defend ourselves in all such cases. Since these matters are still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect how we operate our business, or we may enter into settlements of claims that may also include monetary payments and/or injunctive relief. The adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.
Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict. For example, New York has instituted an opioid excise tax, which went into effect on July 1, 2019, and taxes entities that make the initial sale or distribution of opioid medications into the state. In addition, Rhode Island and Delaware have enacted opioid taxes, Minnesota has enacted increased licensure fees, and other states are considering legislation that could require entities to pay an assessment or tax on the sale or distribution of opioid medications in those states. If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.
Our business, results of operations, and cash flows could be adversely affected by legal proceedings.
We conduct our operations through a variety of businesses, including the distribution of pharmaceuticals, the dispensing of healthcare products, and the provision of services to the pharmaceutical industry. Each of our businesses may cause us to become involved in legal disputes or proceedings involving healthcare fraud and abuse, the False Claims Act, antitrust, class action, commercial, employment, environmental, intellectual property, licensing, and various other claims, including claims related to opioid medications as discussed in the above risk factor. Litigation is costly, time-consuming, and disruptive to ordinary business operations. The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations and financial condition. Violations of various federal and state laws, including with respect to the marketing, sale, purchase, and dispensing of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs. Any settlement, judgment or fine could materially adversely affect our results of operations.
Statutory and/or regulatory violations could also form the basis for qui tam complaints. The qui tam provisions of the federal and various state civil False Claims Acts authorize a private person, known as a relator, to file civil actions under these statutes on behalf of the federal and state governments. Under False Claims Acts, the filing of a qui tam complaint by a relator imposes obligations on government authorities to investigate the allegations and determine whether or not to intervene in the action. Such cases may involve allegations around the marketing, sale, purchase, and/or dispensing of brand and/or generic pharmaceutical products or the provision of services to the pharmaceutical industry. Such complaints are filed under seal and remain sealed until the applicable court orders otherwise. Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations and damages arising from resultant false claims, if the litigation proceeds whether or not government authorities decide to intervene in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.
In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement (see Note 13 of the Notes to Consolidated Financial Statements). The Corporate Integrity Agreement has a five-year term. Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.
Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.
WBA accounted for 30%approximately 34% of our revenue in the fiscal 2016.year ended September 30, 2019. Express Scripts accounted for 16%approximately 13% of our revenue in the fiscal 2016.year ended September 30, 2019. Our top ten customers, including governmental agencies and GPOs, represented approximately 65%64% of revenue in the fiscal 2016 revenue.year ended September 30, 2019. We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract. A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these customers or GPO relationships if we are unable to extend, renew, renegotiate or replace the contracts. The loss of any significant customer or GPO relationship could adversely affect our revenue, results of operations, and cash flows.
Increasing governmental efforts Additionally, from time to regulate the pharmaceutical supply channeltime, significant contracts may be renewed prior to their expiration date. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and pharmaceutical compounding may increase our costs and reduce our profitability.cash flows.
The healthcare industryanticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.
In May 2016, we extended to 2026 our strategic arrangement with WBA - specifically, our distribution agreement under which we distribute drugs to Walgreens pharmacies and our generics purchasing services arrangement under which Walgreens Boots Alliance Development GmbH ("WBAD") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf. This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a result of our generics purchasing services arrangement with WBAD, as well as the potential for exploring innovation together and sharing best practices. The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming. Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; unforeseen changes in the United States is highly regulated ateconomic terms under which we distribute pharmaceuticals to WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the federalanticipated strategic and state levels. There have been increasing effortsfinancial benefits of the relationship.
In addition, WBA has the right, but not the obligation, under the transactions contemplated by Congressthe Framework and stateShareholder Agreements dated March 18, 2013 to make certain additional investments in our common stock. WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement. Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock. We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and federal agencies, including state boardscollaboration we anticipate pursuing with WBA. Many of pharmacy, departmentsthese potential circumstances are outside of healthour control and any of them could result in increased costs, decreased revenue, decreased benefits and the FDA,diversion of management time and attention. If we are unable to regulateachieve our objectives within the pharmaceuticalanticipated time frame, or at all, the expected future benefits may not be realized fully or at all, or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.
A disruption in our distribution systemor generic purchasing services arrangements with WBA could adversely affect our business and pharmacy compounding activities. Regulationfinancial results.
We are the primary distributor of pharmaceutical distribution is intendedproducts for WBA. Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA. If the operations of WBA are seriously disrupted for any reason, whether by natural disaster, labor disruption, regulatory or governmental action, or otherwise, it could adversely affect our business and our sales and profitability. If the generics purchasing services arrangement does not continue to preventbe successful, our margins and results of operations could also be adversely affected.
If our operations are seriously disrupted for any reason, we may have an obligation to pay or credit WBA for failure to supply products. In addition, upon the introduction of counterfeit, adulterated, and/expiration or mislabeled drugs into the pharmaceutical distribution system. Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standardstermination of the DEA, the FDA, various state boards of pharmacy and comparable agencies. In recent years, some states have passeddistribution agreement or proposed laws and regulations, including laws and regulations that are intended to protect the safety of the supply channel but that also may substantially increase the costs and burden of pharmaceutical distribution and pharmaceutical compounding.
At the federal level, final regulations issued pursuant to the Prescription Drug Marketing Act impose pedigree tracking and other chain of custody requirements that increase the costs and/or burden to us of selling to other pharmaceutical distributors and handling product returns. In addition, the FDA Amendments Act of 2007 requires the FDA to establish standards and identify and validate effective technologies for the purpose of securing the pharmaceutical supply chain against counterfeit drugs. These standards include track-and-trace and/or authentication technologies that leverage data carriers applied by the manufacturer to the sellable units and cases. The FDA is also required to develop a standardized numerical identifier ("SNI"). In March 2010, the FDA issued guidance regarding the development of SNIs for prescription drug packages in which the FDA identified package-level SNIs, as an initial step in the FDA's development of additional measures to secure the drug supply chain. In November 2013,
Congress passed the Drug Quality and Security Act ("DQSA"). The DQSA establishes federal traceability standards requiring drugs to be labeled and tracked at the lot level, preempts state drug pedigree requirements, and will eventually require all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system. The DSQA also establishes new requirements for drug wholesale distributors and third party logistics providers, including licensing requirements in states that had not previously licensed such entities.
One additional change resulting from the DQSA is the creation of Section 503B outsourcing facilities as a new category for producers of compounded sterile preparations (“CSPs”), allowing such facilities to voluntarily register with the FDA. Our CSP business locations have registered with the FDA as Section 503B outsourcing facilities and have implemented policies and procedures to achieve compliance with current DQSA requirements for such facilities. However,generics purchasing services arrangement, there can be no assurance that we are fully compliant withor WBA will be willing to renew, on terms favorable to us or at all.
In addition, our business may be adversely affected by any operational, financial, or regulatory difficulties that WBA experiences, including any disruptions of certain of its existing distribution facilities or retail pharmacies resulting from ongoing inspections by the new requirements,DEA and/or state regulatory agencies and any failure to comply may result in additional costs to bring our CSPpossible revocation of the controlled substance registrations for those facilities into compliance. Moreover, the FDA continues to issue draft and final guidance in its efforts to implement the requirements in DQSA, including those relating to current good manufacturing practices and other matters related to 503B outsourcing facilities, which may require changespharmacies.
Tax legislation or challenges to our CSP business, some of which may be significant. Complying with these and other supply chain of custody and pharmaceutical compounding requirements will increase our costs andtax positions could otherwise adversely affect our results of operations.operations and financial condition.
We are a large corporation with operations in the United States and select global markets. As such, we are subject to tax laws and regulations of the U.S. federal, state and local governments, and of various foreign jurisdictions. From time to time, various legislative initiatives, such as the repeal of last-in, first-out ("LIFO") treatment or the promulgation of state opioid taxes and fees, may be proposed that could adversely affect our tax positions and/or our tax liabilities. There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives. We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent. In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations. There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "2017 Tax Act") was enacted and contains significant changes to U.S. income tax law. Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties regarding the geographic mix of earnings in any particular period, and other factors, material adjustments to our tax estimates may impact our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.
The suspension or revocation by federal or state authorities of any of the registrations that must be in effect for our distribution and 503B outsourcing facilities to purchase, compound, store, and/or distribute pharmaceuticals and controlled substances, the refusal by such authorities to issue a registration to any such facility, or any enforcement action or other litigation that arises out of our failure to comply with applicable laws and regulations governing distribution and 503B outsourcing facilities may adversely affect our reputation, our business, and our results of operations.
The DEA, FDA, DOJ, and various other federal and state regulatory authorities regulate the distribution of pharmaceuticals and controlled substances and the compounding of pharmaceuticals that contain controlled substances. We are required to hold valid DEA and state-level licenses, meet various security and operating standards, and comply with the Controlled Substances Act and its implementing regulations governing the sale, marketing, packaging, compounding, holding and distribution of controlled substances. Government authorities may from time to time investigate whether we are in compliance with various security and operating standards applicable to the distribution of controlled substances including whether we are adequately detecting and preventing the illegal diversion of controlled substances. Although we have procedures in place that are intended to ensure compliance with such laws and regulations, there can be no assurance that a regulatory agency or tribunal would conclude that our operations are compliant with applicable laws and regulations. If we were found to be non-compliant with such laws and regulations, federal and state authorities have broad enforcement powers, including (i) the ability to suspend our distribution centers' and 503B outsourcing facilities' licenses to distribute and compound pharmaceutical products (including controlled substances), (ii) seize or recall products, and (iii) impose significant criminal, civil and administrative sanctions for violations of these laws and regulations, each of which could have a material adverse effect on our reputation, business, and results of operations.
We have received, and may in the future receive, requests for information, letters, and subpoenas from the DEA, FDA, various United StatesU.S. Attorneys' Offices of the United States Department of Justice,DOJ, and/or state attorneys general and state regulatory authorities and agencies related to our distribution of controlled substances and our order monitoring program, which is designed to prevent and detect the illegal diversion of controlled substances, or other matters. We generally respond to subpoenas, requests, letters, and other authority and/or agency correspondence in a thorough and timely manner. These responses require time and effort and can result in considerable costs being incurred by the Company,us, such as costs related to addressing the observations listed on FDA Form 483 reports. Such subpoenas, requests and letters can also lead to the assertion of claims or the commencement of civil, criminal, or regulatory legal proceedings against the Company,us, as well as to settlements and the suspension or revocation of registrations required by our distribution and 503B outsourcing facilities, each of which could have a material adverse effect on our reputation, business and results of operations.
TheIn December 2017, following FDA inspections of our 503B outsourcing facilities, we voluntarily suspended production activities at our largest 503B outsourcing facility located in Memphis, Tennessee. In May 2019, PharMEDium reached an agreement on the terms of a consent decree (the “Consent Decree”) with the FDA and other governmental entities enforce the Consumer Protection Branch of the Civil Division of the DOJ. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey, and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to
compliance with applicable current GMPthe requirements under applicableset forth therein. As required by the Consent Decree, we have completed audit inspections by an independent cGMP expert at the Dayton and Sugar Land facilities to determine that the facilities are being operated in conformity with cGMP. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. Through fiscal 2019, our results of operations were adversely impacted by the Memphis suspension. Our results of operations will continue to be adversely impacted until the Memphis facility resumes commercial distribution and we cannot predict if or when the FDA will permit PharMEDium to resume commercial distribution at the Memphis facility.
Separately, we have agreed in several state law through periodic risk-based inspections. It is common forregulatory matters to consent orders or temporary licensing suspensions regarding certain of our 503B outsourcing facilities. Certain other states have requested information concerning the status of operations at some or all of our 503B outsourcing facilities. These state regulatory matters preclude us from commercially distributing into certain states, which could have an adverse impact on our results of operations.
Additionally, the FDA may from time to time issue Form 483 reports to be providedand warning letters in connection with inspectionstheir oversight of 503B outsourcing facilities, and FDA observations may be followed by warning letters or subsequent enforcement actions.facilities. Prior to our acquisition of the business, PharMEDium received a warning letter from the FDA in 2014 following the inspectionand a series of PharMEDium's Mississippi, New Jersey, Tennessee and Texas 503B outsourcing facilities in 2013. The FDA reinspected all of these facilitiesForm 483 reports were issued in 2015 and 2016 and issued FDA Form 483 reports at each offollowing up on the facilities as well as at PharMEDium’s headquarters in Lake Forest, Illinois.2014 letter. We cannot be assured that the FDA and DOJ will be satisfied with the sufficiency or timing of PharMEDium’s corrective actions in response to this warning letter or the Agency’s Form 483 reports and, as such, we cannot predict when or if the FDA will consider the agency’s observations to be fully resolved.reports. A failure to adequatelycomply with the Consent Decree or to address observations identified by the FDA in Form 483 reports or any warning letters issued by the FDA or observations identified by any other federal and state regulatory authority, including a failure to resolve the observations identified by the FDA in the 2014 warning letter and subsequent
FDA Form 483 reports, relating to PharMEDium’s 503B outsourcing facilities, could lead to the suspension of facilities currently in operation, an enforcement action, monetary penalties, and/or license revocation, each of which could have a materialan adverse effect on our reputation, business and results of operations.
Legal, regulatory and legislative changes may adversely affect our business and results of operations.
Both our business and our customers' businesses may be adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services or changing the methodology by which reimbursement levels are determined. Additionally, on occasion, price increases on certain branded and generic pharmaceuticals have been the subject of U.S. Congressional inquiries. Any regulation impacting pharmaceutical pricing could adversely affect our operations.
Federal insurance and health care reform legislation known as the Affordable Care Act became law in March 2010. The Affordable Care Act is intended to expand health insurance coverage, including coverage for at least a portion of drug costs through a combination of insurance market reforms, an expansion of Medicaid, subsidies and health insurance mandates. The Affordable Care Act contains many provisions designed to generate the revenues necessary to fund the coverage expansions and reduce the costs of Medicare and Medicaid. Given the scope of the changes made by the Affordable Care Act and the ongoing implementation efforts, we cannot predict the impact of every aspect of the law on our operations. Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the Affordable Care Act.
The Affordable Care Act changed the formula for Medicaid federal upper limits (“FULs”) for multiple source drugs available for purchase by retail community pharmacies on a nationwide basis to a limit of not less than 175% of the weighted average manufacturer price ("AMP"). On February 1, 2016, CMS published its final rule with comment period to implement the Affordable Care Act’s Medicaid covered outpatient drug provisions, under which CMS will calculate FULs for multiple source drugs as 175 percent of the weighted average of AMPs, with certain exceptions. In addition, the rule requires state Medicaid programs to implement payment methods for brand (non-multiple source) products designed to be consistent with such drugs’ actual acquisition cost (“AAC”). The rule was generally effective on April 1, 2016, and states had until May 2016 to implement the FULs and until April 1, 2017 to implement any changes necessary in light of the AAC standard. Medicaid reimbursement for drugs calculated under the final rule may represent significant reductions from prior reimbursement levels, although the impact of the changes depend upon how the changes are implemented by each state Medicaid program. Any reduction in the Medicaid reimbursement rates to our customers may indirectly impact the prices that we can charge our customers for multisource pharmaceuticals and cause corresponding declines in our profitability.
The Affordable Care Act also amended the Medicaid rebate statute to increase minimum Medicaid rebates paid by pharmaceutical manufacturers and made other changes expected to result in increased Medicaid rebate payments by pharmaceutical manufacturers, which could indirectly impact our business. In addition, the Bipartisan Budget Act of 2015, signed into law on November 2, 2015, extended to generic drugs inflation-based Medicaid drug rebates similar to those that are paid on brand drugs. The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts.
There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business. Unless we are able to develop plans to mitigate the potential impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.
The Medicare Prescription Drug Improvement and Modernization Act of 2003 significantly expanded Medicare coverage for outpatient prescription drugs through the Medicare Part D program. The Part D program has increased the use of pharmaceuticals in the supply channel, which has had a positive impact on our revenues and profitability. There have been additional legislative and regulatory changes to the Part D program since its enactment. There can be no assurances that recent and future changes to the Part D program will not have an adverse impact on our business.
The federal government may adopt measures in the future that would further reduce Medicare and/or Medicaid spending or impose additional requirements on health care entities. For instance, under the "sequestration" provision of the Budget Control Act of 2011, a 2% cut is being made to Medicare provider and plan payments, generally effective for services provided on or after April 1, 2013. Any future reductions in Medicare reimbursement rates could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us. At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have an adverse effect on our business.
ABSG's business may be adversely affected in the future by the impact of declining reimbursement rates for pharmaceuticals and other economic factors.
ABSG sells specialty drugs directly to physicians and community oncology practices and provides a number of services to or through physicians. Drugs that are administered in a physician's office, such as drugs that are infused or injected, are typically covered under Medicare Part B. Declining reimbursement rates for Medicare Part B drugs and other economic factors have caused a number of physician practices, including some of our customers, to move from private practice to hospital settings, where they may purchase their specialty drugs under hospital prime vendor arrangements rather than from specialty distributors like ABSG. Although this trend has slowed down in the past year, it could increase in the future due to various factors, including legislative and regulatory requirements that affect how CMS reimburses for Medicare Part B drugs, as well as the ability of certain hospitals to purchase drugs at significant, statutorily-mandated discounts pursuant to the federal 340B drug discount program for groups of patients. In addition, federal changes in drug reimbursement policy could reduce the rate of reimbursement for drugs covered under Medicare Part B or physician services under Medicare, which could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, and thereby result in corresponding declines in ABSG's profitability. For instance, CMS published a proposed rule on March 11, 2016 that would establish a program to test new Medicare payment methods for certain Part B drugs to determine whether alternative payment designs will reduce Medicare expenditures while maintaining quality of care; that proposed rule has not yet been finalized. At this time, we can provide no assurances that future Medicare reimbursement or policy changes, if adopted, would not have an adverse effect on our business.
Changes to the United States healthcare environment may negatively impact our business and our profitability.
Our products and services are intended to function within the structure of the healthcare financing and reimbursement system currently existing in the United States. In recent years, the healthcare industry has undergone significant changes in an effort to reduce costs and government spending. These changes include an increased reliance on managed care; cuts in certain Medicare funding affecting our healthcare provider customer base; consolidation of competitors, suppliers and customers; and the development of large, sophisticated purchasing groups. We expect the healthcare industry to continue to change significantly in the future. Some of these potential changes, such as a reduction in governmental funding at the state or federal level for certain healthcare services or adverse changes in legislation or regulations governing prescription drug pricing, pharmaceutical compounding, healthcare services or mandated benefits, may cause healthcare industry participants to reduce the amount of our products and services they purchase or the price they are willing to pay for our products and services. We expect continued government and private payor pressure to reduce pharmaceutical pricing. Changes in pharmaceutical manufacturers' pricing or distribution policies could also significantly reduce our profitability.
If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.
We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse. The federal government continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs. Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs. Legislative provisions relating to healthcare fraud and abuse give federal enforcement personnel substantially increased funding, powers and remedies to pursue suspected fraud and abuse, and these enforcement authorities were further expanded by the Affordable Care Act. While we believe that we are in compliance with applicable laws and regulations, many of the regulations applicable to us, including those relating to marketing incentives offered in connection with pharmaceutical sales, are vague or indefinite and have not been interpreted by the courts. They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations. If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid and other federal and state healthcare programs.
Our business and results of operations could be adversely affected by qui tam litigation or other legal proceedings.
Our business involves the manufacture, distribution and dispensing of healthcare products, which may cause us to become involved in legal disputes or proceedings. Violations of various federal and state laws governing the marketing, sale, purchase and dispensing of pharmaceutical products can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs. Any settlement, judgment or fine that is in excess of our insurance limits, or that is not otherwise covered, could adversely affect our results of operations.
Among other things, statutory and/or regulatory violations can form the basis for qui tam complaints to be filed. The qui tam provisions of the federal and various state civil False Claims Acts authorize a private person, known as a relator, to file civil actions under these statutes on behalf of the federal and state governments. Under False Claims Acts, the filing of a qui tam complaint by a relator imposes obligations on government authorities to investigate the allegations and determine whether or not to intervene in the action. Such cases may involve allegations around the marketing, sale, purchase, and/or dispensing of branded and/or generic pharmaceutical products and wrongdoing in the marketing, sale, purchase and/or dispensing of such products. Such complaints are filed under seal and remain sealed until the applicable court orders otherwise.
The Company has learned that there are filings in one or more federal district courts that are under seal and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including our group purchasing organization for oncologists and our oncology distribution business) relating to its distribution of certain pharmaceutical products to providers. With regard to any of these filings, our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations and damages arising from resultant false claims, if government authorities decide to intervene in any such matters and/or if we are found liable for all or any portion of violations alleged in any such matters.
The products compounded by our CSP business are administered by our customers to patients intravenously, and failures or errors in production, labeling, or packaging could contribute to patient harm or death, which may subject us to significant liabilities and reputational harm.
The production, labeling, and packaging of CSPs is inherently risky. Our CSP business sells CSPs to acute care hospitals, freestanding hospital outpatient departments, and ambulatory surgery centers, who then administer the CSPs to patients intravenously or through other injectable routes of administration. There are a number of factors that could result in the injury or death of a patient who receives one of our CSPs, including quality issues, manufacturing or labeling flaws, improper packaging, or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, or safety alert relating to, one or more of our products. In addition, in the ordinary course of business, we may voluntarily recall or retrieve products. Any recall or retreival,retrieval, whether voluntary or requested by the FDA or state regulatory authorities, could result in significant costs and negative publicity. Negative publicity, including regarding a quality or safety issue, whether accurate or inaccurate, could reduce market acceptance of our products, harm our reputation, decrease demand for our products, result in the loss of customers, lead to product withdrawals, and harm our ability to successfully launch new products and services. These problems could also result in enforcement actions by state and federal authorities or other healthcare self-regulatory bodies, or product liability claims or lawsuits, including those brought by individuals or groups seeking to represent a class or establish multidistrict litigation proceedings. Any such action, litigation, recall, or reputational harm even recalls or negative publicity resulting from patient harm or death caused by CSPs prepared by a competitor or a hospital pharmacy could result in a material adverse effect on our business, results of operations, financial condition, and liquidity. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us. Because ofChanges in the increasing cost ofcommercial insurance coverage, wemarket may not be ableimpair or prohibit our ability to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.
A disruption in our distribution or global sourcing arrangements with WBA could adversely affect our business and financial results.
We act as the primary wholesale distribution source for Walgreens' pharmacies in the United States with respect to branded and generic prescription drugs. We are the primary distributor of branded and generic pharmaceuticals for WBA. Our generic pharmaceutical program has also benefited from the global sourcing arrangement with WBA. If the operations of WBA are seriously disrupted for any reason, whether by natural disaster, labor disruption, regulatory or governmental action, or otherwise, it could adversely affect our business and our sales and profitability. If the global sourcing arrangement does not continue to be successful, our margins and results of operations could also be adversely affected.
If our operations are seriously disrupted for any reason, we may have an obligation to pay or credit WBA for failure to supply products. In addition, upon the expiration or termination of the distribution agreement or global sourcing arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.
In addition, our business may be adversely affected by any operational, financial or regulatory difficulties that WBA experiences, including any disruptions of certain of its existing distribution facilities or retail pharmacies resulting from ongoing inspections by the DEA and/or state regulatory agencies and possible revocation of the controlled substance registrations for those facilities and pharmacies.
The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.
In May 2016, we extended to 2026 our strategic arrangement with WBA with the expectation that it would result in various benefits including, among other things, continued cost savings and operating efficiencies, innovation and sharing of best practices. The processes and initiatives needed to achieve and maintain these benefits are complex, costly and time-consuming. Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our global sourcing arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of this strategic arrangement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; unforeseen changes in the economic terms under which we distribute pharmaceuticals to WBA; and whether the unique corporate cultures of separate organizations will continue to work collaboratively in an efficient and effective manner.
In addition, WBA has the right, but not the obligation, under the transactions contemplated by the Framework and Shareholder Agreements dated March 18, 2013 to make additional investments in our Common Stock. Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock. We could also encounter unforeseen costs, circumstances, or issues existing or arising with respect to the transactions and collaboration we anticipate resulting from the Framework and Shareholder Agreements. Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention. If we are unable to achieve our objectives within the anticipated time frame, or at all, the expected future benefits may not be realized fully or at all, or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations and the price of our common stock.
Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate.
As part of our strategy we have recently completed, and expect to continueseek to pursue acquisitions of and investments in other companies. At any particular time, we may be in various stages of assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated. We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.
Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience. If we complete one or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure
of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.
OurAs previously disclosed, we have commenced a comprehensive strategic and financial review of PharMEDium, which remains ongoing. The review includes consideration of the ongoing regulatory, operational, and financial challenges that face PharMEDium as a result of the Consent Decree, state regulatory actions, and related matters. While we are unable to predict the outcome of the review, if we are unable to achieve our objectives within the anticipated time frame, or at all, it could have a material adverse effect on our reputation, results of operations, or financial condition.
Our business and our financial conditionresults of operations may be adversely affected byif we fail to manage and complete divestitures.
We regularly evaluate our global operations.
Our operationsportfolio in jurisdictions outsideorder to determine whether an asset or business may no longer help us meet our objectives. When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of the United States are subject to various risks inherent in global operations. We currently have operations in over 50 countries worldwide. We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risksour strategic objectives. The impact of acquisition described above. At any particular time,a divestiture on our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition. Any of these factors could adversely affect our business, financial position, and results of operations.operations could also be greater than anticipated.
Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.
We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business. For example, we are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”"FCPA"), U.S. export control and trade sanction laws, and similar anti-corruption and international trade laws in certain foreign countries, such as the U.K. Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market. The FCPA generally
prohibits U.S. companies and their officers, directors, employees, and intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining favorable treatment. The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls. If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses. From time to time, we may face audits or investigations by one or more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.
Our results of operations and our financial condition may be adversely affected by our global operations.
Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations. We currently have operations in over 50 countries. We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above. At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition. Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase. Any of these factors could adversely affect our business, financial position, and results of operations.
Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.
If the capital and credit markets experience significant disruption and volatility in the future, there can be no assurance that we will not experience downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit. Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.
Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities. To maintain our ratings, we are required to meet certain financial performance ratios. Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings. Actual or
anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.
Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.
Our relationships with pharmaceutical suppliers give rise to substantial amounts that are due to us from the suppliers, including amounts owed to us for returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers. Volatility of the capital and credit markets, general economic conditions, pending litigation, and regulatory changes may adversely affect the solvency or creditworthiness of our suppliers. The bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.
Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.
Most of our customers buy pharmaceuticals and other products and services from us on credit. Credit is made available to customers based upon our assessment and analysis of creditworthiness. Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured. Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers. The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on our operating revenue and results of operations. As of September 30, 2019, our two largest trade receivable balances due from customers represented approximately 49% and 8% of accounts receivable, net.
Recently, one of our customers, Diplomat Pharmacy, Inc. ("Diplomat"), indicated in a public filing that it believes it is probable it will need to obtain waivers as of December 31, 2019 for breach of certain financial debt covenants in its credit agreement. Diplomat's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the "Diplomat 10-Q") also reflected management's assessment that there is uncertainty regarding its ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to Diplomat’s ability to continue as a going concern.
The Diplomat 10-Q stated that if Diplomat violates its covenants and access to its credit facility is terminated or its indebtedness thereunder is accelerated, it may be unable to repay its obligations due under the credit agreement, which would have a material adverse impact on its liquidity and business. As a result of the foregoing, including the consequences of the going concern assessment of Diplomat's management, we may be unable to recover amounts owed to us and to continue the relationship on our current terms. As of November 15, 2019, our trade receivable balance due from this customer was approximately $109.6 million, none of which was past due as of such date.
Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.
Our businesses rely on sophisticated information systems to obtain, rapidly process, analyze, and manage data to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; to receive, process, and ship orders on a timely basis; to account for other product and service transactions with customers; to manage the accurate billing and collections for thousands of customers; and to process payments to suppliers. We continue to make substantial investments in data centers and information systems, including, but not limited to, a program to enhance and upgrade our information technology systems. Third-party service providers are also responsible for managing a portion of our information systems. To the extent our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected. Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.
Information security risks have generally increased in recent years because of the proliferation of cloud-based infrastructure and other services, new technologies, and the increased sophistication and activities of perpetrators of cyber attacks. A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, increase our costs, and/or cause losses. As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us. Although we believe
that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.
Risks generally associated with data privacy regulation and the international transfer of personal data.
We are required to comply with increasingly complex and changing data privacy regulations both in the United States and beyond that regulate the collection, use, security, processing, and transfer of personal data, including particularly the transfer of personal data between or among countries. Many of these regulations also grant rights to individuals. Many foreign data privacy regulations (including GDPR in the European Union and the Personal Information Protection and Electronic Documents Act in Canada) and certain state regulations (including California's CCPA) are more stringent than those enacted under United States federal law. We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties. That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.
Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.
U.S. generally accepted accounting principles ("GAAP") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual basis, or more frequently if indicators for potential impairment exist. Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time. In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value. The testing required by GAAP involves estimates and judgments by management.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the entry into the Consent Decree, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded an impairment loss in fiscal year 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Although we believe our assumptions and estimates are reasonable and appropriate, any changes in key assumptions, including a failure to meet business plans or other unanticipated events and circumstances such as a rise in interest rates, may affect the accuracy or validity of such estimates. We may be required to record a further significant charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill, indefinite-lived intangible assets, or long-lived assets is determined. Any such charge could have a material adverse impact on our results of operations.
Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.
The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance. Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure of one or more of distribution centers or outsourcing facilities, temporary or long-term disruption in the supply of products, delay in the delivery of products to our distribution centers, and/or disruption of our ability to deliver products to customers. Current or future insurance arrangements may not provide protection for costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical distribution industry in particular are unclear, and changes in the supply, demand, or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.
Declining economic conditions could adversely affect our results of operations and financial condition.
Our operations and performance depend on economic conditions in the United States and other countries where we do business. Deterioration in general economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability. Negative trends in the general economy,
including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products. Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations. Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced. Declining economic conditions may also increase our costs. If the economic conditions in the United States or in the countries where we do business do not improve or deteriorate, our results of operations or financial condition could be adversely affected.
Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption.
If the capital and credit markets experience significant disruption and volatility in the future, there can be no assurance that we will not experience downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit. Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.
Our results of operations may suffer upon the bankruptcy, insolvency or other credit failure of a significant supplier.
Our relationships with pharmaceutical suppliers, including generic pharmaceutical manufacturers, give rise to substantial amounts that are due to us from the suppliers, including amounts owed to us for returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers. Volatility of the capital and credit markets, general economic conditions, and regulatory changes may adversely affect the solvency or creditworthiness of our suppliers. The bankruptcy, insolvency or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.
Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.
Most of our customers buy pharmaceuticals and other products and services from us on credit. Credit is made available to customers based on our assessment and analysis of creditworthiness. Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured. Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers. The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on our operating revenue and results of operations. At September 30, 2016, our two largest trade receivable balances due from customers represented approximately 43% and 10% of accounts receivable, net.
Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.
Our businesses rely on sophisticated information systems to obtain, rapidly process, analyze, and manage data to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; to receive, process, and ship orders on a timely basis; to account for other product and service transactions with customers; to manage the accurate billing and collections for thousands of customers; and to process payments to suppliers. Certain of our businesses continue to make substantial investments in information systems, and third party service providers are also responsible for managing a significant portion of our information systems. To the extent our information systems are not successfully implemented or fail, our business and results of operations may be adversely affected. Our business and results of operations may also be adversely affected if a third party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.
Information security risks have generally increased in recent years because of the proliferation of new technologies and the increased sophistication and activities of perpetrators of cyber attacks. A failure in or breach of our operational or information security systems, or those of our third party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, increase our costs and/or cause losses. As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data and networks from attack, damage or unauthorized access remain a priority for us. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.
Risks generally associated with data privacy regulation and the international transfer of personal data.
We are required to comply with increasingly complex and changing data privacy regulations both in the United States and beyond that regulate the collection, use and transfer of personal data, including particularly the transfer of personal data between or among countries. Many of these foreign data privacy regulations are more stringent than those in the United States. We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties. That or other circumstances related to our collection, use and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.
Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.
We are a large corporation with operations in the United States and select global markets. As such, we are subject to tax laws and regulations of the United States federal, state and local governments and of various foreign jurisdictions. From time to time, various legislative initiatives, such as the repeal of last-in, first-out ("LIFO"), treatment, may be proposed that could adversely affect our tax positions and/or our tax liabilities. There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives. We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent. In addition, United States federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations. There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.
Our goodwill or intangible assets may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
U.S. generally accepted accounting principles ("GAAP") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual basis, or more frequently if indicators for potential impairment exist. Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends or a significant decline in the Company's stock price and/or market capitalization for a sustained period of time. In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our intangible assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value. The testing required by GAAP involves estimates and judgments by management. Although we believe our assumptions and estimates are reasonable and appropriate, any changes in key assumptions, including a failure to meet business plans or other unanticipated events and circumstances such as a rise in interest rates, may affect the accuracy or validity of such estimates. We may be required to record a significant charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill or intangible assets is determined. Any such charge could have a material adverse impact on our results of operations.
Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.
The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods and other forms of severe weather in the U.S. or in other countries in which we operate or are located could adversely affect our operations and financial performance. Natural disasters, power outages or other unexpected events could result in physical damage to and complete or partial closure of one or more of distribution centers or outsourcing facilities, temporary or long-term disruption in the supply of products, delay in the delivery of products to our distribution centers and/or disruption of our ability to deliver products to customers. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
ITEM 2. PROPERTIES
As of September 30, 2016,2019, we conducted our business from office and operating facilities at owned and leased locations throughout the United States (including Puerto Rico) and select global markets. In the aggregate, our facilities occupy approximately 14 million square feet of office and warehouse space, which is either owned or leased under agreements that expire from time to time through 2040.
We lease approximately 185,000 square feetfacilities in Chesterbrook, Pennsylvania and approximately 106,000 square feet in Conshohocken, Pennsylvania for our corporate and ABDC headquarters.
We have 26 full-service ABDC wholesale pharmaceuticalPharmaceutical Distribution Services has a robust distribution facilitiesfacility network in the United States, ranging in size from approximately 53,000 square feet to 328,000 square feet, with an aggregate of approximately 4.7 million square feet. LeasedStates. Significant leased facilities are located in Puerto Rico plus the following states: Arizona, Colorado, Florida, Georgia, Hawaii, Indiana, Kentucky, Minnesota, Mississippi, New York, North Carolina, Utah, and Washington. Owned facilities are located in the following states: Alabama, California, Georgia, Illinois, Kentucky, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, and Virginia.
As of September 30, 2016, the Specialty Group's operations were conducted in 18 locations, two of which are owned, comprising approximately 1.2 million square feet. The Specialty Group's largest leased facility consisted of approximately 273,000 square feet. Its headquarters are located in Texas and it has significant operations in the states of Alabama, Kentucky, Nevada, and Ohio.
As of September 30, 2016,2019, the Consulting Group's operations were conducted in seven leased locations, comprising approximately 668,000 square feet.locations. Its headquarters are located in South Carolina and its other operations are primarily locatedinternationally in Maryland and North Carolina.Canada.
As of September 30, 2016,2019, World Courier's office and operating facilities are located in over 50 countries throughout the world.countries. Its headquarters are located in London, England. Most of the facilities are leased. Significant owned facilities are located in New York, and internationally in Germany, Japan, Singapore, and South Africa.
As of September 30, 2016,2019, MWI's operations were conducted in 19 locations, three of which are owned, in the United States and in the United Kingdom, ranging from approximately 41,000 square feet to 225,000 square feet, with an aggregate of approximately 2.0 million square feet.Kingdom. Leased facilities are located in California, Colorado, Florida, Georgia, Idaho, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Pennsylvania, Texas, Washington, and internationally in the United Kingdom. Significant owned facilities are located in Alabama, Idaho, Texas, and Virginia and internationally in the United Kingdom. Its headquarters are located in Boise, Idaho.
We consider all of our operating and office properties to be in satisfactory condition.
ITEM 3. LEGAL PROCEEDINGS
Legal proceedings in which we are involved are discussed in Note 1513 (Legal Matters and Contingencies) of the Notes to Consolidated Financial Statements appearing in this Annual Report on Form 10-K.
ITEM 4. MINE SAFETY DISCLOSURES
None.Not applicable.
INFORMATION ABOUT OUR EXECUTIVE OFFICERS OF THE REGISTRANT
The following is a list of our executive officers and their ages and positions as of October 31, 2016.November 15, 2019.
|
| | | | |
| Name | | Age | | Current Position with the Company |
| Steven H. Collis | | 5558 | | Chairman, President, and Chief Executive Officer |
John G. ChouSilvana Battaglia | | 60 | | Executive Vice President and General Counsel |
Gina K. Clark | | 59 | | Executive Vice President and Chief Marketing Officer |
James F. Cleary, Jr. | | 53 | | Executive Vice President and President, MWI Veterinary Supply |
Dale Danilewitz | | 54 | | Executive Vice President and Chief Information Officer |
James D. Frary | | 44 | | Executive Vice President and President, AmerisourceBergen Specialty Group |
Kathy H. Gaddes | | 5352 | | Executive Vice President and Chief Human Resources Officer |
TimJohn G. GuttmanChou | | 5763 | | Executive Vice President, Chief Legal Officer and Secretary |
| Gina K. Clark | | 62 | | Executive Vice President and Chief Communications & Administration Officer |
| James F. Cleary | | 56 | | Executive Vice President and Chief Financial Officer |
Peyton R. HowellLeslie E. Donato | | 4950 | | Executive Vice President and Chief Strategy Officer |
| Kathy H. Gaddes | | 56 | | Executive Vice President Global Sourcing & Manufacturer Relationsand Chief Compliance Officer |
| Robert P. Mauch | | 4952 | | Executive Vice President and Group President AmerisourceBergen Drug Corporation |
Sun Park | | 40 | | Executive Vice President, Strategy and Development |
Unless indicated to the contrary, the business experience summaries provided below for our executive officers describe positions held by the named individuals during the last five years.
Mr. Collis has been President and Chief Executive Officer of the Company since July 2011 and Chairman since March 2016. From November 2010 to July 2011, he served as President and Chief Operating Officer. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010. He was Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and was Senior Vice President of the Company and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has been employed by the Company or one of its predecessors for 2225 years.
Ms. Battaglia has been Executive Vice President and Chief Human Resources Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from August 2017 to December 2018 and as Senior Vice President, Global Field Human Resources from May 2011 to August 2017. She also previously worked for Day & Zimmerman and Merck Corporation.
Mr. Chou has been Executive Vice President since August 2011 and became the Chief Legal Officer and Secretary in September 2019. He served as Chief Legal & Business Officer of the Company from May 2017 to September 2019. He served as General Counsel of the Company sincefrom January 2007 and Executive Vice President of the Company since August 2011.to June 2017. From January 2007 to August 2011, Mr. Chou was a Senior Vice President. He has served as Secretary of the Company from February 2006 to May 2012. He was Vice President and Deputy General Counsel from November 2004 to January 2007 and Associate General Counsel from July 2002 to November 2004. Mr. Chou has been employed by the Company for 1417 years.
Ms. Clark becamehas been Executive Vice President since November 2014 and became Chief Communication & Administration Officer in June 2017. She served as Chief Marketing Officer infrom November 2014.2014 to June 2017. Ms. Clark was named Senior Vice President and Chief Marketing Officer in June 2011. She previously served as Senior Vice President of Marketing and Business Development for AmerisourceBergen Specialty Group from January 2007 to June 2011. Prior to joining the Company, she worked in executive leadership roles at Premier Inc. and HealthSouth, including Senior Vice President of Marketing and Alliance Relations, Group Vice President of Relationship Management, and Senior Vice President of Managed Care and National Contracting.
Mr. Cleary becamehas been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Veterinary Supply inAnimal Health from March 2015.2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. sincefrom June 2002.
Mr. Danilewitz becameMs. Donato has been Executive Vice President and Chief Information Officer in November 2014. Mr. Danilewitz has been Senior Vice President and Chief InformationStrategy Officer since June 2012. He served as Chief Information Officer of AmerisourceBergen Specialty Group from March 1999 to May 2012.July 2019. Prior to joining the Company, heshe held management positions within American Airlinesvarious leadership roles at Bayer from May 2009 to May 2019, including Vice President of Strategy, Pharmaceuticals Division, Vice President of Strategy, Bayer Healthcare US, and The Sabre Group. HeVice President & General Manager of Neurology & Hematology. She also worked for Whirlpool CorporationMcKinsey & Company where she was a Partner in the Advanced Technology Group.
Mr. Frary became Executive Vice President, and President, AmerisourceBergen Specialty Group, in November 2014. Mr. Frary was named Senior Vice President and President, AmerisourceBergen Specialty Distribution and Services in April 2010. He was Regional Vice President, East Region of AmerisourceBergen Drug Corporation from October 2007 to April 2010, and Associate Regional Vice President, East Region from May 2007 to September 2007. Before joining the Company, Mr. Frary was a Principal in Mercer Management Consulting's Strategy Group.Healthcare Practice.
Ms. Gaddes became Executive Vice President and Chief Compliance Officer in October 2018. She served as Executive Vice President and Chief Human Resources Officer infrom April 2016.2016 to January 2019. She served as Vice President, Group General Counsel and Secretary from May 2012 to April 2016. She served as Assistant General Counsel, Corporate
and Securities from DecemberOctober 2011 to May 2012. Prior to joining the Company, Ms. Gaddes was Associate Corporate Secretary at ARCO Chemical Company.
Mr. Guttman becameMauch has been Executive Vice President since February 2015 and Chief Financial Officerbecame Group President in November 2014. Mr. Guttman was named Senior Vice President and Chief Financial Officer in May 2012.February 2019. He served as Acting Chief Financial Officer from February 2012 to May 2012. He was ViceGroup President, and Corporate Controller from August 2002 to May 2012. Mr. Guttman has been employed by the Company for 14 years.
Ms. Howell became Executive Vice President and President,Pharmaceutical Distribution & Strategic Global Sourcing & Manufacturer Relations in November 2014. Ms. Howell has been Senior Vice President and President, Global Sourcing and Manufacturer Relations since December 2012. Shefrom June 2017 to February 2019. He served as Senior Vice President, Business Development and President of AmerisourceBergen Consulting Services from May 2010 to December 2012. She was President of Consulting Services and Health Policy, AmerisourceBergen Specialty Group from October 2007 to May 2010. She was President of Lash Group and AmerisourceBergen Specialty Group Manufacturer Services from November 1999 to October 2007. Ms. Howell has been employed by the Company or one of its predecessors for 25 years.
Mr. Mauch became Executive Vice President and President, AmerisourceBergen Drug Corporation infrom February 2015. He2015 to June 2017. Mr. Mauch previously served as Senior Vice President Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for 2225 years.
Mr. Park became Executive Vice President, Strategy and Development in May 2016. He served as Senior Vice President, Business Development from November 2012 to May 2016. Prior to joining the Company, Mr. Park served in various leadership roles at MedImmune and AstraZeneca, and held positions at Charterhouse Group International and Merrill Lynch & Company.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The Company's common stock is traded on the New York Stock Exchange under the trading symbol "ABC." As of October 31, 2016,2019, there were 2,7472,459 record holders of the Company's common stock. The following table sets forth the high and low closing sale prices of the Company's common stock for the periods indicated.
PRICE RANGE OF COMMON STOCK
|
| | | | | | | | |
| | | High | | Low |
| Fiscal Year Ended September 30, 2016 | | |
| | |
|
| First Quarter | | $ | 105.02 |
| | $ | 92.71 |
|
| Second Quarter | | $ | 103.36 |
| | $ | 83.62 |
|
| Third Quarter | | $ | 91.89 |
| | $ | 73.66 |
|
| Fourth Quarter | | $ | 89.89 |
| | $ | 80.16 |
|
| Fiscal Year Ended September 30, 2015 | | |
| | |
|
| First Quarter | | $ | 92.56 |
| | $ | 75.02 |
|
| Second Quarter | | $ | 113.89 |
| | $ | 89.69 |
|
| Third Quarter | | $ | 115.48 |
| | $ | 106.10 |
|
| Fourth Quarter | | $ | 114.95 |
| | $ | 94.99 |
|
In November 2014,2017, our board of directors increased the quarterly dividend by 23%4% from $0.235$0.365 per share to $0.29$0.380 per share. In November 2015,2018, our board of directors increased the quarterly dividend by 17%5% from $0.29$0.380 per share to $0.34 per share. In November 2016, our board of directors increased the quarterly dividend by 7% from $0.34 per share to $0.365$0.400 per share. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Company's board of directors and will depend upon the Company's future earnings, financial condition, capital requirements, and other factors.
Computershare is the Company's transfer agent. Computershare can be reached at (mail) AmerisourceBergen Corporation c/o Computershare, P.O. Box 30170, College Station, TX 77842;50500, Louisville, KY 40233-500; (telephone): Domestic 1-877-296-3711, Domestic TDD 1-800-231-5469,1-800-522-6645, International 1-201-680-6578, or International TDD 1-201-680-6610; and (internet) www.computershare.com.www.computershare.com/investor.
ISSUER PURCHASES OF EQUITY SECURITIES
The following table sets forth the total number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs during each month in the fiscal year ended September 30, 2016.2019.
| | | Period | | Total Number of Shares Purchased | | Average Price Paid Per Share | | Total Number of Shares Purchased as Part of Publicly Announced Programs | | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs | | Total Number of Shares Purchased | | Average Price Paid Per Share | | Total Number of Shares Purchased as Part of Publicly Announced Programs | | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs |
| October 1 to October 31 | | 1,275,000 |
| | $ | 93.00 |
| | 1,275,000 |
| | $ | 2,431,828,347 |
| | 1,386,835 |
| | $ | 90.72 |
| | 1,386,835 |
| | $ | 1,000,000,000 |
|
| November 1 to November 30 | | 190,135 |
| | $ | 95.88 |
| | — |
| | $ | 2,431,828,347 |
| | 62,923 |
| | $ | 89.85 |
| | — |
| | $ | 1,000,000,000 |
|
| December 1 to December 31 | | — |
| | $ | — |
| | — |
| | $ | 2,431,828,347 |
| | 1,319,378 |
| | $ | 75.79 |
| | 1,319,378 |
| | $ | 900,000,064 |
|
| January 1 to January 31 | | 1,063,260 |
| | $ | 94.04 |
| | 1,063,260 |
| | $ | 2,331,837,825 |
| | — |
| | $ | — |
| | — |
| | $ | 900,000,064 |
|
| February 1 to February 29 | | 1,332,084 |
| | $ | 52.66 |
| | 1,332,084 |
| | $ | 2,261,694,960 |
| |
| February 1 to February 28 | | | 157 |
| | $ | 82.79 |
| | — |
| | $ | 900,000,064 |
|
| March 1 to March 31 | | 3,255,981 |
| | $ | 52.66 |
| | 3,255,981 |
| | $ | 2,090,234,575 |
| | 1,252,495 |
| | $ | 78.33 |
| | 1,252,495 |
| | $ | 801,896,921 |
|
| April 1 to April 30 | | 8,431,508 |
| | $ | 54.54 |
| | 8,431,508 |
| | $ | 1,630,408,114 |
| | 116 |
| | $ | 75.35 |
| | — |
| | $ | 801,896,921 |
|
| May 1 to May 31 | | 1,368,588 |
| | $ | 75.28 |
| | 1,360,807 |
| | $ | 2,103,533,257 |
| | 1,038,138 |
| | $ | 79.56 |
| | 1,034,499 |
| | $ | 719,581,614 |
|
| June 1 to June 30 | | 10,671 |
| | $ | 73.63 |
| | 10,149 |
| | $ | 2,102,787,504 |
| | 1,111,252 |
| | $ | 83.29 |
| | 1,111,252 |
| | $ | 627,021,288 |
|
| July 1 to July 31 | | 33 |
| | $ | 81.92 |
| | — |
| | $ | 2,102,787,504 |
| | 139,217 |
| | $ | 84.95 |
| | 139,217 |
| | $ | 615,195,472 |
|
| August 1 to August 31 | | 12,049,393 |
| | $ | 60.38 |
| | 12,013,456 |
| | $ | 1,378,434,875 |
| | 752,384 |
| | $ | 82.85 |
| | 752,048 |
| | $ | 552,888,358 |
|
| September 1 to September 30 | | 6,020,480 |
| | $ | 86.18 |
| | 6,020,480 |
| | $ | 859,615,476 |
| | 1,101,040 |
| | $ | 83.33 |
| | 1,101,040 |
| | $ | 461,135,868 |
|
| Total | | 34,997,133 |
| | $ | 65.39 |
| | 34,762,725 |
| | |
| | 8,163,935 |
| | $ | 82.15 |
| | 8,096,764 |
| | |
|
| |
| (a) | In August 2013, the Company announced a program to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. During the six months ended March 31, 2016, the Company purchased 1.1 million shares of its Common Stock for a total of $100.0 million under this program. In MayNovember 2016, the Company's board of directors authorized a new share purchase program that, together with availability remaining under the existing August 2013 share repurchase program permitsallowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. In September 2016, the Company entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400.0 million for the delivery of 4.5 million shares of its Common Stock. The initial payment of $400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered an additional 0.5 million shares of the Company's Common Stock. The number of shares ultimately received was based on the volume-weighted average price of the Company's Common Stock during the term of the ASR. The Company applied the $400.0 million ASR to the May 2016 share repurchase program. In addition to the ASR transaction, the Company purchased 2.9 million shares of its Common Stock for a total of $231.2 million under the May 2016 program. The Company had $118.8 million of availability remaining under this share repurchase program as of September 30, 2016. |
| |
(b) | In September 2015, the Company announced a special program to purchase up to $2.4$1.0 billion of its outstanding shares of Common Stock,common stock, subject to market conditions. During the fiscal year ended September 30, 2016,2019, the Company purchased 26.31.4 million shares of its Common Stockcommon stock for a total of $1,535.1$125.8 million, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program. |
| |
| (b) | In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program. Theprogram, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had $740.9$461.1 million of availability remaining under this special share repurchase program as of September 30, 2016. However, this availability will not be utilized subsequent to September 30, 2016 as the earnings per share dilution effect of the Warrants was fully mitigated by the Company concurrent with the August 2016 exercise of the 2017 Warrants (see Note 9 of the Notes to Consolidated Financial Statements); therefore, the availability under the Company's share repurchase programs was limited to $118.8 million as of September 30, 2016.program. |
| |
| (c) | Employees surrendered 234,40867,171 shares during the fiscal year ended September 30, 20162019 to meet minimum tax-withholding obligations upon vesting of restricted stock. |
STOCK PERFORMANCE GRAPH
This graph depicts the Company's five year cumulative total stockholder returns relative to the performance of the Standard and Poor's 500 Composite Stock Index, the S&P Health Care Index, and an index of peer companies selected by the Company from the market close on September 30, 20112014 to September 30, 2016.2019. The graph assumes $100 invested at the closing price of the common stock of the Company and of each of the other indices on the New York Stock Exchange on September 30, 2011.2014. The points on the graph represent fiscal year-end index levels based onupon the last trading day in each fiscal quarter. The Peer Group index (which is weighted on the basis of market capitalization) consists of the following companies engaged primarily in wholesale pharmaceutical distribution and related services: McKesson Corporation and Cardinal Health, Inc.
* $100 invested on September 30, 20112014 in stock or index, including reinvestment of dividends.
ITEM 6. SELECTED FINANCIAL DATA
The following table should be read in conjunction with the consolidated financial statements, including the notes thereto, and Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 25. The Company revised its previously reported selected financial data to correct its accounting for certain leases (see Note 2 of the Notes to Consolidated Financial Statements for further details).
| | | | | As of or for the Fiscal Year Ended September 30, | | As of or for the Fiscal Year Ended September 30, |
| (Amounts in thousands, except per share amounts) | | 2016(a) | | 2015(b) | | 2014(c) | | 2013(d) | | 2012(e) | | 2019(a) | | 2018(b) | | 2017(c) | | 2016(d) | | 2015(e) |
| | | | | (As Revised) | | (As Revised) | | (As Revised) | | (As Revised) | |
| Statement of Operations Data: | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|
| Revenue | | $ | 146,849,686 |
| | $ | 135,961,803 |
| | $ | 119,569,127 |
| | $ | 87,959,167 |
| | $ | 78,080,806 |
| | $ | 179,589,121 |
| | $ | 167,939,635 |
| | $ | 153,143,826 |
| | $ | 146,849,686 |
| | $ | 135,961,803 |
|
| Gross profit | | 4,272,606 |
| | 3,529,313 |
| | 2,982,366 |
| | 2,507,819 |
| | 2,634,686 |
| | 5,138,312 |
| | 4,612,317 |
| | 4,546,002 |
| | 4,272,606 |
| | 3,529,313 |
|
| Operating expenses | | 2,746,832 |
| | 3,107,093 |
| | 2,200,275 |
| | 1,605,417 |
| | 1,327,483 |
| | 4,026,389 |
| | 3,168,632 |
| | 3,485,660 |
| | 2,746,832 |
| | 3,107,093 |
|
| Operating income | | 1,525,774 |
| | 422,220 |
| | 782,091 |
| | 902,402 |
| | 1,307,203 |
| | 1,111,923 |
| | 1,443,685 |
| | 1,060,342 |
| | 1,525,774 |
| | 422,220 |
|
| Interest expense, net | | 139,912 |
| | 109,036 |
| | 83,634 |
| | 80,326 |
| | 98,452 |
| | 157,769 |
| | 174,699 |
| | 145,185 |
| | 139,912 |
| | 109,036 |
|
| Income (loss) from continuing operations | | 1,427,929 |
| | (138,165 | ) | | 281,776 |
| | 491,901 |
| | 759,910 |
| |
| Net income (loss) | | 1,427,929 |
| | (138,165 | ) | | 274,230 |
| | 432,173 |
| | 717,535 |
| | 854,135 |
| | 1,615,892 |
| | 364,484 |
| | 1,427,929 |
| | (138,165 | ) |
| Earnings per share from continuing operations — diluted | | $ | 6.32 |
| | $ | (0.63 | ) | | $ | 1.20 |
| | $ | 2.09 |
| | $ | 2.96 |
| |
| Net income (loss) attributable to AmerisourceBergen Corporation | | | $ | 855,365 |
| | $ | 1,658,405 |
| | $ | 364,484 |
| | $ | 1,427,929 |
| | $ | (138,165 | ) |
| Earnings per share — diluted | | $ | 6.32 |
| | $ | (0.63 | ) | | $ | 1.16 |
| | $ | 1.84 |
| | $ | 2.79 |
| | $ | 4.04 |
| | $ | 7.53 |
| | $ | 1.64 |
| | $ | 6.32 |
| | $ | (0.63 | ) |
| Cash dividends declared per common share | | $ | 1.36 |
| | $ | 1.16 |
| | $ | 0.94 |
| | $ | 0.84 |
| | $ | 0.52 |
| | $ | 1.60 |
| | $ | 1.52 |
| | $ | 1.46 |
| | $ | 1.36 |
| | $ | 1.16 |
|
| Weighted average common shares outstanding — diluted | | 225,959 |
| | 217,786 |
| | 235,405 |
| | 235,345 |
| | 256,903 |
| | 211,840 |
| | 220,336 |
| | 221,602 |
| | 225,959 |
| | 217,786 |
|
| Balance Sheet Data: | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|
| Cash and cash equivalents | | $ | 2,741,832 |
| | $ | 2,167,442 |
| | $ | 1,808,513 |
| | $ | 1,231,006 |
| | $ | 1,066,608 |
| | $ | 3,374,194 |
| | $ | 2,492,516 |
| | $ | 2,435,115 |
| | $ | 2,741,832 |
| | $ | 2,167,442 |
|
| Accounts receivable, net | | 9,175,876 |
| | 8,222,951 |
| | 6,312,883 |
| | 6,051,920 |
| | 3,784,619 |
| | 12,386,879 |
| | 11,314,226 |
| | 10,303,324 |
| | 9,175,876 |
| | 8,222,951 |
|
| Merchandise inventories | | 10,723,920 |
| | 9,755,094 |
| | 8,593,852 |
| | 6,981,494 |
| | 5,472,010 |
| |
| Inventories | | | 11,060,254 |
| | 11,918,508 |
| | 11,461,428 |
| | 10,723,920 |
| | 9,755,094 |
|
| Property and equipment, net | | 1,530,682 |
| | 1,192,510 |
| | 1,044,831 |
| | 907,562 |
| | 850,795 |
| | 1,770,516 |
| | 1,892,424 |
| | 1,797,945 |
| | 1,530,682 |
| | 1,192,510 |
|
| Total assets | | 33,656,200 |
| | 27,962,982 |
| | 21,677,432 |
| | 19,022,639 |
| | 15,549,367 |
| | 39,171,980 |
| | 37,669,838 |
| | 35,316,470 |
| | 33,637,501 |
| | 27,962,982 |
|
| Accounts payable | | 23,926,320 |
| | 20,886,439 |
| | 15,592,834 |
| | 13,335,792 |
| | 9,492,589 |
| | 28,385,074 |
| | 26,836,873 |
| | 25,404,042 |
| | 23,926,320 |
| | 20,886,439 |
|
| Long-term debt, including current portion | | 4,205,402 |
| | 3,493,048 |
| | 1,995,632 |
| | 1,396,606 |
| | 1,395,931 |
| |
| Stockholders' equity | | 2,129,404 |
| | 616,386 |
| | 1,943,043 |
| | 2,308,143 |
| | 2,444,774 |
| |
| Total debt | | | 4,172,892 |
| | 4,310,189 |
| | 3,442,055 |
| | 4,186,703 |
| | 3,493,048 |
|
| Total equity | | | 2,993,206 |
| | 3,049,961 |
| | 2,064,461 |
| | 2,129,404 |
| | 616,386 |
|
| Total liabilities and stockholders' equity | | $ | 33,656,200 |
| | $ | 27,962,982 |
| | $ | 21,677,432 |
| | $ | 19,022,639 |
| | $ | 15,549,367 |
| | $ | 39,171,980 |
| | $ | 37,669,838 |
| | $ | 35,316,470 |
| | $ | 33,637,501 |
| | $ | 27,962,982 |
|
| |
| (a) | Includes a $421.3 million impairment of PharMEDium's long-lived assets, net of income tax benefit of $148.7 million; $245.8 million of employee severance, litigation, and other costs, net of income tax benefit of $84.6 million; a $107.8 million gain from antitrust litigation settlements, net of income tax expense of $38.1 million; $51.3 million of PharMEDium remediation costs, net of income tax benefit of $18.1 million; $16.7 million of LIFO credit, net of income tax expense of $5.9 million; a $16.3 million reversal of an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax expense of $5.7 million; and a $10.1 million gain on the sale of an equity investment, net of income tax expense of $3.6 million. |
| |
| (b) | Includes $61.3 million of employee severance, litigation, and other costs, net of income tax benefit of $122.2 million; a $59.7 million goodwill impairment with no income tax benefit; $48.6 million of LIFO expense, net of income tax benefit of $18.7 million; $47.8 million of PharMEDium remediation costs, net of income tax benefit of $18.4 million; a $42.3 million loss on consolidation of equity investments with no income tax benefit; a $30.0 million impairment on a non-customer note receivable with no income tax benefit; a $25.9 million gain from antitrust litigation settlements, net of income tax expense of $10.0 million; a $17.2 million loss on early retirement of debt, net of income tax benefit of $6.6 million; and $15.9 million of expense for an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $6.1 million. |
| |
| (c) | Includes $101.1 million of LIFO credit, net of income tax expense of $56.7 million; a $0.9 million gain from antitrust litigation settlements, net of income tax expense of $0.5 million; and $937.4 million of employee severance, litigation, and other costs, net of income tax benefit of $21.9 million. |
| |
| (d) | Includes $367.2 million of Warrants income, net of income tax benefit of $507.5 million,million; $120.9 million of LIFO expense, net of income tax benefit of $79.3 million,million; an $80.8 million gain from antitrust litigation settlements, net of income tax expense of $53.0 million,million; $62.1 million of employee severance, litigation, and other costs, net of income tax benefit of $40.8 million,million; and a $28.7 million pension settlement charge, net of income tax benefit of $18.9 million. |
| |
(b)(e) | Includes $887.5 million of Warrants expense, net of income tax benefit of $25.3 million,million; $336.2 million of LIFO expense, net of income tax benefit of $206.6 million,million; a $40.6 million gain from antitrust litigation settlements, net of income tax expense of $24.9 million,of$24.9 million; a $30.6 million impairment charge on an equity investment, with no income tax benefit,benefit; and $23.5 million of employee severance, litigation, and other costs, net of income tax benefit of $14.4 million. |
| |
(c) | Includes $397.5 million of Warrants expense, net of income tax benefit of $25.2 million, $214.6 million of LIFO expense, net of income tax benefit of $133.4 million, $20.3 million of loss on early retirement of debt, net of income tax benefit of $12.7 million, a $15.1 million gain from antitrust litigation settlements, net of income tax expense of $9.3 million, and $5.1 million of employee severance, litigation, and other costs, net of income tax benefit of $3.1 million. |
| |
(d) | Includes $169.8 million of LIFO expense, net of income tax benefit of $107.2 million, $76.3 million of Warrants expense, net of income tax benefit of $13.7 million, $14.7 million of employee severance, litigation, and other costs, net of income tax benefit of $8.8 million, and a $14.3 million gain from antitrust litigation settlements, net of income tax expense of $8.6 million. |
| |
(e) | Includes $26.5 million of employee severance, litigation, and other costs, net of income tax benefit of $17.6 million, a $9.1 million gain from antitrust litigation settlements, net of income tax expense of $5.7 million, and $0.4 million of LIFO expense, net of income tax benefit of $0.3 million. |
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein.
We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and Other.other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of our reportable segment presentation.
Pharmaceutical Distribution Services Segment
The Pharmaceutical Distribution Services reportable segment is comprised of two operating segments, which include the operations of ABDC and ABSG. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.
ABDC distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced CSPs,compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.
ABSG, throughThrough a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSGthe Pharmaceutical Distribution Services reportable segment provides third party logistics,data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers.
Our use The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of the term "specialty"retail and "specialty pharmaceutical products" refersinstitutional healthcare providers. Additionally, it delivers packaging solutions to drugs used to treat complex diseases, such as cancer, diabetes,institutional and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms "specialty" and "specialty pharmaceutical products" are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.
Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially all of ABSG's sales consist of specialty pharmaceutical products. ABDC's sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.retail healthcare providers.
Other
Other consists of the ABCS operating segment, the World Courier operating segment, and the MWI operating segment. The results of operations of these operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in "Other" for the purpose of our reportable segment presentation.
ABCS, through a number of operating businesses, providesthat focus on global commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services and other market access programs to pharmaceuticalanimal health (MWI Animal Health). The operating segments that focus on global commercialization services include ABCS and biotechnology manufacturers. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. Courier.
MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers. ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry.
Recent Developments
In August 2016, we and WBA amended the 2017 Warrants so that they became exercisable in whole or in part during the six month period beginning in August 2016 at an exercise price of $52.50. In August 2016, WBA exercised the 2017 Warrants and purchased 22,696,912 shares of our Common Stock for $1,191.6 million. The earnings per share dilutive effect of the exercise of the Warrants was fully mitigated by our hedging a portion of our obligation to deliver common stock with a financial institution and repurchasing additional shares of our Common Stock under special share repurchase programs for our own account over time.
In November 2016, our board of directors authorized a new share repurchase program allowing us to purchase up to $1.0 billion in shares of our Common Stock, subject to market conditions.
Executive Summary
This executive summary provides highlights from the results of operations that follow:
Revenue increased 8.0% from the prior fiscal year as a result of ABDC's increased sales of brand and generic products and the strong revenue growth of ABSG. The addition of MWI, which was acquired in February 2015, also contributed to the revenue growth in the current fiscal year;
Pharmaceutical Distribution gross profit increased 2.9% from the prior fiscal year as the result of the contribution from our recent PharMEDium acquisition and segment revenue growth. Gross profit growth in the current fiscal year benefited from the incremental income from ABDC's participation in the WBA global sourcing arrangement and was adversely impacted by lower generic price appreciation, an increase in generic price deflation, and contract renewals with the Department of Defense ("DOD"), a significant GPO customer, and Kaiser Permanente ("Kaiser"), at less favorable terms;
Total gross profit increased 21.1%6.9% from the prior fiscal year primarily due to the additionrevenue growth of MWI, a reduction in LIFO expense, which was $200.2 million in the current fiscal year in comparison to $542.8 million in the prior fiscal year, and anour Pharmaceutical Distribution Services segment;
Pharmaceutical Distribution Services' gross profit increased gain from antitrust litigation settlements, which was $133.8 million in the current fiscal year in comparison to $65.5 million in the prior fiscal year;
Distribution, selling, and administrative expenses increased 9.6%6.2% from the prior fiscal year primarily due to the additionincrease in revenue largely due to strong specialty product sales, the January 2018 consolidation of MWI,Profarma, and to a lesser extent, PharMEDium;
Total operating expenses werethe January 2018 acquisition of H.D. Smith and was negatively impacted by Warrants. Warrants expense was $140.3 millionour pharmaceutical compounding operations as production at our Memphis facility has been suspended since December 2017. Gross profit in the current fiscal year compared $912.7 million in the prior fiscal year. Warrants expense decreased significantlyOther increased 4.3% from the prior fiscal year primarily due to growth at World Courier and MWI, the declineJanuary 2018 consolidation of the specialty joint venture in our stock price since September 30, 2015. AmortizationBrazil, and ABCS's growth in its Canadian operations. Total gross profit in the current fiscal year was favorably impacted primarily by increases in gains from antitrust litigation settlements, a last-in, first-out ("LIFO") credit in the current year in comparison to a LIFO expense in the prior year, and the reversal of a previously-estimated assessment related to the New York State Opioid Stewardship Act;
Distribution, selling, and administrative expenses increased $96.0 million8.3% from the prior fiscal year as the Pharmaceutical Distribution Services' segment expenses increased by 10.2% from the prior fiscal year primarily due to an increase in costs to support the amortizationincrease in revenue, the January 2018 consolidation of intangible assets originating fromProfarma, and the PharMEDium and MWI acquisitions. We incurred significantly more employee severance costsJanuary 2018 acquisition of H.D. Smith;
Operating income decreased 23.0% in the current fiscal year due to an initiative to improve operating efficiency, and we also incurred a settlement charge during the current fiscal year in connection with the final settlement of our salaried defined benefit pension plan;
Total segment operating income increased by 6.6% compared to the prior fiscal year, primarily due to a $570.0 million impairment of PharMEDium's long-lived assets (see Note 1 of the additions of MWINotes to Consolidated Financial Statements), and PharMEDium;an increase in employee severance, litigation, and
Income taxes were other costs, offset in part by increases in gains from antitrust litigation settlements, a benefit of $37.0 millionLIFO credit in the current fiscal year, as compared toand an expense of $407.1 millionincrease in total operating segment income;
Our effective tax rates were 11.7% and (37.2)% in the prior fiscal year. In November 2015, we received a private letter ruling from the Internal Revenue Service ("IRS"), which entitles us to an income tax deduction equal to the fair value of the Warrants on the date of exercise. As a result, we recorded a deferred tax asset and recognized a tax benefit adjustment of approximately $456 million, which represented the estimated benefit from the tax deduction for the increase in the fair value of the Warrants from the issuance date throughyears ended September 30, 2015. This tax benefit adjustment had a significant impact to our2019 and 2018, respectively. Our effective tax rate in the fiscal year ended September 30, 2016. In March 20162019 was primarily impacted by the $570.0 million impairment of long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements) and August 2016,legal settlements, which changed the Warrants were exercisedmix of domestic and international income. The effective tax rate in the fiscal year ended September 30, 2019 was also impacted by WBA, and an additionala $37.0 million decrease to the Company's transition tax benefit of approximately $52 million was recognized primarily related to the changeTax Cuts and Jobs Act (the "2017 Tax Act"). Our effective tax rate in the fair value of the Warrants fromfiscal year ended September 30, 2015 to their respective exercise dates2018 was primarily impacted by the effect of 2017 Tax Act. Our total income tax benefit in the fiscal 2016. Ouryear ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was alsodetermined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018. Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting; and
Net income and earnings per share were significantly lower in the current fiscal 2016year primarily due to the growth$570.0 million impairment of our international service offerings.long-lived assets and the significant income tax benefit recognized in the prior fiscal year as a result of the 2017 Tax Act.
Results of Operations
Year ended September 30, 20162019 compared withto the Year ended September 30, 20152018
Revenue
|
| | | | | | | | | | |
| | | Fiscal year ended September 30, | | |
| (dollars in thousands) | | 2016 | | 2015 | | Change |
| Pharmaceutical Distribution | | $ | 140,731,224 |
| | $ | 131,480,550 |
| | 7.0% |
| Other | | 6,386,917 |
| | 4,772,178 |
| | 33.8% |
| Intersegment eliminations | | (268,455 | ) | | (290,925 | ) | | (7.7)% |
| Revenue | | $ | 146,849,686 |
| | $ | 135,961,803 |
| | 8.0% |
Revenue increased by 8.0% from the prior fiscal year. See discussions below under "Pharmaceutical Distribution" and "Other" for commentary regarding our revenue growth. |
| | | | | | | | | | |
| | | Fiscal Year Ended September 30, | | |
| (dollars in thousands) | | 2019 | | 2018 | | Change |
| Pharmaceutical Distribution Services | | $ | 172,813,537 |
| | $ | 161,699,343 |
| | 6.9% |
| Other: | | | | | | |
| MWI Animal Health | | 3,975,232 |
| | 3,789,759 |
| | 4.9% |
| Global Commercialization Services | | 2,893,109 |
| | 2,542,971 |
| | 13.8% |
| Total Other | | 6,868,341 |
| | 6,332,730 |
| | 8.5% |
| Intersegment eliminations | | (92,757 | ) | | (92,438 | ) | |
|
| Revenue | | $ | 179,589,121 |
| | $ | 167,939,635 |
| | 6.9% |
We currently expect our revenue growth percentage to be in the mid to high-single digits in fiscal 2017 to increase between 6.5% and 8%.2020. Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new, innovative brand therapies (including biosimilars), the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price increasesinflation and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third partythird-party reimbursement rates to our customers, and changes in Federalfederal government rules and regulations.
Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution SegmentServices segment.
The Pharmaceutical Distribution Services segment grew its revenue by 7.0% from the prior fiscal year. Intrasegment revenues between ABDC and ABSG have been eliminated in the presentation of total Pharmaceutical Distribution revenue. Intrasegment revenues primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC facilities. Intrasegment revenues were $7.6 billion and $6.4 billion in the fiscal years ended September 30, 2016 and 2015, respectively.
ABDC's revenue of $119.8 billion increased 5.6%6.9% from the prior fiscal year, (before intrasegment eliminations). The increase in ABDC's revenue was primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth, including sales to WBA. Revenuegrowth. In addition, revenue increased in the current fiscal year was negatively impacted by lower salesdue to the January 2018 consolidation of products that treat Hepatitis C.Profarma and the January 2018 acquisition of H.D. Smith.
ABSG's revenue of $28.5 billionRevenue in Other increased 17.1%8.5% from the prior fiscal year, (before intrasegment eliminations). The increase in ABSG's revenue wasprimarily due to the continuedABCS's growth in our oncology business (including an increaseits Canadian operations, growth at MWI, growth at World Courier, and the January 2018 consolidation of the specialty joint venture in sales to community oncologists), increased sales in our third party logistics business, and increases in our blood products, vaccine, and physician office distribution businesses.Brazil.
A number of our contracts with customers, including GPOs,group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if anyan existing contract with such customer expires without being extended, renewed, or replaced. During the fiscal year ended September 30, 2016,2019, no significant contracts expired. However, a significant contract with a GPO was renewed, effective April 1, 2016, and our agreement with Kaiser was renewed for a five-year term commencing on July 1, 2016, both at less favorable terms than the previous contracts. Over the next twelve months, only onethere are no significant contract iscontracts scheduled to expire. Our contract with Express Scripts expires in September 2017. Additionally, from time to time, other significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
Other
Revenue in Other increased 33.8% from the prior fiscal year, primarily due to incremental revenue contribution from MWI, which was acquired in February 2015.
Gross Profit
| | | | | Fiscal year ended September 30, | | | Fiscal Year Ended September 30, | |
| (dollars in thousands) | | 2016 | | 2015 | | Change | | 2019 | | 2018 | | Change |
| Pharmaceutical Distribution | | $ | 3,233,283 |
| | $ | 3,141,053 |
| | 2.9% | |
| Pharmaceutical Distribution Services | | | $ | 3,682,986 |
| | $ | 3,466,956 |
| | 6.2% |
| Other | | 1,105,899 |
| | 865,574 |
| | 27.8% | | 1,314,172 |
| | 1,260,485 |
| | 4.3% |
| Intersegment eliminations | | (104 | ) | | — |
| | | (659 | ) | | (609 | ) | |
| Gain from antitrust litigation settlements | | 133,758 |
| | 65,493 |
| | | | 145,872 |
| | 35,938 |
| | |
| LIFO expense | | (200,230 | ) | | (542,807 | ) | | | |
| LIFO credit (expense) | | | 22,544 |
| | (67,324 | ) | | |
| PharMEDium remediation costs | | | (48,603 | ) | | (61,129 | ) | |
| New York State Opioid Stewardship Act | | | 22,000 |
| | (22,000 | ) | |
| Gross profit | | $ | 4,272,606 |
| | $ | 3,529,313 |
| | 21.1% | | $ | 5,138,312 |
| | $ | 4,612,317 |
| | 11.4% |
Gross profit increased 21.1%11.4%, or $743.3$526.0 million, from the prior fiscal year. The increaseGross profit in the current fiscal year was due tofavorably impacted primarily by the increase in gross profit ofin Pharmaceutical Distribution Services, the increase in the gross profit
in Other, the $342.6 million decrease in LIFO expense from the prior fiscal year, and the $68.3 millionan increase in gaingains from antitrust litigation settlements, fromthe LIFO credit in the current year in comparison to a LIFO expense in the prior fiscal year. The decrease in LIFO expense was primarily dueyear, and the reversal of a previously-estimated assessment related to lower brand inflation and higher generic drug deflation.the New York State Opioid Stewardship Act.
Our costscost of goods sold includes a last-in, first-out ("LIFO")LIFO provision that is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors canmay have a material impact to our annual LIFO provision. The LIFO credit in the current fiscal year was primarily driven by lower brand inflation, offset in part by lower generic deflation in comparison to the prior fiscal year.
After FDA inspections of our compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis pending execution of certain remedial measures (see Notes 1 and 13 of the Notes to Consolidated Financial Statements). We continue to incur remediation costs in connection with our compounding operations. Additionally, in April 2019, we ceased production at our compounding facility in Cleveland, Mississippi.
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and required manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, we do not believe a loss contingency is probable.
Pharmaceutical Distribution Services gross profit increased 2.9%6.2%, or $92.2$216.0 million, from the prior fiscal year. The increase wasyear primarily due to the contribution from our recent PharMEDium acquisitionincrease in revenue largely due to strong specialty product sales, the January 2018 consolidation of Profarma, and the growthJanuary 2018 acquisition of ABSG's revenue. Gross profit growth in the current fiscal year benefited from the incremental income from ABDC's participation in the WBA global sourcing arrangementH.D. Smith and was adverselynegatively impacted by lower generic price appreciation, an increase in generic price deflation, and contract renewals with the DOD, a significant GPO customer, and Kaiser, allour pharmaceutical compounding operations as production at less favorable terms.our Memphis facility has been suspended since December 2017. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.30%2.13% in the current fiscal year decreased 9 basis points fromremained relatively flat compared to the prior fiscal year. The decrease from the prior fiscal year was primarily due to lower generic price appreciation, an increase in generic price deflation, contract renewals at less favorable terms, and increased sales to our larger customers that typically have a lower gross profit margin.
Gross profit in Other increased 27.8%4.3%, or $240.3$53.7 million, from the prior fiscal year. The increase wasyear primarily due to growth at World Courier and MWI, the contributionJanuary 2018 consolidation of our February 2015 acquisition of MWI,the specialty joint venture in Brazil, and to a lesser extent, the increaseABCS's growth in ABCS's revenue.its Canadian operations. As a percentage of revenue, gross profit margin in Other of 17.32%19.13% in the current fiscal year decreased from 18.14%19.90% in the prior fiscal year. The decrease from the prior fiscal year was primarily due to the addition of MWI, which has a lower gross profit margin in comparison to other businesses within Other.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $133.8$145.9 million and $65.5$35.9 million during the fiscal years ended September 30, 20162019 and 2015,2018, respectively. The gains were recorded as reductions to cost of goods sold (see Note 1614 of the Notes to Consolidated Financial Statements).
Operating Expenses
| | | | | Fiscal year ended
September 30, | | | Fiscal Year Ended
September 30, | |
| (dollars in thousands) | | 2016 | | 2015 | | Change | | 2019 | | 2018 | | Change |
| | | | | (As Revised) | | |
| Distribution, selling, and administrative | | $ | 2,091,237 |
| | $ | 1,907,840 |
| | 9.6% | | $ | 2,663,508 |
| | $ | 2,460,301 |
| | 8.3% |
| Depreciation and amortization | | 364,735 |
| | 248,635 |
| | 46.7% | | 462,407 |
| | 465,127 |
| | (0.6)% |
| Warrants expense | | 140,342 |
| | 912,724 |
| | | |
| Employee severance, litigation, and other | | 102,911 |
| | 37,894 |
| | | | 330,474 |
| | 183,520 |
| | |
| Pension settlement | | 47,607 |
| | — |
| | |
| Goodwill impairment | | | — |
| | 59,684 |
| |
| Impairment of long-lived assets | | | 570,000 |
| | — |
| |
| Total operating expenses | | $ | 2,746,832 |
| | $ | 3,107,093 |
| |
| | $ | 4,026,389 |
| | $ | 3,168,632 |
| | 27.1% |
Distribution, selling, and administrative expenses increased 9.6%8.3%, or $183.4$203.2 million, from the prior fiscal year primarily due to our February 2015 acquisition of MWI, and to a lesser extent, our November 2015 acquisition of PharMEDium.year. As a percentage of revenue, distribution, selling, and administrative expenses were 1.42%1.48% in the current fiscal year, and represents an increase ofa 2 basis pointspoint increase compared to the prior fiscal year. The increase of 2 basis points wasPharmaceutical Distribution Services' segment expenses increased by 10.2% from the prior fiscal year primarily due to an increase in costs to support revenue growth, the additionJanuary 2018 consolidation of MWI, which has higher operatingProfarma, and the January 2018 acquisition of H.D. Smith. Distribution, selling, and administrative expenses as a percentage of revenue in comparison toOther increased by 2.7% in the Pharmaceutical Distribution segment, offset in part by an initiative to improve operating efficiency across many of our businesses and certain administrative functions.
Depreciation expense increased 10.5% from the priorcurrent fiscal year due to an increase in costs to support revenue growth at MWI, and the amountJanuary 2018 consolidation of capital projects being depreciated. Amortizationthe specialty joint venture in Brazil, offset in part by a reduction in distribution, selling, and administrative expenses at ABCS.
Depreciation expense increased 169.9% from prior fiscal year primarily due to the amortization of intangible assets originating from our MWI and PharMEDium acquisitions.
Warrants expense decreased significantly3.9% from the prior fiscal year primarily due to the decline in our stock price since September 30, 2015. The Warrants were issuedJanuary 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma. Amortization expense decreased 7.6% from the prior fiscal year primarily due to the impairment of PharMEDium intangible assets recorded in March 20132019, offset in connection withpart by the agreementsamortization of intangible assets originating from our January 2018 acquisition of H.D. Smith and arrangements that define our strategic relationship with WBA. The Warrants were exercised by WBA in fullthe January 2018 consolidation of Profarma.
Employee severance, litigation, and other in the fiscal year ended September 30, 2016.2019 included $34.1 million of severance costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D. Smith), and $12.6 million of other restructuring initiatives.
Employee severance, litigation, and other for the fiscal year ended September 30, 2016 included $53.5 million of employee severance and other costs, $19.2 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from our settled salaried defined benefit pension plan to our defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items). Employee severance, litigation, and other for the fiscal year ended September 30, 2015 included $32.6 million of deal-related transaction costs (primarily related to professional fees with respect to the MWI acquisition) and $5.3 million of employee severance and other costs.
We recorded a pension settlement charge of $47.6 million in the fiscal year ended September 30, 20162018 included $36.7 million of severance costs primarily related to position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D. Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.
We recorded a $570.0 million impairment of PharMEDium's long-lived assets in the final settlement of our salaried defined benefit planfiscal year ended September 30, 2019 (see Note 111 of the Notes to Consolidated Financial Statements).
We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our annual goodwill impairment assessment.
Operating Income
| | | | | Fiscal year ended
September 30, | | | Fiscal Year Ended
September 30, | |
| (dollars in thousands) | | 2016 | | 2015 | | Change | | 2019 | | 2018 | | Change |
| | | | | (As Revised) | | |
| Pharmaceutical Distribution | | $ | 1,688,055 |
| | $ | 1,649,741 |
| | 2.3% | |
| Pharmaceutical Distribution Services | | | $ | 1,671,251 |
| | $ | 1,626,748 |
| | 2.7% |
| Other | | 342,416 |
| | 254,506 |
| | 34.5% | | 380,660 |
| | 355,091 |
| | 7.2% |
| Intersegment eliminations | | (103 | ) | | — |
| |
| | (659 | ) | | (609 | ) | |
|
| Total segment operating income | | 2,030,368 |
| | 1,904,247 |
| | 6.6% | | 2,051,252 |
| | 1,981,230 |
| | 3.5% |
| | | | | | | | | | | |
| Gain from antitrust litigation settlements | | 133,758 |
| | 65,493 |
| | | | 145,872 |
| | 35,938 |
| | |
| LIFO expense | | (200,230 | ) | | (542,807 | ) | | | |
| LIFO credit (expense) | | | 22,544 |
| | (67,324 | ) | | |
| PharMEDium remediation costs | | | (69,423 | ) | | (66,204 | ) | |
| New York State Opioid Stewardship Act | | | 22,000 |
| | (22,000 | ) | |
| Acquisition-related intangibles amortization | | (147,262 | ) | | (54,095 | ) | | | | (159,848 | ) | | (174,751 | ) | | |
| Warrants expense | | (140,342 | ) | | (912,724 | ) | | | |
| Employee severance, litigation, and other | | (102,911 | ) | | (37,894 | ) | | | | (330,474 | ) | | (183,520 | ) | | |
| Pension settlement | | (47,607 | ) | | — |
| | |
| Goodwill impairment | | | — |
| | (59,684 | ) | |
| Impairment of long-lived assets | | | (570,000 | ) | | — |
| |
| Operating income | | $ | 1,525,774 |
| | $ | 422,220 |
| | | | $ | 1,111,923 |
| | $ | 1,443,685 |
| | (23.0)% |
Segment operating income is evaluated beforeexcluding gain from antitrust litigation settlements; LIFO expense;credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; Warrants expense; employee severance, litigation, and other; goodwill impairment; and the pension settlement.impairment of long-lived assets.
Pharmaceutical Distribution Services operating income increased 2.3%2.7%, or $38.3$44.5 million, from the prior fiscal year primarily due to the increase in gross profit, offset in part by thean increase in operating expenses. As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 54 basis points from the prior fiscal year primarily due to lower generic price appreciation, an increase in generic price deflation, contract renewals at less favorable terms, and increased sales to our larger customers that typically have a lower gross profit margin, offset in part bycontribution from our initiative to improve operating efficiency.pharmaceutical compounding operations.
Operating income in Other increased 34.5%7.2%, or $87.9$25.6 million, from the prior fiscal year primarily due to the February 2015 acquisitionincrease in gross profit, offset in part by an increase in operating expenses.
We recorded a $13.7 million gain on the sale of MWI.an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.
We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income ) Loss in the fiscal year ended September 30, 2018.
Interest expense, net and the respective weighted average interest rates in fiscal years ended September 30, 2016 and 2015 were as follows (in thousands):follows:
| | | | 2016 | | 2015 | | Fiscal Year Ended September 30, |
| | Amount | | Weighted Average Interest Rate | | Amount | | Weighted Average Interest Rate | | 2019 | | 2018 |
| | | | | | (As Revised) | | | |
| (dollars in thousands) | | | Amount | | Weighted Average Interest Rate | | Amount | | Weighted Average Interest Rate |
| Interest expense | $ | 144,349 |
| | 2.72% | | $ | 112,021 |
| | 2.88% | | $ | 195,474 |
| | 3.73% | | $ | 189,640 |
| | 3.59% |
| Interest income | (4,437 | ) | | 0.45% | | (2,985 | ) | | 0.18% | | (37,705 | ) | | 1.87% | | (14,941 | ) | | 1.18% |
| Interest expense, net | $ | 139,912 |
| | | | $ | 109,036 |
| | | | $ | 157,769 |
| | | | $ | 174,699 |
| | |
Interest expense, net increased 28.3%decreased 9.7%, or $30.9$16.9 million, from the prior fiscal year due to an increase of $1.3 billionyear. The decrease in average borrowingsinterest expense, net from the prior fiscal year primarilywas due to the February 2015 issuance of senior notes totaling $1.0 billion and the February 2015 and November 2015 variable-rate term loan borrowingsan increase in interest income due to finance a portion of the MWI and PharMEDium acquisitions, respectively. Our$752 million increase in our average borrowing rate was lowerinvested cash balance during the current fiscal year primarily as a resultand an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D. Smith and the recent variable-rate financings, which bearJanuary 2018 consolidation of Profarma's debt and related interest at lower rates.expense.
Our interest expense in future periods may vary significantly depending upon changes in net borrowings, interest rates, amendments to our current borrowing facilities, and strategic decisions to deploy our invested cash.
Income taxes were a benefit of $37.0 million inFor the fiscal 2016 compared to an expense of $407.1 million in fiscal 2015. In November 2015, we received a private letter ruling from the Internal Revenue Service ("IRS"), which entitles us to an income tax deduction equal to the fair value of the Warrants on the date of exercise. As a result,year ended September 30, 2018, we recorded a deferred$42.3 million loss in connection with the January 2018 consolidations of Profarma and the specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019. The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an unamortized debt discount and unamortized debt issuance costs.
Our effective tax assetrates were 11.7% and recognized a tax benefit adjustment of approximately $456 million, which represented the estimated benefit from the tax deduction for the increase(37.2)% in the fair value of the Warrants from the issuance date throughfiscal years ended September 30, 2015. This tax benefit adjustment had a significant impact to our2019 and 2018, respectively. Our effective tax rate in the fiscal year ended September 30, 2016. In March 2016 and August 2016,2019 was primarily impacted by the Warrants were exercised by WBA, and an additional tax benefit$570.0 million impairment of approximately $52 million was recognized primarily related to the change in the fair valuelong-lived assets (see Note 1 of the Warrants from September 30, 2015Notes to their respective exercise dates in fiscal 2016. Our incomeConsolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income. The effective tax rate was also favorably impacted in fiscal 2016 due to the growth of our international service offerings.
Net income was $1,427.9 million in the fiscal year ended September 30, 2016. Net loss2019 was $138.2also impacted by a $37.0 million decrease to the Company's transition tax related to the 2017 Tax Act. Our effective tax rate in the fiscal year ended September 30, 2015. Net income for the current and prior fiscal years2018 was significantlyprimarily impacted by Warrants expense, netthe effect of 2017 Tax Act. Our total income taxes.
Year ended September 30, 2015 compared with Year ended September 30, 2014
Revenue
|
| | | | | | | | | | |
| | | Fiscal year ended September 30, | | |
| (dollars in thousands) | | 2015 | | 2014 | | Change |
| Pharmaceutical Distribution | | $ | 131,480,550 |
| | $ | 117,383,967 |
| | 12.0% |
| Other | | 4,772,178 |
| | 2,449,149 |
| | 94.9% |
| Intersegment eliminations | | (290,925 | ) | | (263,989 | ) | | 10.2% |
| Revenue | | $ | 135,961,803 |
| | $ | 119,569,127 |
| | 13.7% |
Revenue increased 13.7% from the prior fiscal year. The increase in revenue was primarily due to increased sales to WBA from the prior fiscal year. Fiscal 2014 revenue included the gradual phase in of the WBA generics business beginning in January 2014. Excluding the incremental sales to WBA, our revenue increased by 7.6% from the prior fiscal year.
Pharmaceutical Distribution Segment
The Pharmaceutical Distribution segment grew its revenue by 12.0% from the prior fiscal year. Intrasegment revenues between ABDC and ABSG have been eliminated in the presentation of total Pharmaceutical Distribution revenue. Intrasegment revenues primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC facilities. Intrasegment revenues were $6.4 billion and $4.2 billion in the fiscal years ended September 30, 2015 and 2014, respectively.
ABDC's revenue of $113.5 billion increased 11.3% from the prior fiscal year (before intrasegment eliminations). The increase in ABDC's revenue was primarily due to increased sales to WBAtax benefit in the fiscal year ended September 30, 2015 (as noted above)2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, increased sales of products that treat Hepatitis C, and overall market growth.
ABSG's revenue of $24.4 billion increased 24.3%both resulting from the prior2017 Tax Act. Additionally, during the fourth quarter of fiscal year (before intrasegment eliminations). The increase in ABSG's revenue2018, a portion of a 2017 legal settlement charge was duedetermined to the continued growth inbe deductible, which favorably impacted our blood products, vaccine and physician office distribution businesses, the impact of manufacturer shifts of certain infused oncology products from full line distribution to specialty distribution, and growth in oncology product sales (including an increase in sales to community oncologists). Excluding the impact of the manufacturer shifts of certain infused oncology products from full line distribution to specialty distribution, ABSG revenue grew by 15.2% ineffective tax rate for the fiscal year ended September 30, 2015.2018. Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.
OtherNet income and earnings per share were significantly lower in the current fiscal year primarily due to the $570.0 million impairment of long-lived assets and the significant income tax benefit recognized in the prior fiscal year as a result of the 2017 Tax Act.
Year ended September 30, 2018 compared to the Year ended September 30, 2017
Revenue
|
| | | | | | | | | | |
| | | Fiscal Year Ended September 30, | | |
| (dollars in thousands) | | 2018 | | 2017 | | Change |
| Pharmaceutical Distribution Services | | $ | 161,699,343 |
| | $ | 147,453,495 |
| | 9.7% |
| Other: | | | | | | |
| MWI Animal Health | | 3,789,759 |
| | 3,636,305 |
| | 4.2% |
| Global Commercialization Services | | 2,542,971 |
| | 2,111,558 |
| | 20.4% |
| Total Other | | 6,332,730 |
| | 5,747,863 |
| | 10.2% |
| Intersegment eliminations | | (92,438 | ) | | (57,532 | ) | | |
| Revenue | | $ | 167,939,635 |
| | $ | 153,143,826 |
| | 9.7% |
Revenue in Other increased 94.9%by 9.7% from the prior fiscal year primary due to the revenue growth of our Pharmaceutical Distribution Services segment.
The Pharmaceutical Distribution Services segment grew its revenue by 9.7% from the prior fiscal year primarily due to the $1.9 billiongrowth of some of its largest customers, overall market growth, and especially strong oncology product sales. In addition, revenue contributionincreased in the prior fiscal year due to the January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Revenue in Other increased 10.2% from the prior fiscal year, primarily due to the January 2018 consolidation of the specialty joint venture in Brazil, ABCS's growth in its Canadian operations, and increased revenue from MWI and an increaseWorld Courier, offset in ABCS revenue.part by a decrease in revenue at ABCS's Lash consulting group.
Gross Profit
| | | | | Fiscal year ended September 30, | | | Fiscal Year Ended September 30, | |
| (dollars in thousands) | | 2015 | | 2014 | | Change | | 2018 | | 2017 | | Change |
| Pharmaceutical Distribution | | $ | 3,141,053 |
| | $ | 2,771,190 |
| | 13.3% | |
| Pharmaceutical Distribution Services | | | $ | 3,466,956 |
| | $ | 3,182,836 |
| | 8.9% |
| Other | | 865,574 |
| | 534,803 |
| | 61.8% | | 1,260,485 |
| | 1,204,545 |
| | 4.6% |
| Intersegment eliminations | | | (609 | ) | | (556 | ) | |
| Gain from antitrust litigation settlements | | 65,493 |
| | 24,436 |
| | | | 35,938 |
| | 1,395 |
| | |
| LIFO expense | | (542,807 | ) | | (348,063 | ) | | | |
| LIFO (expense) credit | | | (67,324 | ) | | 157,782 |
| | |
| PharMEDium remediation costs | | | (61,129 | ) | | — |
| |
| New York State Opioid Stewardship Act | | | (22,000 | ) | | — |
| |
| Gross profit | | $ | 3,529,313 |
| | $ | 2,982,366 |
| | 18.3% | | $ | 4,612,317 |
| | $ | 4,546,002 |
| | 1.5% |
Gross profit increased 18.3%1.5%, or $546.9$66.3 million, from the prior fiscal year. TheGross profit in the fiscal year ended September 30, 2018 was favorably impacted by increases in gross profit in Pharmaceutical Distribution Services and Other and an increase in gains from antitrust litigation settlements. Gross profit was negatively impacted by an increase in LIFO expense in comparison to the prior fiscal year, PharMEDium remediation costs, and an estimated assessment related to the New York State Opioid Stewardship Act.
Pharmaceutical Distribution Services gross profit increased 8.9%, or $284.1 million, from the prior fiscal year primarily due to the increase in Pharmaceutical Distribution gross profit,revenue, the increase inJanuary 2018 consolidation of Profarma, and the gross profitJanuary 2018 acquisition of Other, and larger gains from antitrust litigation settlements and wasH.D. Smith, offset in part by the $194.7 million increase in LIFO expense from the prior fiscal year. The increase in LIFO expense was primarily due to higher brand inflation anda lower generic drug deflation resulting from the generics pricing environment.
Pharmaceutical Distribution gross profit increased 13.3%, or $369.9 million, from the prior fiscal year. The increase was due to higher brand and generic sales volume largely attributable to WBA (as noted above). Gross profit also increased due to the growth of our specialty distribution businesses and an increase in income resultingcontribution from our participationpharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in December 2017 at our global sourcing arrangement with WBAD. Gross profit growth in the current year was adversely impacted by the renewal of our contract with the DOD at less favorable terms and lower generic price appreciation.Memphis facility. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.39%2.14% in the current fiscal year increased 3ended September 30, 2018 decreased 2 basis points from the prior fiscal year. The increasedecrease in gross profit margin from the prior fiscal year was primarily due to the increase in ABDC and ABSG sales volume and incremental incomea lower contribution from our participationpharmaceutical compounding operations and due to increased sales to our larger customers, which typically have lower gross profit margins, offset in our global sourcing arrangement with WBAD.part by the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith.
Gross profit in Other increased 61.8%4.6%, or $330.8$55.9 million, from the prior fiscal year. The increase wasyear primarily due to World Courier and the contributionJanuary 2018 consolidation of our MWI acquisition, and, to a lesser extent, the increasespecialty joint venture in Brazil, offset in part by lower gross profit at ABCS, and World Courier's revenue.specifically the Lash consulting group. As a percentage of revenue, gross profit margin in Other of 18.14%19.90% in the current fiscal year ended September 30, 2018 decreased from 21.84%20.96% in the prior fiscal year. The decreasedecline in gross profit margin from the prior fiscal year was primarily due to the contribution from our MWI acquisition and the increasedecrease in ABCS distribution revenue, both of which have a lower gross profit margin in comparison to other businesses within Other.at ABCS, specifically the Lash consulting group.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $65.5$35.9 million and $24.4$1.4 million during the fiscal years ended September 30, 20152018 and 2014,2017, respectively. The gains were recorded as reductions to cost of goods sold.sold (see Note 14 of the Notes to Consolidated Financial Statements).
Operating Expenses
| | | | | Fiscal year ended September 30, | | | Fiscal Year Ended
September 30, | |
| (dollars in thousands) | | 2015 | | 2014 | | Change | | 2018 | | 2017 | | Change |
| | | (As Revised) | | (As Revised) | | |
| Distribution, selling, and administrative | | $ | 1,907,840 |
| | $ | 1,580,664 |
| | 20.7% | | $ | 2,460,301 |
| | $ | 2,128,730 |
| | 15.6% |
| Depreciation and amortization | | 248,635 |
| | 188,680 |
| | 31.8% | | 465,127 |
| | 397,603 |
| | 17.0% |
| Warrants expense | | 912,724 |
| | 422,739 |
| | | |
| Employee severance, litigation and other | | 37,894 |
| | 8,192 |
| | | |
| Employee severance, litigation, and other | | | 183,520 |
| | 959,327 |
| | |
| Goodwill impairment | | | 59,684 |
| | — |
| |
| Total operating expenses | | $ | 3,107,093 |
| | $ | 2,200,275 |
| |
| | $ | 3,168,632 |
| | $ | 3,485,660 |
| | (9.1)% |
Distribution, selling, and administrative expenses increased 20.7%decreased 15.6%, or $327.2$331.6 million, from the prior fiscal year as the Pharmaceutical Distribution Services' segment expenses increased by 19.4% from the prior fiscal year primarily due to the fiscal 2015January 2018 consolidation of Profarma, the January 2018 acquisition of MWI. In addition, operatingH.D. Smith, and the duplicate costs resulting from the implementation of new information technology systems. Distribution, selling, and administrative expenses duringin Other increased by 8.2% in the current fiscal year were higherended September 30, 2018 primarily to support its revenue growth, the increaseJanuary 2018 consolidation of the specialty joint venture in our revenue, includingBrazil, and due to duplicate costs resulting from the WBA volume, which was not fully phased in during the prior fiscal year. More specifically, expenses related to payroll (including incentive compensation), delivery, andimplementation of new information technology were higher in the current fiscal year.systems. As a percentage of revenue, distribution, selling, and administrative expenses were 1.40%1.46% in the current fiscal year ended September 30, 2018, and represent anrepresents a 7 basis point increase of 8 basis points in comparisoncompared to the prior fiscal year. The increase was primarily due to our acquisition of MWI, which has higher operating expensesin expense as a percentage of revenue in comparison to Pharmaceutical Distribution.the prior fiscal year was primarily due to the January 2018 consolidation of Profarma and the specialty joint venture in Brazil.
Depreciation expense increased 19.8% from the prior fiscal year due to an increase in the amount of capital projects being depreciated.property and equipment placed into service relating to our distribution infrastructure and various technology assets. Amortization expense increased 12.9% from the prior fiscal year primarily due to the amortization of newly acquired intangible assets originating from our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Employee severance, litigation, and other in the fiscal year ended September 30, 2018 included $36.7 million of severance costs primarily related to position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D. Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.
Employee severance, litigation, and other in the MWI acquisition.fiscal year ended September 30, 2017 included $7.8 million of employee severance costs primarily related to position eliminations as we began to reorganize to further align our organization to our customers' needs, $917.6 million of litigation costs primarily related to litigation settlements and accruals, $17.0 million of acquisition-related deal and integration costs, $13.3 million of other restructuring initiatives, and $3.7 million related to our business transformation efforts.
Warrants expense increased significantlyOperating Income
|
| | | | | | | | | | |
| | | Fiscal Year Ended
September 30, | | |
| (dollars in thousands) | | 2018 | | 2017 | | Change |
| Pharmaceutical Distribution Services | | $ | 1,626,748 |
| | $ | 1,643,629 |
| | (1.0)% |
| Other | | 355,091 |
| | 373,797 |
| | (5.0)% |
| Intersegment eliminations | | (609 | ) | | (556 | ) | | |
| Total segment operating income | | 1,981,230 |
| | 2,016,870 |
| | (1.8)% |
| | | | | | | |
| Gain from antitrust litigation settlements | | 35,938 |
| | 1,395 |
| | |
| LIFO (expense) credit | | (67,324 | ) | | 157,782 |
| | |
| PharMEDium remediation costs | | (66,204 | ) | | — |
| | |
| New York State Opioid Stewardship Act | | (22,000 | ) | | — |
| | |
| Acquisition-related intangibles amortization | | (174,751 | ) | | (156,378 | ) | | |
| Employee severance, litigation, and other | | (183,520 | ) | | (959,327 | ) | | |
| Goodwill impairment | | (59,684 | ) | | — |
| | |
| Operating income | | $ | 1,443,685 |
| | $ | 1,060,342 |
| | 36.2% |
Segment operating income is evaluated excluding gain from antitrust litigation settlements; LIFO (expense) credit; PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; and goodwill impairment.
Pharmaceutical Distribution Services operating income decreased 1.0%, or $16.9 million, from the prior fiscal year primarily due to thean increase in our stock price since September 30, 2014.
Employee severance, litigation, and other for the fiscal year ended September 30, 2015 included $32.6 million of deal-related transaction costs (primarily related to professional fees with respect to the MWI acquisition) and $5.3 million of employee severance and other related costs. Employee severance, litigation, and other for the fiscal year ended September 30, 2014 included $6.3 million of deal-related transaction costs and $1.9 million of employee severance and other related costs.
Operating Income
|
| | | | | | | | | | |
| | | Fiscal year ended
September 30, | | |
| (dollars in thousands) | | 2015 | | 2014 | | Change |
| | | (As Revised) | | (As Revised) | | |
| Pharmaceutical Distribution | | $ | 1,649,741 |
| | $ | 1,409,199 |
| | 17.1% |
| Other | | 254,506 |
| | 150,617 |
| | 69.0% |
| Total segment operating income | | 1,904,247 |
| | 1,559,816 |
| | 22.1% |
| | | | | | | |
| Gain from antitrust litigation settlements | | 65,493 |
| | 24,436 |
| | |
| LIFO expense | | (542,807 | ) | | (348,063 | ) | | |
| Acquisition-related intangibles amortization | | (54,095 | ) | | (23,167 | ) | | |
| Warrants expense | | (912,724 | ) | | (422,739 | ) | | |
| Employee severance, litigation, and other | | (37,894 | ) | | (8,192 | ) | | |
| Operating income | | $ | 422,220 |
| | $ | 782,091 |
| | |
Segment operating income is evaluated before gain from antitrust litigation settlements; LIFO expense; acquisition-related intangibles amortization; warrants expense; and employee severance, litigation, and other.
Pharmaceutical Distribution operating income increased 17.1%, or $240.5 million, from the prior fiscal year due to the increase in gross profit,expenses, offset in part by thean increase in operating expenses from the prior fiscal year.gross profit. As a percentage of revenue, Pharmaceutical Distribution Services operating income margin increased 5decreased 10 basis points from the prior fiscal year primarily due to the increase in ABDC and ABSG sales volume and incremental incomea lower contribution from our participationpharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in the global sourcing arrangement with WBAD, and was offset in part by the DOD contract renewal and a decrease in generic price appreciation.
December 2017 at our Memphis facility.
Operating income in Other increased 69.0%decreased 5.0%, or $103.9$18.7 million, from the prior fiscal year primarily asdue to a result ofdecrease in operating income at ABCS, specifically the contribution ofLash consulting group, offset in part by the operating income increase at World Courier.
We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in connection with our annual goodwill impairment assessment.
We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal 2015 MWI acquisition.year ended September 30, 2018.
Interest expense, net and the respective weighted average interest rates in fiscal 2015 and 2014 were as follows (in thousands):follows:
| | | | | 2015 | | 2014 | | Fiscal Year Ended September 30, |
| | | Amount | | Weighted Average Interest Rate | | Amount | | Weighted Average Interest Rate | | 2018 | | 2017 |
| | | (As Revised) | | (As Revised) | | |
| (dollars in thousands) | | | Amount | | Weighted Average Interest Rate | | Amount | | Weighted Average Interest Rate |
| Interest expense | | $ | 112,021 |
| | 2.88% | | $ | 84,475 |
| | 3.84% | | $ | 189,640 |
| | 3.59% | | $ | 149,042 |
| | 2.99% |
| Interest income | | (2,985 | ) | | 0.18% | | (841 | ) | | 0.27% | | (14,941 | ) | | 1.18% | | (3,857 | ) | | 0.52% |
| Interest expense, net | | $ | 109,036 |
| | | | $ | 83,634 |
| | | | $ | 174,699 |
| | | | $ | 145,185 |
| | |
Interest expense, net increased 30.4%20.3%, or $25.4$29.5 million, from the prior fiscal year. The increase in interest expense, net from the prior fiscal year due to an increase of $1.4 billion in average borrowingswas primarily due to the February 2015December 2017 issuance of our $500 million 3.25% senior notes our $500 million 4.25% senior notes, and our variable-rate term loan borrowing to finance a portionour January 2018 acquisition of H.D. Smith and the MWI acquisition. Our average borrowing rate was lower duringJanuary 2018 consolidation of Profarma's debt and related interest expense. Average borrowings increased by $519.8 million in the current fiscal year primarily asin comparison to the prior fiscal year.
In connection with our incremental Brazil investments, we adjusted the carrying values of our previously held equity interests in Profarma and the specialty joint venture to equal their fair values. The adjustments resulted in a resultloss of $42.3 million, which was comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the remeasurement of Profarma's previously held interest, and an $8.8 million loss on the remeasurement of the recent financings, which bearspecialty joint venture's previously held equity interest at lower rates.(see Note 2 of the Notes to Consolidated Financial Statements).
DuringFor the fiscal 2015,year ended September 30, 2018, we recorded a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019 (see Note 6 of the Notes to Consolidated Financial Statements). The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an impairment charge of $30.6 million relating to our 19.9% minority ownership interest in a pharmaceutical wholesaler in Brazil. The impairment charge was based on our determination that the declineunamortized debt discount and unamortized debt issuance costs.
Our effective tax rates were (37.2)% and 60.3% in the pharmaceutical wholesaler's stock price from the date on which the investment was made tofiscal years ended September 30, 2015 was other-than-temporary.
Income2018 and 2017, respectively. Our effective tax expense was $407.1 million in fiscal 2015 compared to $388.1 million in fiscal 2014.
Net loss was $138.2 millionrate in the fiscal year ended September 30, 2015. Diluted loss per share2018 was primarily impacted by the effect of $0.63the 2017 Tax Act. Our total income tax benefit in the fiscal year ended September 30, 20152018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was drivendetermined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018. The effective tax rate for the fiscal year ended September 30, 2017 was negatively impacted by non-deductible legal settlement charges. Our effective tax rates for the fiscal years ended September 30, 2018 and 2017 were favorably impacted by our international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.
Net income attributable to AmerisourceBergen Corporation was significantly higher in the fiscal year ended September 30, 2018 primarily due to the significant Warrants expense2017 Tax Act and LIFO expense.legal settlement charges that were incurred in the prior fiscal year.
Critical Accounting Policies and Estimates
Critical accounting policies are those policies whichthat involve accounting estimates and assumptions that can have a material impact on our financial position and results of operations and require the use of complex and subjective estimates based upon past experience and management's judgment. Actual results may differ from these estimates due to uncertainties inherent in such estimates. Below are those policies applied in preparing our financial statements that management believes are the most dependent onupon the application of estimates and assumptions. For a complete list of significant accounting policies, see Note 1 of the Notes to the Consolidated Financial Statements.
AllowanceAllowances for Returns and Doubtful Accounts and Reserve for Customer Sales Returns
Trade receivables are primarily comprised of amounts owed to us for our pharmaceutical distribution and services activities and are presented net of an allowance for doubtful accounts and a reserve for customer sales returns.returns and an allowance for doubtful accounts. Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends. The allowance for returns as of September 30, 2019 and 2018 was $1,147.5 million and $988.8 million, respectively.
In determining the appropriate allowance for doubtful accounts, we consider a combination of factors, such as the aging of trade receivables, industry trends, and our customers' financial strength, credit standing, and payment and default history. Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts. The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables. Each of our business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based onupon historical experience and for specific credit problems when they arise. We write off balances against the reserves when collectability is deemed remote. Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly. There were no significant changes to this process during the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments. Schedule II of this Form 10-K sets forth a rollforward of the allowance for doubtful accounts and reserve for customer sales returns.
Bad debt expense for the fiscal years ended September 30, 2016, 2015,2019, 2018, and 20142017 was $13.1$25.2 million, $8.1$16.7 million, and $26.6$8.9 million, respectively. An increase or decrease of 0.1% in the 20162019 allowance as a percentage of trade receivables would
result in an increase or decrease in the provision on accounts receivable of approximately $9.2$12.5 million. The allowance for doubtful accounts was $69.8$76.4 million and $82.4$61.1 million as of September 30, 20162019 and 2015,2018, respectively.
Supplier ReservesSchedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.
Business Combinations
The assets acquired and liabilities assumed upon the acquisition or consolidation of a business are recorded at fair value, with the residual of the purchase price allocated to goodwill. We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed. Such valuations require management to make significant judgments, estimates, and assumptions, especially with respect to intangible assets. Management makes estimates of fair value based upon assumptions it believes to be reasonable. These estimates are based upon historical experience and information obtained from the management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain of the intangible assets include, but are not limited to: discount rates and expected future cash flows from and economic lives of customer relationships, trade names, existing technology, and other intangible assets. Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. We identify our reporting units based upon our management reporting structure, beginning with our operating segments. We aggregate two or more components within an operating segment that have similar economic characteristics. We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among other, industry and market conditions, overall financial performance, and relevant entity-specific events. If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis. We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, we elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, we utilize an income-based approach to value our reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. We generally believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction. The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While we use the best available information to prepare our cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. We estimate the fair value of our indefinite-lived intangibles using the relief from royalty method. We believe the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
We establish reserves against amounts due fromcompleted our suppliers relatingrequired annual impairment tests of goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual impairment test (see Note 5 of the Notes to various priceConsolidated Financial Statements). No goodwill impairments were recorded in the fiscal years ended September 30, 2019 and rebate incentives, including deductions or billings taken against payments otherwise2017. No indefinite-lived intangible impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.
We perform a recoverability assessment of our long-lived assets when impairment indicators are present.
PharMEDium's long-lived assets were tested for recoverability in fiscal 2019 and 2018 due to them. These reserve estimates are established basedthe existence of impairment indicators. After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the judgmentterms of management after carefullya consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are acceptable. PharMEDium has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the statuslikelihood of higher operating and compliance costs. We believe that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
We updated our recoverability assessment of PharMEDium’s long-lived assets as of September 30, 2019. We concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
Our income tax expense, deferred tax assets and liabilities, and uncertain tax positions reflect management's assessment of estimated future taxes to be paid on items in the financial statements. Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities, as well as net operating loss and tax credit carryforwards for tax purposes.
We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain. Expiring carryforwards and the required valuation allowances are adjusted annually. After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.
We prepare and file tax returns based upon our interpretation of tax laws and regulations and record estimates based upon these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities. Inherent uncertainties exist in estimates of tax contingencies due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdictions' tax court systems. Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.
We believe that our estimates for the valuation allowances against deferred tax assets and the amount of benefits recognized in our financial statements for uncertain tax positions are appropriate based upon current outstanding claims, historical experience withfacts and circumstances. However, others applying reasonable judgment to the suppliers,same facts and circumstances could develop a different estimate and the specific incentive programs, and any other pertinent information available to us. We evaluateamount ultimately paid upon resolution of issues raised may differ from the amounts due from our suppliers on a continual basisaccrued.
The significant assumptions and adjust the reserve estimates when appropriate based on changes in factual circumstances. An increase or decrease of 0.1%described in the 2016 supplier reserve balances as a percentagepreceding paragraphs are important contributors to the ultimate effective tax rate in each year. If any of trade payables would result inour assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $9.7 million in the fiscal year ended September 30, 2019.
For a complete discussion on the impact of the 2017 Tax Act, refer to Note 4 of the Notes to Consolidated Financial Statements.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 75% of goods soldour inventories as of September 30, 2019 and 2018 has been determined using the LIFO method. If we had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. We recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively. We recorded LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by approximately $23.9 million. The ultimate outcome of any outstanding claimchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be different fromimpacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to our estimate.annual LIFO provision.
Loss Contingencies
In the ordinary course of business, we become involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought in some matters, and some matters may require years to resolve. We record a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency in the footnotes to our financial statements. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made.
Merchandise Inventories
Inventories Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13 of the Notes to Consolidated Financial Statements. Although we are stated atnot able to predict the loweroutcome or reasonably estimate a range of costpossible losses in these matters, an adverse judgment or market. Cost for approximately 79% and 80%negotiated resolution in any of our inventories at September 30, 2016 and 2015, respectively, has been determined using the last-in, first-out ("LIFO") method. If we had used the first-in, first-out ("FIFO") method of inventory valuation, which approximates current replacement cost, inventories wouldthese matters could have been approximately $1,624.8 million and $1,424.6 million higher than the amounts reported at September 30, 2016 and 2015, respectively. We recorded a LIFO charge of $200.2 million, $542.8 million, and $348.1 million in fiscal 2016, 2015, and 2014 respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict.
Equity Investments
We use the equity method of accounting for our investments in entities in which we have significant influence; generally, this represents an ownership interest of between 20% and 50%. Unrealized losses that are determined to be other-than-temporary impairment losses are recorded as a component of earnings in the period in which that determination is made. We recorded an impairment charge of $30.6 million in fiscal 2015 related to our minority ownership interest in a pharmaceutical wholesaler in Brazil. The impairment charge was basedmaterial adverse effect on our determination that the decline in the pharmaceutical wholesaler's stock price from the date on which the investment was made to September 30, 2015 was other-than-temporary. There were no impairment charges on equity investments in fiscal 2016 or 2014.
Business Combinations
The purchase priceresults of an acquired company, including the fair value of any contingent consideration, is allocated between tangible and intangible assets acquired and liabilities assumed from the acquired business based on their estimated fair values, with the residual of the purchase price recorded as goodwill. We engage third party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed. Such valuations require management to make significant judgments, estimates, and assumptions, especially with respect to intangible assets. Management makes estimates of fair value based upon assumptions it believes to be reasonable. These estimates are based on historical experience and information obtained from the management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain of the intangible assets include, but are not limited to: future expected cash flows from and economic lives of customer relationships, trade names, existing technology, and other intangible assets, and discount rates. Unanticipated events and circumstances may occur which may affect the accuracy or validity of such assumptions or estimates.
Goodwill and Intangible Assets
Goodwill and other intangible assets with indefinite lives, certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, we can elect to perform a qualitative analysis to determine if it is more likely than not that the fair values of its reporting units and indefinite lived intangible assets are less than the respective carrying values of those reporting units and indefinite lived intangible assets. We elected to bypass performing the qualitative analysis and went directly to performing the first step quantitative analysis of the goodwill and indefinite lived intangible asset impairment tests in the current year. We may elect to perform the qualitative analysis in future periods.
The first step in the quantitative process for the goodwill impairment test is to compare the carrying amount of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required and no impairment loss is recognized. If the carrying amount exceeds the fair value, then the second step must be completed, which involves allocating the fair value of the reporting unit to each asset and liability, with the excess being implied goodwill. An impairment loss occurs if the amount of the recorded goodwill exceeds the implied goodwill. We would be required to record any such impairment losses.
We identify our reporting units based on our management reporting structure, and our reporting units are the same as our operating segments. Generally, goodwill arises from acquisitions of specific operating companies and is assigned to the reporting unit in which a particular operating company resides.
We utilize an income-based approach to value the reporting units. The income-based approach relies on a discounted cash flow analysis to determine the fair value of each reporting unit, which considers forecasted cash flows discounted at an appropriate discount rate. We believe that market participants would use a discounted cash flow analysis to determine the fair value of its reporting units in a sale transaction. The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equity and debt, including a risk premium. While we use the best available information to prepare our cash flow and discount rate assumptions, actual futureoperations, consolidated financial position, cash flows or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.
The impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. We estimate the fair value of our indefinite-lived intangibles using the relief from royalty method. We believe the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such trademarks and trade names and not having to pay a royalty for their use.
We completed our required annual impairment tests relating to goodwill and other intangible assets with indefinite lives in the fourth quarter of fiscal 2016, 2015, and 2014, and determined that there were no impairments.
Share-Based Compensation
We utilize a binomial option pricing model to determine the fair value of share-based compensation expense, which involves the use of several assumptions, including expected term of the option, expected volatility, risk-free interest rate, dividend yield, and forfeiture rate. The expected term of options represents the period of time that the options granted are expected to be outstanding and is based on historical experience. Expected volatility is based on historical volatility of our Common Stock as well as other factors, such as implied volatility. The fair value of performance stock units is determined by the grant date market price of our Common Stock and the compensation expense associated with the non-vested performance stock units is dependent on our periodic assessment of the probability of the targets being achieved and our estimate of the number of shares that will ultimately be issued.
Income Taxes
Our income tax expense, deferred tax assets and liabilities, and uncertain tax positions reflect management's assessment of estimated future taxes to be paid on items in the financial statements. Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities, as well as net operating loss and tax credit carryforwards for tax purposes.
We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain. Expiring carryforwards and the required valuation allowances are adjusted annually. After application of the
valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.
We prepare and file tax returns based on our interpretation of tax laws and regulations and record estimates based on these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities. Inherent uncertainties exist in estimates of tax contingencies due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdictions' tax court systems. Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based on the technical merits of the position.
We believe that our estimates for the valuation allowances against deferred tax assets and the amount of benefits recognized in our financial statements for uncertain tax positions are appropriate based on current facts and circumstances. However, others applying reasonable judgment to the same facts and circumstances could develop a different estimate and the amount ultimately paid upon resolution of issues raised may differ from the amounts accrued.
The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year. If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income from continuing operations before income taxes would have caused income tax expense to change by $13.9 million in fiscal 2016.liquidity.
Liquidity and Capital Resources
The following table illustrates our debt structure atas of September 30, 2016,2019, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, and the overdraft facility (in thousands):facility:
| | | | | Outstanding Balance | | Additional Availability | |
| (in thousands) | | | Outstanding Balance | | Additional Availability |
| Fixed-Rate Debt: | | |
| | |
| | |
| | |
|
| $600,000, 1.15% senior notes due 2017 | | $ | 599,874 |
| | $ | — |
| |
| $400,000, 4.875% senior notes due 2019 | | 398,808 |
| | — |
| |
| $500,000, 3.50% senior notes due 2021 | | 499,639 |
| | — |
| | $ | 498,908 |
| | $ | — |
|
| $500,000, 3.40% senior notes due 2024 | | 498,919 |
| | — |
| | 497,744 |
| | — |
|
| $500,000, 3.25% senior notes due 2025 | | 497,771 |
| | — |
| | 496,311 |
| | — |
|
| $750,000, 3.45% senior notes due 2027 | | | 743,099 |
| | — |
|
| $500,000, 4.25% senior notes due 2045 | | 499,116 |
| | — |
| | 494,514 |
| | — |
|
| $500,000, 4.30% senior notes due 2047 | | | 492,488 |
| | — |
|
| Nonrecourse debt | | | 75,196 |
| | — |
|
| Total fixed-rate debt | | 2,994,127 |
| | — |
| | 3,298,260 |
| | — |
|
| | | | | | | | | |
| Variable-Rate Debt: | | |
| | |
| | |
| | |
|
| Revolving credit note | | — |
| | 75,000 |
| | — |
| | 75,000 |
|
| Receivables securitization facility due 2018 | | 500,000 |
| | 950,000 |
| |
| Term loans due in 2020 | | 700,000 |
| | — |
| |
| Multi-currency revolving credit facility due 2020 | | — |
| | 1,400,000 |
| |
| Overdraft facility due in 2021 (£30,000) | | 11,275 |
| | 27,656 |
| |
| Term loan due 2020 | | | 399,778 |
| | — |
|
| Overdraft facility due 2021 (£30,000) | | | 32,573 |
| | 4,314 |
|
| Receivables securitization facility due 2022 | | | 350,000 |
| | 1,100,000 |
|
| Multi-currency revolving credit facility due 2024 | | | — |
| | 1,400,000 |
|
| Nonrecourse debt | | | 92,281 |
| | — |
|
| Total variable-rate debt | | 1,211,275 |
| | 2,452,656 |
| | 874,632 |
| | 2,579,314 |
|
| Total debt | | $ | 4,205,402 |
| | $ | 2,452,656 |
| | $ | 4,172,892 |
| | $ | 2,579,314 |
|
Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, hashave provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock, and our hedging strategy (see below for further details).stock.
Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our Common Stock,common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.
As discussed in the Risk Factors and in Note 13 of the Notes to Consolidated Financial Statements, we are a party to discussions with the objective of reaching potential terms of a broad resolution of the remaining opioid-litigation and claims. Although we are not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on our financial position, cash flows or liquidity.
As of September 30, 20162019 and 2015,2018, our cash and cash equivalents held by foreign subsidiaries were $582.9$826.8 million and $266.3$842.5 million, respectively. We expect that the growth of our cashrespectively, and cash equivalents held by foreign subsidiaries willare generally
be based in U.S. dollar denominated holdings. AmountsOur position is that we are not permanently reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. In fiscal year ended September 30, 2019, we repatriated $350.0 million of cash held by foreign subsidiaries are generally subject to U.S. income taxation on repatriation to the U.S. We do not have any plans to repatriate these amounts to the U.S., as our foreign subsidiaries intend to indefinitely reinvest this cash in foreign investments or foreign operations.use for general corporate purposes.
We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, canmay require the use of our credit facilities to fund short-term capital needs. Our cash balance in the fiscal years ended September 30, 20162019 and 20152018 needed to be supplemented by intra-period credit facility borrowings to cover short-term working capital needs. Our cash balance in the fiscal year ended September 30, 2016 also needed to be supplemented by intra-period credit facility borrowings to cover a portion of the purchase price of PharMEDium in advance of securing long-term financing. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 20162019 and 20152018 was $1,018.2$240.6 million and $15.9$1,508.2 million, respectively. We had $8,333.7$606.0 million, $111.1$25,115.3 million, and $17,584.5$9,324.7 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, respectively. Additionally,
In December 2017, we issued $750 million of 3.45% senior notes due December 15, 2027 (the "2027 Notes") and $500 million of 4.30% senior notes due December 15, 2047 ("the 2047 Notes"). The 2027 Notes were sold at 99.76% of the principal amount and have an effective yield of 3.48%. The 2047 Notes were sold at 99.51% of the principal amount and have an effective yield of 4.33%. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears and commenced on June 15, 2018.
We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018.
In the fiscal year ended September 30, 2016,2017, we borrowed $500.0repaid the $600 million of 1.15% senior notes that became due, and we repaid $150.0 million of amounts outstanding under our receivables securitization facility that we used to finance principal payments that we elected to make on the November 2015 Term Loan (seeLoans (defined below).
We have a $1.4 billion multi-currency senior unsecured revolving credit facility which was scheduled to expire in November 2020, (the "Multi-Currency("Multi-Currency Revolving Credit Facility") with a syndicate of lenders.lenders, which was scheduled to expire in October 2023. In November 2016,September 2019, we entered into an amendment with the syndicate of lenders to, among other things, extend the maturity date to November 2021.September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based onupon our debt rating and ranges from 6970 basis points to 110112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee atas of September 30, 2016)2019) and from 0 basis points to 1012.5 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based onupon our debt rating, ranging from 65 basis points to 1512.5 basis points, annually, of the total commitment (9 basis points atas of September 30, 2016)2019). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of excluded subsidiaries and asset sales, with which we arewere compliant with as of September 30, 2016.2019.
We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of September 30, 20162019 and 2015.2018.
We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2018.October 2021. In June 2016,September 2019, we amended the Receivables Securitization Facilityentered into an amendment to increase the borrowing capacity from $950 million to $1,450 million, and in November 2016, we extendedextend the maturity date to November 2019. In June 2016, we utilized the increased capacity to borrow $500 million on the Receivables Securitization Facility to finance $500 million of principal payments that we elected to make on the November 2015 Term Loan, as the Receivables Securitization Facility bears interest at a lower rate.September 2022. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based onupon prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we arewere compliant as of September 30, 2016.2019.
In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.
In connection with the Receivables Securitization Facility, ABDCAmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. ABDCAmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.
We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have ana £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short term,short-term, normal trading cycle fluctuations related to our MWI business. In February 2016 we amended the Overdraft Facility to
extend the maturity date from November 2016 to February 2021 and increase the borrowing capacity from £20 million to £30 million.
In February 2015,October 2018, we entered intorefinanced $400 million of outstanding term loans by issuing a $1.0 billionnew $400 million variable-rate term loan ("February 2015October 2018 Term Loan"), which matures in October 2020. Through September 30, 2016, we elected to make early principal payments of $700 million on the February 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The February 2015October 2018 Term Loan bears interest at a rate equal either to a base rate or LIBOR, plus a margin or a LIBOR rate, plus a margin.of 65 basis points. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over a LIBOR rate (100 basis points at September 30, 2015) and 0 to 25 basis points over a base rate. The February 2015October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company waswe were compliant as of September 30, 2016.2019
In November 2015, we entered into a $1.0 billion variable-rate term loan ("November 2015 Term Loan"),addition to the 2027 Notes and the 2047 Notes, both of which matureswere issued in 2020. Inthe fiscal 2016, we elected to make payments of $575 million on the November 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or a LIBOR rate, plus a margin. The margin is based on our public debt ratings of the Company and ranges from 75 basis points to 125 basis points over a LIBOR rate (100 basis points as ofyear ended September 30, 2016) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2016. We used the proceeds from the November 2015 Term Loan to finance a portion of the cash consideration paid in connection with the acquisition of PharMEDium.
We2018, we have $600 million of 1.15% senior notes due May 15, 2017 (the "2017 Notes"), $400 million of 4.875% senior notes due November 15, 2019 (the "2019 Notes"), $500 million of 3.50% senior notes due November 15, 2021, (the "2021 Notes"), and $500 million of 3.40% senior notes due May 15, 2024, (the "2024 Notes"$500 million of 3.25% senior notes due March 1, 2025, and $500 million of 4.25% senior notes due March 1, 2045 (collectively, the "Notes"). Interest on the 2017 Notes, the 2019 Notes, the 2021 Notes, and the 2024 Notes is payable semiannually in arrears.
In November 2012, our boardNonrecourse debt is comprised of directors authorized a program allowing usshort-term and long-term debt belonging to purchase up to $750 millionthe Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of our outstanding sharesthe loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2014, we purchased $363.0 million to complete our authorization under this program.Brazil subsidiaries.
In August 2013, our board of directors approved a program allowing us to purchase up to $750 million in shares of our Common Stock, subject to market conditions. During fiscal 2014 and 2015, we purchased $174.7 million and $300.8 million, respectively, under this share repurchase program. During the six months ended March 31, 2016, we purchased $100.0 million of our Common Stock under this program. In May 2016, our board of directors authorized a new share purchase program that, together with availability remaining under the existing August 2013 share repurchase program, permits us to purchase up to $750 million in shares of our Common Stock, subject to market conditions. In September 2016, we entered into an ASRAccelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400$400.0 million for shares of our Common Stock.common stock. The initial payment of $400$400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered additional shares to us. The number of shares ultimately received was based onupon the volume-weighted average price of our Common Stockcommon stock during the term of the ASR. We applied the $400$400.0 million ASR to the May 2016 share repurchase program. In addition toDuring the ASR,fiscal year ended September 30, 2017, we purchased $231.2an additional $118.8 million of our Common Stockcommon stock to complete our authorization under the May 2016 program. As of September 30, 2016, we had $118.8 million of availability remaining under the May 2016 repurchasethis program.
In March 2013, we and WBA entered into various agreements and arrangements pursuant to which subsidiaries of WBA were granted the right to purchase a minority equity position in us, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of our Common Stock in open market transactions (approximately 7% of our Common Stock on a fully diluted basis as of the date of issuance of the Warrants described below, assuming their exercise in full). In connection with these arrangements, wholly-owned subsidiaries of WBA were issued (a) warrants to purchase up to an aggregate of 22,696,912 shares of our Common Stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in MarchNovember 2016, (the "2016 Warrants"), and (b) warrants to purchase up to 22,696,912 shares of our Common Stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (the "2017 Warrants" and together with the 2016 Warrants, the "Warrants").
In June 2013, we commenced a hedging strategy by entering into a contract with a financial institution pursuant to which we executed a series of issuer capped call transactions ("Capped Calls"). The Capped Calls gave us the right to buy shares of our Common Stock subject to the Warrants at specified prices at maturity. This hedge transaction was completed in January 2014, and included the purchase of Capped Calls on a total of 27.2 million shares of our Common Stock for a total premium of $368.7 million.
Subsequently, we paid a premium of $100.0 million in January 2015 to increase the cap price on certain of the Capped Calls subject to the 2016 Warrants. The Capped Calls allowed us to acquire shares of our Common Stock at strike prices of $51.50 and $52.50 and have expiration dates ranging from February 2016 through October 2017. The Capped Calls permitted net share
settlement, which is limited by caps on the market price of our Common Stock. We accounted for the Capped Calls as equity contracts and therefore the above premiums were recorded as a reduction to paid-in capital.
In fiscal 2014 and 2015, we purchased $1,774.1 million of our Common Stock under special share repurchase programs to further mitigate the potentially dilutive effect of the Warrants and supplement our previously executed warrant hedging strategy.
In March 2015, we further supplemented our hedging strategy by entering into a contract with a financial institution pursuant to which we executed a series of issuer call options ("Call Options"). The Call Options gave us the right to buy shares of our Common Stock subject to the Warrants at specified prices between April 2015 and October 2015. In total, we purchased Call Options on six million shares of our Common Stock for a total premium of $80.0 million. We accounted for the Call Options as equity contracts and therefore, the above premium was recorded as a reduction to paid-in capital.
In September 2015, our board of directors authorized a new special share repurchase program allowing us to purchase up to $2.4$1.0 billion in shares of our Common Stock,common stock, subject to market conditions. During the fiscal year ended September 30, 2016,2017, we purchased $1,535.1$211.1 million under this share repurchase program. During the fiscal year ended September 30, 2018, we purchased $663.1 million of our Common Stockcommon stock under (allthis program, which included $24.0 million of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, we purchased $125.8 million of our common stock under the Call Options and Capped Calls)this program, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete our authorization under this program. We
In October 2018, our board of directors authorized a new share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, we had $740.9$461.1 million of availability remaining under this special share repurchase program asprogram.
In March 2016, the 2016 Warrants were exercised for $1,168.9 million in cash. In August 2016, the 2017 Warrants were amended so that they became exercisable in whole or in part during the six month period beginning in August 2016 at an exercise price of $52.50. In August 2016, the 2017 Warrants were exercised by WBA for $1,191.6 million in cash.
The earnings per share dilutive effect of the Warrants was fully mitigated by our hedging a portion of our obligation to deliver Common Stock with a financial institution and repurchasing additional shares of our Common Stock under the special share repurchase programs, as described above, for our own account over time.
Followingfollowing is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and financing obligations, and minimum payments on our other commitments at September 30, 2016 (in thousands):
|
| | | | | | | | | | | | | | | | | | | |
| Payments Due by Period | Debt, Including Interest Payments | | Operating Leases | | Financing Obligations 1 | | Other Commitments | | Total |
| Within 1 year | $ | 728,932 |
| | $ | 63,072 |
| | $ | 23,062 |
| | $ | 55,038 |
| | $ | 870,104 |
|
| 1-3 years | 715,222 |
| | 103,556 |
| | 47,450 |
| | 58,181 |
| | 924,409 |
|
| 4-5 years | 1,265,898 |
| | 71,067 |
| | 38,622 |
| | 19,318 |
| | 1,394,905 |
|
| After 5 years | 2,616,000 |
| | 77,916 |
| | 72,008 |
| | — |
| | 2,765,924 |
|
| Total | $ | 5,326,052 |
| | $ | 315,611 |
| | $ | 181,142 |
| | $ | 132,537 |
| | $ | 5,955,342 |
|
| | | | | | | | | | |
1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future noncash termination of the financing obligation.
|
We outsource to IBM Global Services a significant portion of our corporate and ABDC data center operations. The remaining commitment under our arrangement, which expires in January 2021, is approximately $112.8 million as of September 30, 2016,2019:
|
| | | | | | | | | | | | | | | | | | | | |
| Payments Due by Period (in thousands) | | Debt, Including Interest Payments | | Operating Leases | | Financing Obligations 1 | | Other Commitments | | Total |
| Within 1 year | | $ | 260,630 |
| | $ | 94,958 |
| | $ | 22,468 |
| | $ | 107,167 |
| | $ | 485,223 |
|
| 1-3 years | | 1,584,747 |
| | 156,226 |
| | 66,704 |
| | 64,575 |
| | 1,872,252 |
|
| 4-5 years | | 710,156 |
| | 119,884 |
| | 71,226 |
| | 56,023 |
| | 957,289 |
|
| After 5 years | | 3,291,377 |
| | 177,267 |
| | 270,410 |
| | 105,105 |
| | 3,844,159 |
|
| Total | | $ | 5,846,910 |
| | $ | 548,335 |
| | $ | 430,808 |
| | $ | 332,870 |
| | $ | 7,158,923 |
|
| | | | | | | | | | | |
1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation. |
The 2017 Tax Act requires a one-time transition tax to be recognized on historical foreign earnings and profits. We currently estimate that our liability related to the transition tax is $182.6 million, net of overpayments and tax credits, as of September 30, 2019, which $45.1 million represents ouris payable in installments over a six-year period commencing in January 2021. The transition tax commitment in fiscal 2017, and is included in "Other commitments"Commitments" in the above table.
Our liability for uncertain tax positions was $88.2$124.2 million (including interest and penalties) as of September 30, 2016.2019. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.
During the fiscal 2016,years ended September 30, 2019 and 2018, our operating activities provided $3,178.5cash of $2,344.0 million of cash in comparison to cash provided by operations of $3,922.2and $1,411.4 million, in the prior fiscal year.respectively. Cash provided by operations in the fiscal 2016year ended September 30, 2019 was principally the result of an increase in accounts payable of $3,011.5$1,561.0 million, non-cash items of $1,120.7 million, and net income of $1,427.9 million, and non-cash items of $722.4$854.1 million, offset in part by an increase in accounts receivable of $912.7 million and an increase in merchandise inventories of $1,107.3$1,241.9 million. The non-cash items were comprised primarily of $232.5 million of depreciation expense, $200.2 million of LIFO expense, and $159.6 million of amortization expense. The increase in accounts payable was primarily driven by the timing of scheduled payments to suppliers. Non-cash items were comprised primarily of a $570 million impairment of PharMEDium's long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements), $321.1 million of depreciation expense, and $176.4 million of amortization expense. The increase in merchandise inventoriesaccounts receivable was the result of our revenue growth and the timing of payments tofrom our suppliers. Accounts receivable and merchandise inventories increased as a result of our overall revenue growth.
customers.
Deterioration inof general economic conditions, among other factors, could adversely affect the amountnumber of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers. In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms. Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.
We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon an annual average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.
|
| | | | | | |
| | | Fiscal year ended September 30, |
| | | 2016 | | 2015 | | 2014 |
| Days sales outstanding | | 21.6 | | 20.0 | | 19.8 |
| Days inventory on-hand | | 30.0 | | 29.5 | | 28.1 |
| Days payable outstanding | | 56.9 | | 51.9 | | 45.3 |
The increase in days payable outstanding from fiscal 2015 to fiscal 2016 has benefited from the increase in purchases of merchandise inventories from certain pharmaceutical manufacturers with longer payment terms. |
| | | | | | |
| | | Fiscal Year Ended September 30, |
| | | 2019 | | 2018 | | 2017 |
| Days sales outstanding | | 25.2 | | 24.5 | | 23.8 |
| Days inventory on hand | | 28.4 | | 29.9 | | 30.1 |
| Days payable outstanding | | 57.6 | | 56.7 | | 57.4 |
Our cash flows from operating activities can vary significantly from period to period based onupon fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. We expect our days sales outstanding to increase in fiscal 2017 as a result of a gradual change in payment terms with our largest customer. Operating cash flows during the fiscal 2016year ended September 30, 2019 included $123.5$167.4 million of interest payments and $17.5$117.7 million of income tax payments, net of refunds. Operating cash flows during the fiscal 2015year ended September 30, 2018 included $91.5$162.1 million of interest payments and $299.6$104.0 million of income tax payments, net of refunds. Operating cash flows during the fiscal year ended September 30, 2017 included $125.3 million of interest payments and $105.0 million of income tax payments, net of refunds.
During the fiscal 2015,years ended September 30, 2018 and 2017, our operating activities provided $3,922.2cash of $1,411.4 million of cash in comparison to cash provided by operations of $1,464.7and $1,504.1 million, in fiscal 2014.respectively. Cash provided by operations in the fiscal 2015year ended September 30, 2018 was principally the result of net income of $1,615.9 million, an increase in accounts payable of $4,957.2$859.0 million, and non-cash itemsan increase in income taxes payable of $1,833.4$209.9 million, offset in part by an increase in accounts receivable of $1,478.8 million, an increase in merchandise inventories of $1,379.2$657.8 million and loss from continuing operationsa decrease in accrued expenses and other liabilities of $138.2$551.1 million. The non-cash items were comprised primarily of $912.7 million of Warrants expense and $542.8 million of LIFO expense. The increase in accounts payable was primarily driven by the timing of scheduled payments to our suppliers. The increase in merchandise inventoriesincome taxes payable was primarily driven by a one-time transition tax on historical foreign earnings and profits through December 31, 2017 in connection with tax reform. The decrease in accrued expenses was primarily driven by the payment of a legal settlement of $625.0 million, plus interest (see Note 13 of the Notes to the Consolidated Financial Statements). The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers. Non-cash items were comprised primarily of a $795.5 million deferred income tax benefit, $318.5 million of depreciation expense, and $191.6 million of amortization expense. The deferred income tax benefit was primarily the result of applying a lower U.S. federal income tax rate to our suppliers. Accounts receivable increased from September 30, 2014, reflecting our increased revenue volume, including additional sales to WBA. We also increased our merchandise inventories at September 30, 2015 to support increasenet deferred tax liabilities as of December 31, 2017 in business volume.connection with tax reform.
Capital expenditures in the fiscal 2016, 2015,years ended September 30, 2019, 2018, and 20142017 were $464.6$310.2 million, $231.6$336.4 million, and $264.5$466.4 million, respectively. Significant capital expenditures in fiscal 20162019 included costs associated with expanding distribution capacity,the construction of a new support facility and technology initiatives, including costs related to the development of track-and-traceenhancing and upgrading our information technology and the expansion of support facilities.systems. Significant capital expenditures in fiscal 20152018 and 2017 included technology initiatives, including costs related to the further development ofenhancing and upgrading our primary ERP system,information technology systems and costs associated with building our new nationalexpanding distribution center, and expansion of support facilities. Significant capital expenditures in fiscal 2014 included infrastructure and technology-related costs to on-board the incremental WBA distribution volume, costs associated with building our new national distribution center, and other technology initiatives, including costs related to the further development of our primary ERP system.capacity.
We currently expect to spend approximately $500$400 million for capital expenditures during fiscal 2017.2020. Larger 20172020 capital expenditures will include buildingcosts related to new distribution centers and/or replacing or upgrading existing distribution centers, information system investmentsfacilities and various technology initiatives.
We acquired businesses to support a data center consolidation, track-and-trace technology, and a new operating systemour animal health business for certain business units.
Cost of acquired companies, net of cash acquired, in fiscal 2016 was $2,731.4$54.0 million and primarily consisted of our PharMEDium acquisition. Cost of$70.0 million in the fiscal years ended September 30, 2019 and 2018, respectively. In the fiscal year ended September 30, 2018, we acquired companies, net of cash acquired, in fiscal 2015 was $2,633.4 million and primarily consisted of our MWI acquisition. In fiscal 2014, we invested $117.8 million to acquire a minority ownership interest in aH.D. Smith, the largest independent pharmaceutical wholesaler in the United States, for $815.0 million. In addition, we made incremental investments in Brazil and to form a specialty joint venturetotaling $78.1 million. The cash used for the above investments was offset by $179.6 million of cash consolidated in connection with the same entity. InBrazil investments (see Note 2 of the Notes to Consolidated Financial Statements).
Net cash used in financing activities in the fiscal 2016, we invested an additional $17.2year ended September 30, 2019 principally resulted from $674.0 million in that same pharmaceutical wholesalerpurchases of our common stock, and specialty joint venture.$339.0 million in cash dividends paid on our common stock.
Net cash used in financing activities in the fiscal year ended September 30, 2018 principally included the early retirement of the $400 million of 4.875% senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.
Net cash provided by financing activities in the fiscal 2016year ended September 30, 2017 primarily included $2,360.5the $600.0 million received upon the exerciserepayment of the Warrants by WBA and $1.0 billion of borrowings under our November 2015 Term Loan. We used a portion of the proceeds from the exercise of the Warrants to purchase our Common Stock under our special share repurchase program. In fiscal 2016, 2015, and 2014, we paid $2,266.31.15% senior notes, $329.9 million $1,859.1 million, and $753.9 million, respectively, forin purchases of our Common Stock. We used the proceeds from the November 2015 Term Loan to fund a portion ofcommon stock, and $320.3 million in cash dividends paid on our November 2015 acquisition of PharMEDium.
Net cash provided by financing activities in fiscal 2015 included $1.0 billion of borrowings under our February 2015 term loan and $996.4 million of proceeds related to the February 2015 issuance of our 2025 Notes and 2045 Notes. We used the proceeds from these financing activities to fund a portion of our February 2015 acquisition of MWI.
In fiscal 2015 and 2014, we paid $180.0 million and $211.4 million, respectively, to purchase or amend Capped Calls and Call Options, to hedge the potential dilution associated with the Warrants upon their exercise.common stock.
Our board of directors approved the following quarterly dividend increases:
| | Dividend Increases | | | | Per Share | | | | Per Share | | |
| Date | | New Rate | | Old Rate | | % Increase | | New Rate | | Old Rate | | % Increase |
| November 2013 | | $0.235 | | $0.210 | | 12% | |
| November 2014 | | $0.290 | | $0.235 | | 23% | |
| November 2015 | | $0.340 | | $0.290 | | 17% | |
| November 2016 | | $0.365 | | $0.340 | | 7% | | $0.365 | | $0.340 | | 7% |
| November 2017 | | | $0.380 | | $0.365 | | 4% |
| November 2018 | | | $0.400 | | $0.380 | | 5% |
We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.
Market Risk
We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. In fiscal 2016, we used a $1.0We had $0.9 billion variable rate term loan to finance a portion of the PharMEDium acquisition price. We also borrowed $500 million from the Receivables Securitization Facility to finance $500 millionvariable-rate debt outstanding as of principal payments that we elected to make on the November 2015 Term Loan.September 30, 2019. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect atas of September 30, 2016.2019.
We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $2,741.8$3,374.2 million in cash and cash equivalents atas of September 30, 2016.2019. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.
We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. Revenue from our foreign operations is less than oneapproximately two percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of September 30, 2016, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$37.4 million outstanding note.
Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "will," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changechanges in circumstances.circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical market growth rates; substantial defaults in payment,supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material reduction in purchases by or the loss, bankruptcy or insolvencyadverse resolution of a major customer; changes to the customer or supplier mix;pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; the disruption of AmerisourceBergen's cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and AmerisourceBergen,the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global sourcinggeneric purchasing services arrangement; changes in the United States healthcare and regulatory environment, including changestax laws or legislative initiatives that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regardingadversely affect the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances andCompany’s tax positions and/or the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuitsCompany’s tax liabilities or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals;challenges to the Company’s tax positions; regulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business or the related consent decree; suspension of production of CSPs, including continued suspension at PharMEDium's Memphis facility; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations or PharMEDium), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of PharMEDium, or the inability to capture all of the anticipated synergies related thereto; regulatory actionthereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company’s cash flow and ability to return value to its stockholders in connectionaccordance with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business;its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; interest rate and foreign currency exchange rate fluctuations; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen's tax positions and/or AmerisourceBergen's tax liabilities or adverse resolution of challenges to AmerisourceBergen's tax positions; natural disasters or other unexpected events that affect AmerisourceBergen's operations; the impairment of goodwill or other intangible assets, resulting in a charge to earnings; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen'sthe Company’s business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this MD&A,Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act.The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company's most significant market risks are the effects of changing interest rates, foreign currency risk, and the changes in the price of the Company's common stock. See discussion on page 41 under the heading "Market Risk," which is incorporated by reference herein.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Stockholders and Board of Directors and Stockholders of AmerisourceBergen Corporation
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of AmerisourceBergen Corporation and subsidiaries (the Company) as of September 30, 20162019 and 2015, and2018, the related consolidated statements of operations, comprehensive income, changes in stockholders’stockholders' equity, and cash flows for each of the three years in the period ended September 30, 2016. Our audits also included2019, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the "consolidated financial statements"). TheseIn our opinion, the consolidated financial statements and schedule arepresent fairly, in all material respects, the responsibilityfinancial position of the Company’s management. Our responsibility is to express an opinion on these financial statementsCompany at September 30, 2019 and schedule based on our audits.
2018, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2019, in conformity with U.S. generally accepted accounting principles.
We conducted our auditsalso have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States). (PCAOB), the Company's internal control over financial reporting as of September 30, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated November 19, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includesmisstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supportingregarding the amounts and disclosures in the financial statements. An auditOur audits also includes assessingincluded evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
In our opinion,The critical audit matters communicated below are matters arising from the current period audit of the financial statements referredthat were communicated or required to above present fairly,be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in all material respects, the consolidated financial position of AmerisourceBergen Corporation and subsidiaries at September 30, 2016 and 2015, and the consolidated results of their operations and their cash flows for each of the three years in the period ended September 30, 2016, in conformity with U.S. generally accepted accounting principles. Also, inany way our opinion on the related financial statement schedule, when considered in relation to the basicconsolidated financial statements, taken as a whole, presents fairly in all material respectsand we are not, by communicating the information set forth therein.critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
We also have audited, in accordance with the standards |
| |
| Legal Contingencies |
| Description of the Matter | As discussed in Note 13 of the consolidated financial statements, the Company is involved in lawsuits, administrative proceedings, government subpoenas, government investigations and other disputes. The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. The Company also performs an assessment of the materiality of legal contingencies where a loss is either reasonably possible or it is reasonably possible that an exposure to loss exists in excess of the amount accrued. If it is reasonably possible that such a loss or an additional loss may have been incurred and the effect on the consolidated financial statements is material, the Company discloses the nature of the loss contingency and an estimate of the possible loss or range of loss or a statement that such an estimate cannot be made within the notes to the consolidated financial statements. |
| |
|
| |
| For example, as of September 30, 2019, a significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiary AmerisourceBergen Drug Corporation ("ABDC")), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications ("opioid matters"). Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by other parties. While the Company is currently engaged in negotiations with plaintiffs’ representatives regarding a potential settlement framework, it continues to litigate the opioid matters. The Company has not recognized a liability related to the potential framework as of September 30, 2019. |
| |
| Auditing management's determination of whether a loss for a legal contingency is probable and reasonably estimable, reasonably possible or remote, and the related disclosures, is highly subjective and requires significant judgment. For instance, auditing management's judgments related to the opioid matters was challenging due to the significant judgment applied in determining the likelihood of resolution of the opioid matters through settlement or litigation given the current status of negotiations with plaintiffs' representatives and the complexity and uncertainty associated with any potential settlement. |
| |
How We Addressed the Matter in Our Audit
| We tested the Company's internal controls that address the risks of material misstatement related to the completeness, valuation, presentation and disclosure of legal contingencies. This included testing controls related to the Company's process for identification, recognition, measurement and disclosure of legal contingencies, including the opioid matters. For example, we tested controls over management’s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures. We also tested controls over management's assessment of the likelihood of the resolution of the opioid matters through settlement or litigation. |
| |
| To test the Company's legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company's analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations, and obtaining written representations from executives of the Company. We also compared the Company's assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company's assessment for outstanding legal contingencies at the balance sheet date. For example, for the opioid matters, we considered the litigation, claims or assessments, progress of the respective legal cases, communications with plaintiffs and the experience of other similar entities when evaluating the Company's conclusions. |
| |
| For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies. We assessed the Company’s estimate of the amount of the loss, for both contingencies that are probable and reasonably possible, through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external legal counsel, inspection of court rulings, and inspection of settlement agreements. We also obtained written representations from executives of the Company. |
| |
|
| |
| Goodwill - Identification of Reporting Units |
| Description of the Matter | The Company tests goodwill for impairment at the level of reporting referred to as a reporting unit. As discussed in Note 1 of the consolidated financial statements, the Company identified its reporting units based upon its management reporting structure. Goodwill arising from acquisitions has been assigned to the reporting unit or units as of the acquisition date that are expected to benefit from the synergies of the combination. When identifying its reporting units, the Company has aggregated two or more components within an operating segment that have similar economic characteristics. |
| |
| The determination of whether two or more components within an operating segment have similar economic characteristics requires the Company to evaluate the characteristics of the respective components, which include the similarity of long-term gross margins, the nature of the products and services, the nature of the production processes, the type or class of customer, the methods used to distribute products or provide their services, and the nature of the regulatory environment. However, not each of these factors must be met for two components to be considered economically similar, and the considerations are not limited to these factors. |
| |
| Auditing management's determination of reporting units is highly subjective and significant judgment is involved when evaluating whether two or more components have similar economic characteristics for purposes of aggregation into a single reporting unit. A change in the judgment used in the determination of a reporting unit could result in goodwill impairment. |
| |
| How We Addressed the Matter in Our Audit | We tested the Company's internal controls related to management's identification of its reporting units. For example, we tested controls over management's review of documentation of the criteria assessed when determining whether one or more components within an operating segment have similar economic characteristics. |
| |
| To test the Company's aggregation of two or more components within an operating segment into a single reporting unit, our substantive audit procedures included, among others, evaluating whether the aggregated components have similar economic characteristics. As part of our evaluation, we considered (i) the similarity of long-term gross margins of the aggregated components; (ii) the similarity of the nature of the regulatory environments of the aggregated components; (iii) the similarity of the products and services of the aggregated components; (iv) the similarity of the types or classes of customer of the aggregated components, and (v) the methods used to distribute products or provide services of the aggregated components. We corroborated the Company’s assessment of aggregation of components by reviewing reports used by segment management, including the financial performance of the respective components, to assess the aggregation criteria. |
| |
| PharMEDium long-lived asset impairment |
Description of the Matter
| As discussed in Note 1 of the consolidated financial statements, the Company recognized an impairment loss on PharMEDium's long-lived assets. The continued suspension of production activities at PharMEDium’s compounding facility in Memphis, Tennessee, and further negotiations with the FDA and DOJ regarding a potential consent decree resulted in the Company revising its long-range plan and identifying an impairment indicator of the asset group. At March 31, 2019, the Company evaluated the PharMEDium long-lived assets for recoverability utilizing undiscounted cash flows that were based on the weighted average of multiple strategic alternatives and determined that the assets were not recoverable and were therefore impaired. As a result, the Company recognized a $570 million impairment loss, which represented the amount by which the carrying value exceeded the estimated fair value of these assets. |
| |
| Auditing the Company's impairment loss on PharMEDium's long-lived assets was complex due to the significant estimation uncertainty in determining the fair value of the PharMEDium asset group. Significant assumptions used in the Company's fair value estimate of the PharMEDium asset group included (i) the discount rate; (ii) the period in which PharMEDium will resume production at or near capacity; (iii) estimated revenue growth rates; (iv) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs; and (v) future economic conditions and demand. Each of these assumptions was forward-looking and could have been affected by the outcome of the negotiations with the FDA and DOJ, the provisions of the final consent decree, the results of the third-party audits, and future economic conditions and demand. |
|
| |
How We Addressed the Matter in Our Audit
| We tested the Company's internal controls over the process for the recognition and measurement of the long-lived asset impairment. For example, we tested controls over management’s review of the forecasted cash flows and their review of the significant assumptions and other inputs used in the fair value measurement, such as the discount rate. |
| |
| To test the PharMEDium long-lived asset impairment loss, our substantive audit procedures included, among others, the performance of a sensitivity analysis of the assumptions to evaluate the change in the fair value of the PharMEDium asset group resulting from changes in the assumptions and therefore identify the assumptions that have the most significant impact on the fair value calculation. We involved valuation specialists to assist with our evaluation of the methodology used by the Company and significant assumptions used in the fair value measurement of the PharMEDium asset group, including the evaluation of the reasonableness of the discount rate selected by the Company. We compared the forecasted cash flows to business plans, current industry, market and economic trends, and information from discussions with management and external legal counsel about the status of negotiations with the FDA and DOJ, reviewed the provisions of the final consent decree and compared previous forecasts to actual results to assess the forecasted cash flows utilized in the fair value measurement. |
| |
We have served as the Company's auditor since 1985.
Philadelphia, Pennsylvania
November 22, 201619, 2019
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| | | | | | | | September 30, |
| (in thousands, except share and per share data) | | September 30, 2016 | | September 30, 2015 | | 2019 | | 2018 |
| | | | | (As Revised) | |
| ASSETS | | |
| | |
| | |
| | |
|
| Current assets: | | |
| | |
| | |
| | |
|
| Cash and cash equivalents | | $ | 2,741,832 |
| | $ | 2,167,442 |
| | $ | 3,374,194 |
| | $ | 2,492,516 |
|
Accounts receivable, less allowances for returns and doubtful accounts: 2016 — $905,345; 2015 — $899,764 | | 9,175,876 |
| | 8,222,951 |
| |
| Merchandise inventories | | 10,723,920 |
| | 9,755,094 |
| |
Accounts receivable, less allowances for returns and doubtful accounts: 2019 — $1,222,906; 2018 — $1,036,333 | | | 12,386,879 |
| | 11,314,226 |
|
| Inventories (Note 1) | | | 11,060,254 |
| | 11,918,508 |
|
| Right to recover asset (Note 1) | | | 1,147,483 |
| | — |
|
| Prepaid expenses and other | | 210,219 |
| | 189,001 |
| | 163,244 |
| | 169,122 |
|
| Total current assets | | 22,851,847 |
| | 20,334,488 |
| | 28,132,054 |
| | 25,894,372 |
|
| | | | | | | | | |
| Property and equipment, at cost: | | |
| | |
| | |
| | |
|
| Land | | 40,290 |
| | 39,499 |
| | 44,142 |
| | 39,875 |
|
| Buildings and improvements | | 859,148 |
| | 653,542 |
| | 942,129 |
| | 1,086,909 |
|
| Machinery, equipment, and other | | 1,717,298 |
| | 1,449,545 |
| | 2,362,869 |
| | 2,281,124 |
|
| Total property and equipment | | 2,616,736 |
| | 2,142,586 |
| | 3,349,140 |
| | 3,407,908 |
|
| Less accumulated depreciation | | (1,086,054 | ) | | (950,076 | ) | | (1,578,624 | ) | | (1,515,484 | ) |
| Property and equipment, net | | 1,530,682 |
| | 1,192,510 |
| | 1,770,516 |
| | 1,892,424 |
|
| | | | | | | | | |
| Goodwill | | 5,991,497 |
| | 4,144,391 |
| | 6,705,507 |
| | 6,664,272 |
|
| Other intangible assets | | 2,967,849 |
| | 1,993,119 |
| | 2,294,836 |
| | 2,947,828 |
|
| Other assets | | 314,325 |
| | 298,474 |
| | 269,067 |
| | 270,942 |
|
| | | | | | | | | |
| TOTAL ASSETS | | $ | 33,656,200 |
| | $ | 27,962,982 |
| | $ | 39,171,980 |
| | $ | 37,669,838 |
|
| | | | | | | | | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| | |
| | |
| | |
|
| | | | | | | | | |
| Current liabilities: | | |
| | |
| | |
| | |
|
| Accounts payable | | $ | 23,926,320 |
| | $ | 20,886,439 |
| | $ | 28,385,074 |
| | $ | 26,836,873 |
|
| Accrued expenses and other | | 743,839 |
| | 691,788 |
| | 1,057,208 |
| | 881,157 |
|
| Short-term debt | | 611,149 |
| | — |
| | 139,012 |
| | 151,657 |
|
| Total current liabilities | | 25,281,308 |
| | 21,578,227 |
| | 29,581,294 |
| | 27,869,687 |
|
| | | | | | | | | |
| Long-term debt | | 3,594,253 |
| | 3,493,048 |
| | 4,033,880 |
| | 4,158,532 |
|
| Long-term financing obligation | | 275,991 |
| | 246,177 |
| | 320,518 |
| | 352,296 |
|
| Accrued income taxes | | | 284,075 |
| | 299,600 |
|
| Deferred income taxes | | 2,214,774 |
| | 1,944,240 |
| | 1,860,195 |
| | 1,829,410 |
|
| Other liabilities | | 160,470 |
| | 84,904 |
| | 98,812 |
| | 110,352 |
|
| | | | | | |
| Commitments and contingencies (Note 13) | | |
|
| |
|
|
| Stockholders' equity: | | |
| | |
| | |
| | |
|
Common stock, $0.01 par value — authorized, issued, and outstanding: 600,000,000 shares, 277,753,762 shares and 220,050,502 shares at September 30, 2016, respectively, and 600,000,000 shares, 274,991,824 shares and 206,891,873 shares at September 30, 2015, respectively | | 2,778 |
| | 2,750 |
| |
Common stock, $0.01 par value — authorized, issued, and outstanding: 2019 — 600,000,000 shares, 285,295,170 shares and 206,760,654 shares; 2018 — 600,000,000 shares, 283,588,463 shares and 213,217,882 shares | | | 2,853 |
| | 2,836 |
|
| Additional paid-in capital | | 4,333,001 |
| | 3,736,477 |
| | 4,850,142 |
| | 4,715,473 |
|
| Retained earnings | | 2,303,941 |
| | 1,164,489 |
| | 4,235,491 |
| | 3,720,582 |
|
| Accumulated other comprehensive loss | | (114,308 | ) | | (136,333 | ) | | (111,965 | ) | | (79,253 | ) |
| Treasury stock, at cost: 2016 — 57,703,260 shares; 2015 — 68,099,951 shares | | (4,396,008 | ) | | (4,150,997 | ) | |
| Total stockholders' equity | | 2,129,404 |
| | 616,386 |
| |
| Treasury stock, at cost: 2019 — 78,534,516 shares; 2018 — 70,370,581 shares | | | (6,097,604 | ) | | (5,426,814 | ) |
| Total AmerisourceBergen Corporation stockholders' equity | | | 2,878,917 |
| | 2,932,824 |
|
| Noncontrolling interest | | | 114,289 |
| | 117,137 |
|
| Total equity | | | 2,993,206 |
| | 3,049,961 |
|
| | | | | | |
|
| |
|
|
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | | $ | 33,656,200 |
| | $ | 27,962,982 |
| | $ | 39,171,980 |
| | $ | 37,669,838 |
|
See notes to consolidated financial statements.
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
| | | | | Fiscal Year Ended September 30, | | Fiscal Year Ended September 30, |
| (in thousands, except per share data) | | 2016 | | 2015 | | 2014 | | 2019 | | 2018 | | 2017 |
| | | | | (As Revised) | | (As Revised) | |
| Revenue | | $ | 146,849,686 |
| | $ | 135,961,803 |
| | $ | 119,569,127 |
| | $ | 179,589,121 |
| | $ | 167,939,635 |
| | $ | 153,143,826 |
|
| Cost of goods sold | | 142,577,080 |
| | 132,432,490 |
| | 116,586,761 |
| | 174,450,809 |
| | 163,327,318 |
| | 148,597,824 |
|
| Gross profit | | 4,272,606 |
| | 3,529,313 |
| | 2,982,366 |
| | 5,138,312 |
| | 4,612,317 |
| | 4,546,002 |
|
| Operating expenses: | | |
| | |
| | |
| | |
| | |
| | |
|
| Distribution, selling, and administrative | | 2,091,237 |
| | 1,907,840 |
| | 1,580,664 |
| | 2,663,508 |
| | 2,460,301 |
| | 2,128,730 |
|
| Depreciation | | 212,242 |
| | 192,144 |
| | 162,718 |
| | 294,965 |
| | 283,971 |
| | 237,100 |
|
| Amortization | | 152,493 |
| | 56,491 |
| | 25,962 |
| | 167,442 |
| | 181,156 |
| | 160,503 |
|
| Warrants | | 140,342 |
| | 912,724 |
| | 422,739 |
| |
| Employee severance, litigation, and other | | 102,911 |
| | 37,894 |
| | 8,192 |
| | 330,474 |
| | 183,520 |
| | 959,327 |
|
| Pension settlement | | 47,607 |
| | — |
| | — |
| |
| Goodwill impairment | | | — |
| | 59,684 |
| | — |
|
| Impairment of long-lived assets (Note 1) | | | 570,000 |
| | — |
| | — |
|
| Operating income | | 1,525,774 |
| | 422,220 |
| | 782,091 |
| | 1,111,923 |
| | 1,443,685 |
| | 1,060,342 |
|
| Other (income) loss | | (5,048 | ) | | 13,598 |
| | (4,360 | ) | | (12,952 | ) | | 25,469 |
| | (2,730 | ) |
| Impairment charge on equity investment | | — |
| | 30,622 |
| | — |
| |
| Interest expense, net | | 139,912 |
| | 109,036 |
| | 83,634 |
| | 157,769 |
| | 174,699 |
| | 145,185 |
|
| Loss on consolidation of equity investments | | | — |
| | 42,328 |
| | — |
|
| Loss on early retirement of debt | | — |
| | — |
| | 32,954 |
| | — |
| | 23,766 |
| | — |
|
| Income from continuing operations before income taxes | | 1,390,910 |
| | 268,964 |
| | 669,863 |
| |
| Income tax (benefit) expense | | (37,019 | ) | | 407,129 |
| | 388,087 |
| |
| Income (loss) from continuing operations | | 1,427,929 |
| | (138,165 | ) | | 281,776 |
| |
| Loss from discontinued operations | | — |
| | — |
| | (7,546 | ) | |
| Net income (loss) | | $ | 1,427,929 |
| | $ | (138,165 | ) | | $ | 274,230 |
| |
| Income before income taxes | | | 967,106 |
| | 1,177,423 |
| | 917,887 |
|
| Income tax expense (benefit) | | | 112,971 |
| | (438,469 | ) | | 553,403 |
|
| Net income | | | 854,135 |
| | 1,615,892 |
| | 364,484 |
|
| Net loss attributable to noncontrolling interest | | | 1,230 |
| | 42,513 |
| | — |
|
| Net income attributable to AmerisourceBergen Corporation | | | $ | 855,365 |
| | $ | 1,658,405 |
| | $ | 364,484 |
|
| | | | | | | | | | | | | |
| Earnings per share: | | |
| | |
| | |
| | |
| | |
| | |
|
| Basic earnings per share: | | |
| | |
| | |
| |
| Continuing operations | | $ | 6.73 |
| | $ | (0.63 | ) | | $ | 1.24 |
| |
| Discontinued operations | | — |
| | — |
| | (0.03 | ) | |
| Total | | $ | 6.73 |
| | $ | (0.63 | ) | | $ | 1.21 |
| |
| | | | | | | | |
| Diluted earnings per share: | | |
| | |
| | |
| |
| Continuing operations | | $ | 6.32 |
| | $ | (0.63 | ) | | $ | 1.20 |
| |
| Discontinued operations | | — |
| | — |
| | (0.03 | ) | |
| Rounding | | — |
| | — |
| | (0.01 | ) | |
| Total | | $ | 6.32 |
| | $ | (0.63 | ) | | $ | 1.16 |
| |
| Basic | | | $ | 4.07 |
| | $ | 7.61 |
| | $ | 1.67 |
|
| Diluted | | | $ | 4.04 |
| | $ | 7.53 |
| | $ | 1.64 |
|
| | | | | | | | | | | | | |
| Weighted average common shares outstanding: | | |
| | |
| | |
| | |
| | |
| | |
|
| Basic | | 212,206 |
| | 217,786 |
| | 227,367 |
| | 210,165 |
| | 217,872 |
| | 218,375 |
|
| Diluted | | 225,959 |
| | 217,786 |
| | 235,405 |
| | 211,840 |
| | 220,336 |
| | 221,602 |
|
See notes to consolidated financial statements.
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2016 | | 2015 | | 2014 |
| | | | | (As Revised) | | (As Revised) |
| Net income (loss) | | $ | 1,427,929 |
| | $ | (138,165 | ) | | $ | 274,230 |
|
| Other comprehensive income (loss): | | |
| | |
| | |
|
| Net change in foreign currency translation adjustments | | (9,311 | ) | | (84,142 | ) | | (18,544 | ) |
| Benefit plan funded status adjustments net of tax of $333, $1,055, and $1,361, respectively | | (562 | ) | | (4,607 | ) | | 2,400 |
|
| Pension plan adjustment, net of tax of $19,054 | | 31,538 |
| | — |
| | — |
|
| Other | | 360 |
| | 4,462 |
| | (419 | ) |
| Total other comprehensive income (loss) | | 22,025 |
| | (84,287 | ) | | (16,563 | ) |
| Total comprehensive income (loss) | | $ | 1,449,954 |
| | $ | (222,452 | ) | | $ | 257,667 |
|
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Net income | | $ | 854,135 |
| | $ | 1,615,892 |
| | $ | 364,484 |
|
| Other comprehensive (loss) income: | | |
| | |
| | |
|
| Foreign currency translation adjustments | | (32,957 | ) | | (36,904 | ) | | 16,540 |
|
| Loss on consolidation of equity investments | | — |
| | 45,941 |
| | — |
|
| Other | | (271 | ) | | (756 | ) | | 1,918 |
|
| Total other comprehensive (loss) income | | (33,228 | ) | | 8,281 |
| | 18,458 |
|
| Total comprehensive income | | 820,907 |
| | 1,624,173 |
| | 382,942 |
|
| Comprehensive loss attributable to noncontrolling interest | | 1,746 |
| | 50,829 |
| | — |
|
| Comprehensive income attributable to AmerisourceBergen Corporation | | $ | 822,653 |
| | $ | 1,675,002 |
| | $ | 382,942 |
|
See notes to consolidated financial statements.
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
| | | (in thousands, except per share data) | | Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Loss | | Treasury | | Total | | Common Stock | | Additional Paid-in Capital | | Retained Earnings | | Accumulated Other Comprehensive Loss | | Treasury Stock | | Non-controlling Interest | | Total |
| September 30, 2013 (As Revised) | | $ | 2,678 |
| | $ | 2,360,992 |
| | $ | 1,496,812 |
| | $ | (35,483 | ) | | $ | (1,516,856 | ) | | $ | 2,308,143 |
| |
| Net income (As Revised) | | |
| | |
| | 274,230 |
| | |
| | |
| | 274,230 |
| |
| Other comprehensive loss | | |
| | |
| | |
| | (16,563 | ) | | |
| | (16,563 | ) | |
| Cash dividends, $0.94 per share | | |
| | |
| | (214,469 | ) | | |
| | |
| | (214,469 | ) | |
| September 30, 2016 | | | $ | 2,778 |
| | $ | 4,333,001 |
| | $ | 2,303,941 |
| | $ | (114,308 | ) | | $ | (4,396,008 | ) | | $ | — |
| | $ | 2,129,404 |
|
| Adoption of ASU 2016-09 (see Note 1) | | | — |
| | — |
| | 47,063 |
| | — |
| | — |
| | — |
| | 47,063 |
|
| Net income | | | — |
| | — |
| | 364,484 |
| | — |
| | — |
| | — |
| | 364,484 |
|
| Other comprehensive income | | | — |
| | — |
| | — |
| | 18,458 |
| | — |
| | — |
| | 18,458 |
|
| Cash dividends, $1.46 per share | | | — |
| | — |
| | (320,270 | ) | | — |
| | — |
| | — |
| | (320,270 | ) |
| Exercises of stock options | | 30 |
| | 81,535 |
| | |
| | |
| | |
| | 81,565 |
| | 25 |
| | 102,898 |
| | — |
| | — |
| | — |
| | — |
| | 102,923 |
|
| Excess tax benefit related to share-based compensation | | |
| | 46,341 |
| | |
| | |
| | |
| | 46,341 |
| |
| Share-based compensation expense | | |
| | 43,107 |
| | |
| | |
| | |
| | 43,107 |
| | — |
| | 62,206 |
| | — |
| | — |
| | — |
| | — |
| | 62,206 |
|
| Common stock purchases for employee stock purchase plan | | |
| | (206 | ) | | |
| | |
| | |
| | (206 | ) | | — |
| | (467 | ) | | — |
| | — |
| | — |
| | — |
| | (467 | ) |
| Warrants expense | | |
| | 422,739 |
| | |
| | |
| | |
| | 422,739 |
| |
| Purchases of call options | | |
| | (205,320 | ) | | |
| | |
| | |
| | (205,320 | ) | |
| Purchases of common stock | | | — |
| | — |
| | — |
| | — |
| | (329,929 | ) | | — |
| | (329,929 | ) |
| Settlement of accelerated share repurchase transaction | | | — |
| | 20,000 |
| | — |
| | — |
| | (20,000 | ) | | — |
| | — |
|
| Employee tax withholdings related to restricted share vesting | | | — |
| | — |
| | — |
| | — |
| | (9,411 | ) | | — |
| | (9,411 | ) |
| Other | | | 3 |
| | (3 | ) | | — |
| | — |
| | — |
| | — |
| | — |
|
| September 30, 2017 | | | 2,806 |
| | 4,517,635 |
| | 2,395,218 |
| | (95,850 | ) | | (4,755,348 | ) | | — |
| | 2,064,461 |
|
| Consolidation of variable interest entity | | | — |
| | — |
| | — |
| | — |
| | — |
| | 167,966 |
| | 167,966 |
|
| Net income (loss) | | | — |
| | — |
| | 1,658,405 |
| | — |
| | — |
| | (42,513 | ) | | 1,615,892 |
|
| Other comprehensive income (loss) | | | — |
| | — |
| | — |
| | 16,597 |
| | — |
| | (8,316 | ) | | 8,281 |
|
| Cash dividends, $1.52 per share | | | — |
| | — |
| | (333,041 | ) | | — |
| | — |
| | — |
| | (333,041 | ) |
| Exercises of stock options | | | 27 |
| | 138,429 |
| | — |
| | — |
| | — |
| | — |
| | 138,456 |
|
| Share-based compensation expense | | | — |
| | 62,316 |
| | — |
| | — |
| | — |
| | — |
| | 62,316 |
|
| Common stock purchases for employee stock purchase plan | | | — |
| | (341 | ) | | — |
| | — |
| | — |
| | — |
| | (341 | ) |
| Purchases of common stock | | |
| | |
| | |
| | |
| | (789,927 | ) | | (789,927 | ) | | — |
| | — |
| | — |
| | — |
| | (663,220 | ) | | — |
| | (663,220 | ) |
| Employee tax withholdings related to restricted share vesting | | |
| | |
| | |
| | |
| | (6,597 | ) | | (6,597 | ) | | — |
| | — |
| | — |
| | — |
| | (8,246 | ) | | — |
| | (8,246 | ) |
| Other | | 3 |
| | (3 | ) | | |
| | |
| | |
| | — |
| | 3 |
| | (2,566 | ) | | — |
| | — |
| | — |
| | — |
| | (2,563 | ) |
| September 30, 2014 (As Revised) | | 2,711 |
| | 2,749,185 |
| | 1,556,573 |
| | (52,046 | ) | | (2,313,380 | ) | | 1,943,043 |
| |
| Net loss (As Revised) | | |
| | |
| | (138,165 | ) | | |
| | |
| | (138,165 | ) | |
| September 30, 2018 | | | 2,836 |
| | 4,715,473 |
| | 3,720,582 |
| | (79,253 | ) | | (5,426,814 | ) | | 117,137 |
| | 3,049,961 |
|
| Adoption of ASC 606 (Note 1) | | | — |
| | — |
| | (1,482 | ) | | — |
| | — |
| | (1,102 | ) | | (2,584 | ) |
| Net income (loss) | | | — |
| | — |
| | 855,365 |
| | — |
| | — |
| | (1,230 | ) | | 854,135 |
|
| Other comprehensive loss | | |
| | |
| | |
| | (84,287 | ) | | |
| | (84,287 | ) | | — |
| | — |
| | — |
| | (32,712 | ) | | — |
| | (516 | ) | | (33,228 | ) |
| Cash dividends, $1.16 per share | | |
| | |
| | (253,919 | ) | | |
| | |
| | (253,919 | ) | |
| Cash dividends, $1.60 per share | | | — |
| | — |
| | (338,974 | ) | | — |
| | — |
| | — |
| | (338,974 | ) |
| Exercises of stock options | | 36 |
| | 105,839 |
| | |
| | |
| | |
| | 105,875 |
| | 15 |
| | 76,219 |
| | — |
| | — |
| | — |
| | — |
| | 76,234 |
|
| Excess tax benefit related to share-based compensation | | |
| | 88,116 |
| | |
| | |
| | |
| | 88,116 |
| |
| Share-based compensation expense | | |
| | 60,944 |
| | |
| | |
| | |
| | 60,944 |
| | — |
| | 58,874 |
| | — |
| | — |
| | — |
| | — |
| | 58,874 |
|
| Common stock purchases for employee stock purchase plan | | |
| | (328 | ) | | |
| | |
| | |
| | (328 | ) | |
| Warrants expense | | |
| | 912,724 |
| | |
| | |
| | |
| | 912,724 |
| |
| Purchases of call options | | |
| | (180,000 | ) | | |
| | |
| | |
| | (180,000 | ) | |
| Purchases of common stock | | |
| | |
| | |
| | |
| | (1,823,106 | ) | | (1,823,106 | ) | | — |
| | — |
| | — |
| | — |
| | (664,803 | ) | | — |
| | (664,803 | ) |
| Employee tax withholdings related to restricted share vesting | | |
| | |
| | |
| | |
| | (14,511 | ) | | (14,511 | ) | | — |
| | — |
| | — |
| | — |
| | (5,987 | ) | | — |
| | (5,987 | ) |
| Other | | 3 |
| | (3 | ) | | |
| | |
| | |
| | — |
| | 2 |
| | (424 | ) | | — |
| | — |
| | — |
| | — |
| | (422 | ) |
| September 30, 2015 (As Revised) | | 2,750 |
| | 3,736,477 |
| | 1,164,489 |
| | (136,333 | ) | | (4,150,997 | ) | | 616,386 |
| |
| Net income | | |
| | |
| | 1,427,929 |
| | |
| | |
| | 1,427,929 |
| |
| Other comprehensive income | | |
| | |
| | |
| | 22,025 |
| | |
| | 22,025 |
| |
| Cash dividends, $1.36 per share | | |
| | |
| | (288,477 | ) | | |
| | |
| | (288,477 | ) | |
| Exercises of stock options | | 22 |
| | 74,746 |
| | |
| | |
| | |
| | 74,768 |
| |
| Share-based compensation expense | | |
| | 64,992 |
| | |
| | |
| | |
| | 64,992 |
| |
| Common stock purchases for employee stock purchase plan | | |
| | (548 | ) | | |
| | |
| | |
| | (548 | ) | |
| Warrants expense | | |
| | 140,342 |
| | |
| | |
| | |
| | 140,342 |
| |
| Exercises of warrants | | | | 336,998 |
| | | | | | 2,023,481 |
| | 2,360,479 |
| |
| Purchases of common stock | | |
| | |
| | |
| | |
| | (1,866,344 | ) | | (1,866,344 | ) | |
| Accelerated share repurchase transaction | | | | (20,000 | ) | | | | | | (380,000 | ) | | (400,000 | ) | |
| Employee tax withholdings related to restricted share vesting | | |
| | |
| | |
| | |
| | (22,148 | ) | | (22,148 | ) | |
| Other | | 6 |
| | (6 | ) | | |
| | |
| | |
| | — |
| |
| September 30, 2016 | | $ | 2,778 |
| | $ | 4,333,001 |
| | $ | 2,303,941 |
| | $ | (114,308 | ) | | $ | (4,396,008 | ) | | $ | 2,129,404 |
| |
| September 30, 2019 | | | $ | 2,853 |
| | $ | 4,850,142 |
| | $ | 4,235,491 |
| | $ | (111,965 | ) | | $ | (6,097,604 | ) | | $ | 114,289 |
| | $ | 2,993,206 |
|
See notes to consolidated financial statements.
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW |
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2016 | | 2015 | | 2014 |
| | | | | (As Revised) | | (As Revised) |
| OPERATING ACTIVITIES | | |
| | |
| | |
|
| Net income (loss) | | $ | 1,427,929 |
| | $ | (138,165 | ) | | $ | 274,230 |
|
| Loss from discontinued operations | | — |
| | — |
| | 7,546 |
|
| Income (loss) from continuing operations | | 1,427,929 |
| | (138,165 | ) | | 281,776 |
|
| Adjustments to reconcile income (loss) from continuing operations to net cash provided by operating activities: | | |
| | |
| | |
|
| Depreciation, including amounts charged to cost of goods sold | | 232,538 |
| | 193,290 |
| | 165,479 |
|
| Amortization, including amounts charged to interest expense | | 159,628 |
| | 62,698 |
| | 31,138 |
|
| Provision for doubtful accounts | | 13,124 |
| | 8,119 |
| | 26,634 |
|
| (Benefit) provision for deferred income taxes | | (130,927 | ) | | 20,826 |
| | 38,001 |
|
| Warrants expense | | 140,342 |
| | 912,724 |
| | 422,739 |
|
| Share-based compensation | | 64,992 |
| | 60,944 |
| | 43,107 |
|
| LIFO expense | | 200,230 |
| | 542,807 |
| | 348,063 |
|
| Pension settlement | | 47,607 |
| | — |
| | — |
|
| Loss on sale of businesses | | — |
| | 12,953 |
| | — |
|
| Impairment charge on equity investment | | — |
| | 30,622 |
| | — |
|
| Loss on early retirement of debt | | — |
| | — |
| | 32,954 |
|
| Other | | (5,171 | ) | | (11,604 | ) | | (6,539 | ) |
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: | | |
| | |
| | |
|
| Accounts receivable | | (912,724 | ) | | (1,478,793 | ) | | (938,286 | ) |
| Merchandise inventories | | (1,107,252 | ) | | (1,379,189 | ) | | (1,304,569 | ) |
| Prepaid expenses and other assets | | (46,159 | ) | | (37,131 | ) | | 21,107 |
|
| Accounts payable | | 3,011,508 |
| | 4,957,227 |
| | 2,255,321 |
|
| Accrued expenses, income taxes, and other liabilities | | 82,832 |
| | 164,900 |
| | 55,275 |
|
| Net cash provided by operating activities-continuing operations | | 3,178,497 |
| | 3,922,228 |
| | 1,472,200 |
|
| Net cash used in operating activities-discontinued operations | | — |
| | — |
| | (7,546 | ) |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | | 3,178,497 |
| | 3,922,228 |
| | 1,464,654 |
|
| INVESTING ACTIVITIES | | |
| | |
| | |
|
| Capital expenditures | | (464,616 | ) | | (231,585 | ) | | (264,457 | ) |
| Cost of acquired companies, net of cash acquired | | (2,731,356 | ) | | (2,633,412 | ) | | (9,103 | ) |
| Cost of equity investments | | (19,034 | ) | | — |
| | (117,794 | ) |
| Proceeds from sales of businesses | | — |
| | 17,163 |
| | — |
|
| Proceeds from sales of investment securities available-for-sale | | 101,829 |
| | — |
| | — |
|
| Purchases of investment securities available-for-sale | | (42,083 | ) | | (86,214 | ) | | — |
|
| Other | | (13,919 | ) | | 2,883 |
| | 7,199 |
|
| NET CASH USED IN INVESTING ACTIVITIES | | (3,169,179 | ) | | (2,931,165 | ) | | (384,155 | ) |
| FINANCING ACTIVITIES | | |
| | |
| | |
|
| Term loan and senior note borrowings | | 1,000,000 |
| | 1,996,390 |
| | 1,097,927 |
|
| Term loan repayments | | (800,000 | ) | | (500,000 | ) | | (531,525 | ) |
| Borrowings under revolving and securitization credit facilities | | 8,846,876 |
| | 111,100 |
| | 17,584,500 |
|
| Repayments under revolving and securitization credit facilities | | (8,333,662 | ) | | (111,100 | ) | | (17,584,500 | ) |
| Purchases of common stock | | (2,266,344 | ) | | (1,859,106 | ) | | (753,926 | ) |
| Exercises of warrants | | 2,360,479 |
| | — |
| | — |
|
Exercises of stock options, including excess tax benefits of $0, $88,116, and $46,341, in fiscal 2016, 2015, and 2014, respectively | | 74,768 |
| | 193,991 |
| | 127,906 |
|
| Cash dividends on common stock | | (288,477 | ) | | (253,919 | ) | | (214,469 | ) |
| Purchases of call options | | — |
| | (180,000 | ) | | (211,397 | ) |
| Debt issuance costs and other | | (28,568 | ) | | (29,490 | ) | | (17,508 | ) |
| NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES | | 565,072 |
| | (632,134 | ) | | (502,992 | ) |
| INCREASE IN CASH AND CASH EQUIVALENTS | | 574,390 |
| | 358,929 |
| | 577,507 |
|
| Cash and cash equivalents at beginning of year | | 2,167,442 |
| | 1,808,513 |
| | 1,231,006 |
|
| CASH AND CASH EQUIVALENTS AT END OF YEAR | | $ | 2,741,832 |
| | $ | 2,167,442 |
| | $ | 1,808,513 |
|
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| OPERATING ACTIVITIES | | |
| | |
| | |
|
| Net income | | $ | 854,135 |
| | $ | 1,615,892 |
| | $ | 364,484 |
|
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | | | |
|
| Depreciation, including amounts charged to cost of goods sold | | 321,102 |
| | 318,483 |
| | 262,420 |
|
| Amortization, including amounts charged to interest expense | | 176,410 |
| | 191,626 |
| | 169,911 |
|
| Provision for doubtful accounts | | 25,196 |
| | 16,660 |
| | 8,934 |
|
| Provision (benefit) for deferred income taxes | | 28,537 |
| | (795,524 | ) | | 319,069 |
|
| Share-based compensation expense | | 58,874 |
| | 62,316 |
| | 62,206 |
|
| LIFO (credit) expense | | (22,544 | ) | | 67,324 |
| | (157,782 | ) |
| Impairment of long-lived assets | | 570,000 |
| | — |
| | — |
|
| Gain on sale of an equity investment | | (13,692 | ) | | — |
| | — |
|
| Goodwill impairment | | — |
| | 59,684 |
| | — |
|
| Impairment of non-customer note receivable | | — |
| | 30,000 |
| | — |
|
| Loss on consolidation of equity investments | | — |
| | 42,328 |
| | — |
|
| Loss on early retirement of debt | | — |
| | 23,766 |
| | — |
|
| Other | | (23,193 | ) | | (19,078 | ) | | 7,744 |
|
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: | | |
| | |
| | |
|
| Accounts receivable | | (1,241,890 | ) | | (657,770 | ) | | (1,277,896 | ) |
| Inventories | | (167,990 | ) | | (4,923 | ) | | (431,454 | ) |
| Prepaid expenses and other assets | | (6,733 | ) | | (57,211 | ) | | 33,646 |
|
| Accounts payable | | 1,561,048 |
| | 859,036 |
| | 1,473,389 |
|
| Income taxes payable | | (13,353 | ) | | 209,899 |
| | 27,192 |
|
| Accrued expenses and other liabilities | | 238,116 |
| | (551,120 | ) | | 642,275 |
|
| NET CASH PROVIDED BY OPERATING ACTIVITIES | | 2,344,023 |
| | 1,411,388 |
| | 1,504,138 |
|
| INVESTING ACTIVITIES | | |
| | |
| | |
|
| Capital expenditures | | (310,222 | ) | | (336,411 | ) | | (466,397 | ) |
| Cost of acquired companies, net of cash acquired | | (63,951 | ) | | (785,299 | ) | | (61,648 | ) |
| Cost of equity investments | | — |
| | — |
| | (11,347 | ) |
| Proceeds from sale of business | | — |
| | — |
| | 12,094 |
|
| Proceeds from sales of investment securities available-for-sale | | — |
| | — |
| | 74,778 |
|
| Purchases of investment securities available-for-sale | | — |
| | — |
| | (48,635 | ) |
| Other | | (1,659 | ) | | 10,596 |
| | 3,114 |
|
| NET CASH USED IN INVESTING ACTIVITIES | | (375,832 | ) | | (1,111,114 | ) | | (498,041 | ) |
| FINANCING ACTIVITIES | | |
| | |
| | |
|
| Senior notes and other loan borrowings | | 506,948 |
| | 1,314,430 |
| | — |
|
| Senior notes and other loan repayments | | (510,863 | ) | | (681,001 | ) | | (750,000 | ) |
| Borrowings under revolving and securitization credit facilities | | 640,126 |
| | 25,129,704 |
| | 9,336,400 |
|
| Repayments under revolving and securitization credit facilities | | (769,284 | ) | | (25,127,438 | ) | | (9,335,953 | ) |
| Payment of premium on early retirement of debt | | — |
| | (22,348 | ) | | — |
|
| Purchases of common stock | | (674,031 | ) | | (639,235 | ) | | (329,929 | ) |
| Exercises of stock options | | 76,234 |
| | 138,456 |
| | 102,923 |
|
| Cash dividends on common stock | | (338,974 | ) | | (333,041 | ) | | (320,270 | ) |
| Tax withholdings related to restricted share vesting | | (5,987 | ) | | (8,246 | ) | | (9,411 | ) |
| Other | | (10,682 | ) | | (14,154 | ) | | (6,574 | ) |
| NET CASH USED IN FINANCING ACTIVITIES | | (1,086,513 | ) | | (242,873 | ) | | (1,312,814 | ) |
| INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | | 881,678 |
| | 57,401 |
| | (306,717 | ) |
| Cash and cash equivalents at beginning of year | | 2,492,516 |
| | 2,435,115 |
| | 2,741,832 |
|
| CASH AND CASH EQUIVALENTS AT END OF YEAR | | $ | 3,374,194 |
| | $ | 2,492,516 |
| | $ | 2,435,115 |
|
See notes to consolidated financial statements.
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 20162019
Note 1. Summary of Significant Accounting Policies
AmerisourceBergen Corporation and its subsidiaries, including less than wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to increaseimprove the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
Basis of Presentation
The accompanying financial statements present the consolidated financial statements include the accountsposition, results of operations, and cash flows of the Company and its wholly-owned subsidiaries as of the dates and for the fiscal yearsperiods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
Recently Adopted Accounting Pronouncements
In November 2015,March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU")ASU No. 2015-17, "Income Taxes2016-09, "Compensation - Stock Compensation (Topic 740) —Balance Sheet Classification of Deferred Taxes"718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2015-17"2016-09"). ASU 2015-172016-09 requires that all deferredincome tax assetseffects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and liabilities, along with any related valuation allowance, be classifiedto make a policy election to account for forfeitures as noncurrent on the balance sheet. The guidance does not change the existing requirement that prohibits companies from offsetting deferred tax liabilities from one jurisdiction against deferred assets of another jurisdiction.they occur. ASU 2015-17 is2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. As ofOn October 1, 2015,2016, the Company early adopted ASU 2015-17,2016-09, which resulted in a cumulative adjustment to retained earnings and the reclassificationestablishment of $1,135.0a deferred tax asset of $47.1 million from current Deferred Income Taxesfor previously unrecognized tax benefits. The Company elected to long-term Deferred Income Taxes onadopt the September 30, 2015 Consolidated balance sheet.
Recently Issued Accounting Pronouncements Not Yet AdoptedStatement of Cash Flows presentation of the excess tax benefits prospectively.
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 —- "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 was originally scheduled to be effective for annual reporting periods beginning after December 15, 2016, including interim periods within those reporting periods. In July 2015, the Financial Accounting Standards Board deferred the effective date of ASU 2014-09 by one year.
In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) —- Principal versus Agent Considerations" ("ASU 2016-08"), which clarifiesclarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) —- Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amendsamended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company mustwas required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09. Entities are permitted to adopt the standards2014-09, collectively ASC 606.
The Company adopted ASC 606 as early as the original public entity effective date of ASU 2014-09, and either full orOctober 1, 2018 on a modified retrospective application is required.basis for all open contracts as of October 1, 2018. The Company has not yet selectedadoption had an adoption date or a transition method for ASU 2014-09, 2016-08, and 2016-10 and is currently evaluating theimmaterial impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of the above standards will have on its financial statements.
In April 2015, the FASB issued ASU No. 2015-03, "Interest — Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs" ("ASU 2015-03"). ASU 2015-03 specifies that debt issuance costs related to a note shall be reported on the balance sheet asCompany's October 1, 2018 retained earnings and will not have a direct reduction from the face amount of the note. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015 and interim periods within those fiscal years. ASU 2015-03 will require the
Company to reclassify its capitalized debt issuance costs currently recorded as assetsmaterial impact on the consolidated condensed balance sheets. ASU 2015-03 will have no effect on the Company's revenues, results of operations, or liquidity.cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.
The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.
For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.
Recently Issued Accounting Pronouncements Not Yet Adopted
In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842"))." ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years.
The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.
The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately $550 million based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early and a modified retrospective application is required.in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on the its financial statements.
In March 2016, the FASB issued ASU No. 2016-09, "Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 will require all income tax effects of awards to be recognized in the income statement when the awards vest or are settled. It also will allow an employer to repurchase more of an employee's shares than it may currently for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period. The updated guidance provides companies with alternative methods of adoption, with certain items that are allowed to be applied retrospectively and certain other items that are only to be applied prospectively in the period of adoption. The Company has not yet selected a transition method and is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements.
In August 2016, the FASB issued ASU No. 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" ("ASU 2016-15"). ASU 2016-15 aims to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for annual reporting periods beginning after December 15, 2017 and interim periods within those fiscal years. Entities are permitted to adopt the standard early in any interim or annual period, and a retrospective application is required. The Company is currently evaluating the impact of adopting this new accounting guidance and, therefore, cannot reasonably estimate the impact that the adoption of this standard will have on its financial statements.guidance.
As of September 30, 2016,2019, there arewere no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The purchase price of an acquired company, including the fair value of contingent consideration, is allocated between tangible and intangible assets acquired and liabilities assumed from the acquired business based on theirare recorded at fair values,value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Concentrations of Credit Risk and Allowance for Doubtful Accounts
The Company sells its merchandise inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivablereceivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal 2016,year ended September 30, 2019, Walgreens Boots Alliance, Inc.
("WBA"), accounted for 30%approximately 34% of revenue and represented approximately 43%49% of accounts receivable, net (afterof incentives, owed to it) as of September 30, 2016.2019. Express Scripts, Inc., the Company's second largest customer in the fiscal 2016,year ended September 30, 2019, accounted for 16%approximately 13% of revenue and represented approximately 10%8% of accounts receivable net as of September 30, 2016.2019. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The
calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based onupon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the footnotesnotes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made (seemade. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 15).13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 16)14).
Derivative Financial Instruments
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
The Company had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$37.4 million note outstanding as of September 30, 2016.
Equity Method Investments
The Company uses the equity method of accounting for its investments in entities in which it has significant influence; generally, this represents an ownership interest of between 20% and 50% (see Note 4). Declines in value that are determined to be other-than-temporary are recorded as impairment charges as a component of earnings in the period in which that determination is made.
The Company recorded an impairment charge of $30.6 million in fiscal 2015 related to its minority interest in a pharmaceutical wholesaler in Brazil. The impairment charge was based on the determination by the Company that the decline in the pharmaceutical wholesaler's stock price from the date on which the investment was made to September 30, 2015 was other-than temporary. There were no impairment charges on equity investments in fiscal 2016 or 2014.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative analysisassessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative analysisassessment and went directly to performing the first stepour annual quantitative analysisassessments of the goodwill and indefinite-lived intangible asset impairment tests in the current year. The Company may elect to perform the qualitative analysis in future periods.assets.
The first step in the quantitative analysis for the goodwill impairment test isrequires us to compare the carrying amountvalue of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, then the second step must be completed, which involves allocatingdifference between the carrying value and the fair value of the reporting unit to each asset and liability, with the excess being implied goodwill. Anis recorded as an impairment loss, occurs if the amount of which may not exceed the recordedtotal amount of goodwill exceeds the implied goodwill. The Company would be required to record any such impairment losses.
The Company identifies its reporting units based on its management reporting structure, and its reporting units are the same as its operating segments. Generally, goodwill arises from acquisitions of specific operating companies and is assignedallocated to the reporting unit in whichunit.
When performing a particular operating company resides.
Thequantitative impairment assessment, the Company usesutilizes an income-based approach to value its reporting units.units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, to determine the fair value of each reporting unit, which considers forecasted cash flows discounted at an appropriate discount rate.rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of itsthe Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both equitydebt and debt,equity, including a risk premium. While the Company uses the best available information to prepare its cash flowflows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and otherindefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. The Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). NaN goodwill impairments were recorded in the fiscal years ended September 30, 2016, 2015,2019 and 2014,2017. NaN indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and as a result, determined that there were no impairments.2017.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest
compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based onupon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based onupon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Investment Securities Available-For-SaleInventories
The Company's marketable debt securities have been classified and accounted for as available-for-sale. Management determines the appropriate classification of its investmentsInventories are stated at the timelower of purchase and reevaluatescost or market. Cost for approximately 75% of the classifications at each balance sheet date. The Company classifies its marketable debt securitiesCompany's inventories as either short-term or long-term based on each instrument's underlying contractual maturity date. Marketable debt securities with maturities of 12 months or less are classified as short-term and marketable debt securities with maturities greater than 12 months are classified as long-term. The Company's marketable debt securities are carried at fair value, with unrealized gains and losses reported as a component of Accumulated Other Comprehensive Loss in Stockholders' Equity, with the exception of unrealized losses believed to be other-than-temporary, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method. As of September 30, 2016,2019 and 2018 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. The Company recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.
For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's investment securities available-for-sale was $26.1 million, allshare of which was within Prepaid Expensesearnings and losses is recorded in Other onIncome (Loss) in the Company's consolidated balance sheets. AsConsolidated Statements of September 30, 2015,Operations. The Company monitors its investments for impairment by considering factors such as the fair valueoperating performance of the Company's investment securities available-for-sale was $86.2 million, $50.8 million of which was within Prepaid Expenses and Othercurrent economic and $35.4 million of which was within Other Assets on the Company's consolidated balance sheets.market conditions.
Leases
The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's consolidated balance sheet.Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's consolidated balance sheetConsolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's consolidated balance sheet.Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term.term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Manufacturer Incentives
The Company accounts forconsiders fees and other incentives received from its suppliers relating to the purchase or distribution of inventory as a reduction to cost of goods sold. The Company considers these fees and other incentives to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Merchandise Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 79% and 80% of the Company's inventories at September 30, 2016 and 2015, respectively, has been determined using the last-in, first-out (LIFO) method. If the Company had used the first-in, first-out (FIFO) method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,624.8 million and $1,424.6 million higher than the amounts reported at September 30, 2016 and 2015, respectively. The Company recorded LIFO expense of $200.2 million, $542.8 million, and $348.1 million in fiscal 2016, 2015, and 2014, respectively. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturing pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.
The Company recognizes revenue related to the distribution of products at a point in time when persuasive evidencetitle and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of anthe product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement exists, product has been delivered or services have been rendered, the price is fixed or determinable, and collectability is reasonably assured. Revenue, as reflected in the accompanying consolidated statements of operations, is net of estimated sales returns and allowances.
allowances, other customer incentives, and sales tax.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer. Atcustomer based upon historical return trends. As of September 30, 20162019 and 2015,2018, the Company's accrual for estimated customer sales returns was $856.3$1,147.5 million and $841.3$988.8 million, respectively.
The Company reports the gross dollar amount of bulk deliveries to customer warehouses in revenue and the related costs in cost of goods sold. Bulk delivery transactions are arranged by the Company at the express direction of the customer, and involve either drop shipments from the supplier directly to customers' warehouse sites or cross-dock shipments from the supplier In fiscal 2019, due to the Company for immediate shipment to the customers' warehouse sites. The Company is a principal to these transactions because it is the primary obligor and has the ultimate and contractual responsibility for fulfillment and acceptabilityadoption of the products purchased, and it bears full risk of delivery and loss for products, whether the products are drop-shipped or shipped via cross-dock. The Company also bears full credit risk associated with the creditworthiness of any bulk delivery customer. As a result,ASC 606, the Company records bulk deliveriesan asset for the right to customer warehousesrecover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as gross revenues. Gross profit earned by the Company on bulk deliveries was not material in any year presented.of September 30, 2018 and for all prior periods.
Share-Based Compensation
The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and reportsperformance stock units is based upon the relatedgrant date market price of the Company’s common stock.
Share-based compensation expense is recognized over the requisite service period within distribution, sellingDistribution, Selling, and administrative expensesAdministrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Share-based compensation expense is recognized over the requisite service period. The benefits of tax deductions in excess of recognized compensation expense ("excess tax benefits") are reported as a financing cash flow. There were no excess tax benefits related to share-based compensation for the fiscal year ended September 30, 2016. Excess tax benefits related to share-based compensation was $88.1 million and $46.3 million for the fiscal years ended September 30, 2015 and 2014, respectively. The fair value of performance stock units is determined based upon the grant date market price of the Company's Common Stock, and the compensationCompensation expense associated with nonvested performance stock units is dependent onupon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).
Shipping and Handling Costs
Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $494.7$619.7 million, $419.2$590.8 million, and $348.3$517.3 million for the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, respectively, are included in distribution, selling,Distribution, Selling, and administrative expenses.Administrative in the Company's Consolidated Statements of Operations.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based onupon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based onupon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
Warrants
The Company accounted for the warrants issued to subsidiaries of WBA (collectively, the "Warrants") in accordance with the guidance for equity-based payments to non-employees. Using a binomial lattice model approach, the fair value of the Warrants was initially measured at the date of issuance, and the related expenses were recognized over the vesting period as an operating expense. The fair value of the Warrants was remeasured at the end of each reporting period, and an adjustment was recorded in the statement of operations to record the impact as if the newly measured fair value of the awards had been used in recognizing expense starting when the awards were originally issued and through the remeasurement date. In fiscal 2016, the Warrants were exercised by WBA in full (see Note 9).
Note 2. Revision of Previously Issued Financial Statements2. Acquisitions and Investments
NEVSCO
As a result of the Company’s planned expansion of new distribution facilities, it engaged in a review of the accounting treatment of leases. As part of this review, the Company assessed its historical application of ASC 840 regarding lessee involvement in the construction of leased assets, and identified corrections to be made in its accounting for these leases. In a number of its leases, the Company made payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, ASC 840 defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost on the balance sheet with a corresponding financing obligation. In these situations, the Company has not historically accounted for the total project costs of the lessor as owned assets. Additionally, upon completion of the lessor's project, the Company must perform a sale-leaseback analysis pursuant to ASC 840 to determine if it can derecognize these assets and the related financing obligations from its consolidated balance sheet. In a substantial number of its leases, due to many of the same factors that require it to account for the total project costs as owned assets during the construction period (for example, the Company funding a portion of the construction costs) it is deemed to have "continuing involvement," which precludes the Company from derecognizing these leased assets when construction is complete. In such cases, the leased assets and the related financing obligations remain on the consolidated balance sheet and are amortized over the life of the assets and the lease term, respectively.
Upon conclusion of its recently conducted lease review, the Company recorded a cumulative adjustment as of September 30, 2013 for all affected leases resulting in a $104.0 million increase to total assets, all of which were construction assets recorded as property and equipment, and a $115.6 million increase to total liabilities, primarily current and long-term financing obligations. Additionally, the Company recorded a cumulative, net of tax, impact to retained earnings of $11.6 million as of October 1, 2013. The Company revised prior years’ financial statements and reduced diluted earnings per share by $0.01 in the fiscal years ended September 30, 2015 and 2014. The Company no longer reports rent expense for the leased facilities that are owned for accounting purposes. Instead, rental payments under the leases are recognized as a reduction of the financing obligation and as interest expense. Additionally, depreciation expense is recorded as construction assets are depreciated over their useful lives. These corrections had no impact on the net increase in cash and cash equivalents during the fiscal years 2015 and 2014.
The following illustrates the impact the aforementioned adjustments had on the Company's previously issued financial statements:
CONSOLIDATED BALANCE SHEET
|
| | | | | | | | | | | | |
| | | September 30, 2015 |
| (in thousands, except share and per share data) | | As Previously Reported | | Adjustments | | As Revised |
| | | | | | | |
| ASSETS | | |
| | | | |
|
| Current assets: | | |
| | | | |
|
| Cash and cash equivalents | | $ | 2,167,442 |
| | $ | — |
| | $ | 2,167,442 |
|
| Accounts receivable, less allowances for returns and doubtful accounts | | 8,222,951 |
| | — |
| | 8,222,951 |
|
| Merchandise inventories | | 9,755,094 |
| | — |
| | 9,755,094 |
|
| Prepaid expenses and other | | 189,001 |
| | — |
| | 189,001 |
|
| Total current assets | | 20,334,488 |
| | — |
| | 20,334,488 |
|
| | | | | | | |
| Property and equipment, at cost: | | |
| | | | |
|
| Land | | 39,499 |
| | — |
| | 39,499 |
|
| Buildings and improvements | | 413,854 |
| | 239,688 |
| | 653,542 |
|
| Machinery, equipment, and other | | 1,449,545 |
| | — |
| | 1,449,545 |
|
| Total property and equipment | | 1,902,898 |
| | 239,688 |
| | 2,142,586 |
|
| Less accumulated depreciation | | (923,647 | ) | | (26,429 | ) | | (950,076 | ) |
| Property and equipment, net | | 979,251 |
| | 213,259 |
| | 1,192,510 |
|
| | | | | | | |
Goodwill 1 | | 4,130,825 |
| | 13,566 |
| | 4,144,391 |
|
Other intangible assets 1 | | 1,993,119 |
| | — |
| | 1,993,119 |
|
| Other assets | | 298,474 |
| | — |
| | 298,474 |
|
| | | | | | | |
| TOTAL ASSETS | | $ | 27,736,157 |
| | $ | 226,825 |
| | $ | 27,962,982 |
|
| | | | | | | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| | | | |
|
| | | | | | | |
| Current liabilities: | | |
| | | | |
|
| Accounts payable | | $ | 20,886,439 |
| | $ | — |
| | $ | 20,886,439 |
|
| Accrued expenses and other | | 679,309 |
| | 12,479 |
| | 691,788 |
|
| Total current liabilities | | 21,565,748 |
| | 12,479 |
| | 21,578,227 |
|
| | | | | | | |
| Long-term debt | | 3,493,048 |
| | — |
| | 3,493,048 |
|
| Long-term financing obligation | | — |
| | 246,177 |
| | 246,177 |
|
Deferred income taxes 2 | | 1,954,205 |
| | (9,965 | ) | | 1,944,240 |
|
| Other liabilities | | 89,636 |
| | (4,732 | ) | | 84,904 |
|
| | | | | | | |
| Total stockholders' equity | | 633,520 |
| | (17,134 | ) | | 616,386 |
|
| | | | | | | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | | $ | 27,736,157 |
| | $ | 226,825 |
| | $ | 27,962,982 |
|
1 Amounts as previously reported have been revised to report Goodwill separately from total intangible assets.
2 Amount as previously reported has been revised to give effect to the retrospective adjustment resulting from the adoption of ASU 2015-17.
CONSOLIDATED STATEMENT OF OPERATIONS
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2015 |
| (in thousands, except per share data) | | As Previously Reported | | Adjustments | | As Revised |
| Revenue | | $ | 135,961,803 |
| | $ | — |
| | $ | 135,961,803 |
|
| Cost of goods sold | | 132,432,490 |
| | — |
| | 132,432,490 |
|
| Gross profit | | 3,529,313 |
| | — |
| | 3,529,313 |
|
| Operating expenses: | | |
| | | | |
|
| Distribution, selling, and administrative | | 1,918,045 |
| | (10,205 | ) | | 1,907,840 |
|
| Depreciation | | 186,789 |
| | 5,355 |
| | 192,144 |
|
| Amortization | | 56,491 |
| | — |
| | 56,491 |
|
| Warrants | | 912,724 |
| | — |
| | 912,724 |
|
| Employee severance, litigation, and other | | 37,894 |
| | — |
| | 37,894 |
|
| Operating income | | 417,370 |
| | 4,850 |
| | 422,220 |
|
| Other loss | | 13,598 |
| | — |
| | 13,598 |
|
| Impairment charge on equity investment | | 30,622 |
| | — |
| | 30,622 |
|
| Interest expense, net | | 99,001 |
| | 10,035 |
| | 109,036 |
|
| Income from operations before income taxes | | 274,149 |
| | (5,185 | ) | | 268,964 |
|
| Income tax expense | | 409,036 |
| | (1,907 | ) | | 407,129 |
|
| Net loss | | $ | (134,887 | ) | | $ | (3,278 | ) | | $ | (138,165 | ) |
| | | | | | | |
| Earnings per share: | | |
| | | | |
|
| Basic | | $ | (0.62 | ) | | $ | (0.01 | ) | | $ | (0.63 | ) |
| Diluted | | $ | (0.62 | ) | | $ | (0.01 | ) | | $ | (0.63 | ) |
| | | | | | | |
| Weighted average common shares outstanding: | | |
| | | | |
|
| Basic | | 217,786 |
| | — |
| | 217,786 |
|
| Diluted | | 217,786 |
| | — |
| | 217,786 |
|
CONSOLIDATED STATEMENT OF OPERATIONS
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2014 |
| (in thousands, except per share data) | | As Previously Reported | | Adjustments | | As Revised |
| Revenue | | $ | 119,569,127 |
| | $ | — |
| | $ | 119,569,127 |
|
| Cost of goods sold | | 116,586,761 |
| | — |
| | 116,586,761 |
|
| Gross profit | | 2,982,366 |
| | — |
| | 2,982,366 |
|
| Operating expenses: | | |
| | |
| | |
|
| Distribution, selling, and administrative | | 1,587,261 |
| | (6,597 | ) | | 1,580,664 |
|
| Depreciation | | 159,328 |
| | 3,390 |
| | 162,718 |
|
| Amortization | | 25,962 |
| | — |
| | 25,962 |
|
| Warrants | | 422,739 |
| | — |
| | 422,739 |
|
| Employee severance, litigation, and other | | 8,192 |
| | — |
| | 8,192 |
|
| Operating income | | 778,884 |
| | 3,207 |
| | 782,091 |
|
| Other income | | (4,360 | ) | | — |
| | (4,360 | ) |
| Interest expense, net | | 76,862 |
| | 6,772 |
| | 83,634 |
|
| Loss on early retirement of debt | | 32,954 |
| | — |
| | 32,954 |
|
| Income from continuing operations before income taxes | | 673,428 |
| | (3,565 | ) | | 669,863 |
|
| Income tax expense | | 389,398 |
| | (1,311 | ) | | 388,087 |
|
| Income from continuing operations | | 284,030 |
| | (2,254 | ) | | 281,776 |
|
| Loss from discontinued operations | | (7,546 | ) | | — |
| | (7,546 | ) |
| Net income | | $ | 276,484 |
| | $ | (2,254 | ) | | $ | 274,230 |
|
| | | | | | | |
| Earnings per share: | | |
| | |
| | |
|
| Basic earnings per share: | | |
| | |
| | |
|
| Continuing operations | | $ | 1.25 |
| | $ | (0.01 | ) | | $ | 1.24 |
|
| Discontinued operations | | (0.03 | ) | | — |
| | (0.03 | ) |
| Total | | $ | 1.22 |
| | $ | (0.01 | ) | | $ | 1.21 |
|
| | | | | | | |
| Diluted earnings per share: | | |
| | |
| | |
|
| Continuing operations | | $ | 1.21 |
| | $ | (0.01 | ) | | $ | 1.20 |
|
| Discontinued operations | | (0.03 | ) | | — |
| | (0.03 | ) |
| Rounding | | (0.01 | ) | | — |
| | (0.01 | ) |
| Total | | $ | 1.17 |
| | $ | (0.01 | ) | | $ | 1.16 |
|
| | | | | | | |
| Weighted average common shares outstanding: | | |
| | |
| | |
|
| Basic | | 227,367 |
| | — |
| | 227,367 |
|
| Diluted | | 235,405 |
| | — |
| | 235,405 |
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2015 |
| (in thousands) | | As Previously Reported | | Adjustments | | As Revised |
| Net loss | | $ | (134,887 | ) | | $ | (3,278 | ) | | $ | (138,165 | ) |
| Other comprehensive loss: | | |
| | |
| | |
|
| Net change in foreign currency translation adjustments | | (84,142 | ) | | — |
| | (84,142 | ) |
| Benefit plan funded status adjustments net of tax of $1,055 | | (4,607 | ) | | — |
| | (4,607 | ) |
| Other | | 4,462 |
| | — |
| | 4,462 |
|
| Total other comprehensive loss | | (84,287 | ) | | — |
| | (84,287 | ) |
| Total comprehensive loss | | $ | (219,174 | ) | | $ | (3,278 | ) | | $ | (222,452 | ) |
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2014 |
| (in thousands) | | As Previously Reported | | Adjustments | | As Revised |
| Net income | | $ | 276,484 |
| | $ | (2,254 | ) | | $ | 274,230 |
|
| Other comprehensive loss: | | |
| | |
| | |
|
| Net change in foreign currency translation adjustments | | (18,544 | ) | | — |
| | (18,544 | ) |
| Benefit plan funded status adjustments net of tax of $1,361 | | 2,400 |
| | — |
| | 2,400 |
|
| Other | | (419 | ) | | — |
| | (419 | ) |
| Total other comprehensive loss | | (16,563 | ) | | — |
| | (16,563 | ) |
| Total comprehensive income | | $ | 259,921 |
| | $ | (2,254 | ) | | $ | 257,667 |
|
CONSOLIDATED STATEMENT OF CASH FLOWS
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2015 |
| (in thousands) | | As Previously Reported | | Adjustments | | As Revised |
| OPERATING ACTIVITIES | | |
| | |
| | |
|
| Net loss | | $ | (134,887 | ) | | $ | (3,278 | ) | | $ | (138,165 | ) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | | |
| | | | |
|
| Depreciation, including amounts charged to cost of goods sold | | 187,935 |
| | 5,355 |
| | 193,290 |
|
| Amortization, including amounts charged to interest expense | | 61,665 |
| | 1,033 |
| | 62,698 |
|
| Provision for doubtful accounts | | 8,119 |
| | — |
| | 8,119 |
|
| Provision for deferred income taxes | | 22,733 |
| | (1,907 | ) | | 20,826 |
|
| Warrants expense | | 912,724 |
| | — |
| | 912,724 |
|
| Share-based compensation | | 60,944 |
| | — |
| | 60,944 |
|
LIFO expense 1 | | 542,807 |
| | — |
| | 542,807 |
|
| Loss on sale of businesses | | 12,953 |
| | — |
| | 12,953 |
|
| Impairment charge on equity investment | | 30,622 |
| | — |
| | 30,622 |
|
| Other | | (11,604 | ) | | — |
| | (11,604 | ) |
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: | | |
| | | | |
|
| Accounts receivable | | (1,478,793 | ) | | — |
| | (1,478,793 | ) |
Merchandise inventories 1 | | (1,379,189 | ) | | — |
| | (1,379,189 | ) |
| Prepaid expenses and other assets | | (37,131 | ) | | — |
| | (37,131 | ) |
| Accounts payable | | 4,957,227 |
| | — |
| | 4,957,227 |
|
| Accrued expenses, income taxes, and other liabilities | | 164,254 |
| | 646 |
| | 164,900 |
|
| NET CASH PROVIDED BY OPERATING ACTIVITIES | | 3,920,379 |
| | 1,849 |
| | 3,922,228 |
|
| INVESTING ACTIVITIES | | |
| | |
| | |
|
| Capital expenditures | | (231,585 | ) | | — |
| | (231,585 | ) |
| Cost of acquired companies, net of cash acquired | | (2,633,412 | ) | | — |
| | (2,633,412 | ) |
| Proceeds from sales of businesses | | 17,163 |
| | — |
| | 17,163 |
|
| Purchases of investment securities available-for-sale | | (86,214 | ) | | — |
| | (86,214 | ) |
| Other | | 2,883 |
| | — |
| | 2,883 |
|
| NET CASH USED IN INVESTING ACTIVITIES | | (2,931,165 | ) | | — |
| | (2,931,165 | ) |
| FINANCING ACTIVITIES | | |
| | |
| | |
|
| Term loan and senior note borrowings | | 1,996,390 |
| | — |
| | 1,996,390 |
|
| Term loan repayments | | (500,000 | ) | | — |
| | (500,000 | ) |
| Borrowings under revolving and securitization credit facilities | | 111,100 |
| | — |
| | 111,100 |
|
| Repayments under revolving and securitization credit facilities | | (111,100 | ) | | — |
| | (111,100 | ) |
| Purchases of common stock | | (1,859,106 | ) | | — |
| | (1,859,106 | ) |
| Exercises of stock options, including excess tax benefits of $88,116 | | 193,991 |
| | — |
| | 193,991 |
|
| Cash dividends on common stock | | (253,919 | ) | | — |
| | (253,919 | ) |
| Purchases of call options | | (180,000 | ) | | — |
| | (180,000 | ) |
| Debt issuance costs and other | | (27,641 | ) | | (1,849 | ) | | (29,490 | ) |
| NET CASH USED IN FINANCING ACTIVITIES | | (630,285 | ) | | (1,849 | ) | | (632,134 | ) |
| INCREASE IN CASH AND CASH EQUIVALENTS | | 358,929 |
| | — |
| | 358,929 |
|
| Cash and cash equivalents at beginning of year | | 1,808,513 |
| | — |
| | 1,808,513 |
|
| CASH AND CASH EQUIVALENTS AT END OF YEAR | | $ | 2,167,442 |
| | $ | — |
| | $ | 2,167,442 |
|
1 Amounts as previously reported have been revised to report LIFO Expense separately from the change in Merchandise Inventories.
CONSOLIDATED STATEMENT OF CASH FLOWS
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, 2014 |
| (in thousands) | | As Previously Reported | | Adjustments | | As Revised |
| OPERATING ACTIVITIES | | |
| | |
| | |
|
| Net income | | $ | 276,484 |
| | $ | (2,254 | ) | | $ | 274,230 |
|
| Loss from discontinued operations | | 7,546 |
| | — |
| | 7,546 |
|
| Income from continuing operations | | 284,030 |
| | (2,254 | ) | | 281,776 |
|
| Adjustments to reconcile income from continuing operations to net cash provided by operating activities | | |
| | |
| | |
|
| Depreciation, including amounts charged to cost of goods sold | | 162,089 |
| | 3,390 |
| | 165,479 |
|
| Amortization, including amounts charged to interest expense | | 30,644 |
| | 494 |
| | 31,138 |
|
| Provision for doubtful accounts | | 26,634 |
| | — |
| | 26,634 |
|
| Provision for deferred income taxes | | 39,312 |
| | (1,311 | ) | | 38,001 |
|
| Warrants expense | | 422,739 |
| | — |
| | 422,739 |
|
| Share-based compensation | | 43,107 |
| | — |
| | 43,107 |
|
LIFO expense 1 | | 348,063 |
| | — |
| | 348,063 |
|
| Loss on early retirement of debt | | 32,954 |
| | — |
| | 32,954 |
|
| Other | | (6,539 | ) | | — |
| | (6,539 | ) |
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: | | |
| | | | |
|
| Accounts receivable | | (938,286 | ) | | — |
| | (938,286 | ) |
Merchandise inventories 1 | | (1,304,569 | ) | | — |
| | (1,304,569 | ) |
| Prepaid expenses and other assets | | 21,107 |
| | — |
| | 21,107 |
|
| Accounts payable | | 2,255,321 |
| | — |
| | 2,255,321 |
|
| Accrued expenses, income taxes, and other liabilities | | 54,093 |
| | 1,182 |
| | 55,275 |
|
| Net cash provided by operating activities-continuing operations | | 1,470,699 |
| | 1,501 |
| | 1,472,200 |
|
| Net cash used in operating activities-discontinued operations | | (7,546 | ) | | — |
| | (7,546 | ) |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | | 1,463,153 |
| | 1,501 |
| | 1,464,654 |
|
| INVESTING ACTIVITIES | | |
| | |
| | |
|
| Capital expenditures | | (264,457 | ) | | — |
| | (264,457 | ) |
| Cost of acquired companies, net of cash acquired | | (9,103 | ) | | — |
| | (9,103 | ) |
| Cost of equity investments | | (117,794 | ) | | — |
| | (117,794 | ) |
| Other | | 7,199 |
| | — |
| | 7,199 |
|
| NET CASH USED IN INVESTING ACTIVITIES | | (384,155 | ) | | — |
| | (384,155 | ) |
| FINANCING ACTIVITIES | | |
| | |
| | |
|
| Senior note borrowings | | 1,097,927 |
| | — |
| | 1,097,927 |
|
| Senior note repayments | | (531,525 | ) | | — |
| | (531,525 | ) |
| Borrowings under revolving and securitization credit facilities | | 17,584,500 |
| | — |
| | 17,584,500 |
|
| Repayments under revolving and securitization credit facilities | | (17,584,500 | ) | | — |
| | (17,584,500 | ) |
| Purchases of common stock | | (753,926 | ) | | — |
| | (753,926 | ) |
| Exercises of stock options, including excess tax benefits of $46,341 | | 127,906 |
| | — |
| | 127,906 |
|
| Cash dividends on common stock | | (214,469 | ) | | — |
| | (214,469 | ) |
| Purchases of call options | | (211,397 | ) | | — |
| | (211,397 | ) |
| Debt issuance costs and other | | (16,007 | ) | | (1,501 | ) | | (17,508 | ) |
| NET CASH USED IN FINANCING ACTIVITIES | | (501,491 | ) | | (1,501 | ) | | (502,992 | ) |
| INCREASE IN CASH AND CASH EQUIVALENTS | | 577,507 |
| | — |
| | 577,507 |
|
| Cash and cash equivalents at beginning of year | | 1,231,006 |
| | — |
| | 1,231,006 |
|
| CASH AND CASH EQUIVALENTS AT END OF YEAR | | $ | 1,808,513 |
| | $ | — |
| | $ | 1,808,513 |
|
1 Amounts as previously reported have been revised to report LIFO Expense separately from the change in Merchandise Inventories.
Note 3. Acquisitions
On February 24, 2015,December 2017, the Company acquired MWINortheast Veterinary Supply Inc.Company ("MWI"NEVSCO") for a purchase price$70.0 million. NEVSCO was an independent, regional distributor of $2.6 billion. MWI is a leading animal health distribution company inveterinary pharmaceuticals and medical supplies serving primarily the northeast region of the United States and in the United Kingdom. For reportable segment presentation, MWI's operating results arestrengthens MWI Animal Health's ("MWI") support of independent veterinary practices and provides even greater value and care to current and future animal health customers. NEVSCO is included within Other.the MWI operating segment.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $1.2 billion,$30.4 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $346.9$8.5 million, $440.0$6.7 million, and $327.1$2.9 million, respectively. The fair value of the intangible assets acquired totaled $1.5 billion andof $29.8 million primarily consisted of customer relationships, of $1.1 billion, trade name of $344.0 million, and software technology of $11.0 million. The Company established a deferred tax liability of $570.7 million primarily in connection withwhich the intangible assets acquired. The Company is amortizing the fair valuesover its estimated useful life of the acquired customer relationships and software technology over the remaining useful lives of 20 years and 8 years, respectively. The trade name has been determined to have an indefinite life.15 years. Goodwill and intangiblesintangible assets resulting from the acquisition are not deductible for income tax purposes.
On November 6, 2015,H.D. Smith
In January 2018, the Company acquired PharMEDium Healthcare Holdings, Inc.H.D. Smith Holding Company ("PharMEDium"H.D. Smith") for $2.7 billion in cash, which included certain purchase price adjustments. PharMEDium is a leading national provider$815.0 million. The Company funded the acquisition through the issuance of outsourced compounded sterile preparations ("CSPs"new long-term debt (see Note 6) to acute care hospitals. H.D. Smith was the largest independent pharmaceutical wholesaler in the United States. PharMEDium is a componentStates and provides full-line distribution of AmerisourceBergen Drug Corporation ("ABDC") withinbrand, generic, and specialty drugs, as well as high-value services and solutions for manufacturers and healthcare providers. H.D. Smith's customers included retail pharmacies, specialty pharmacies, long-term care facilities, institutional/hospital systems, and independent physicians and clinics. The acquisition strengthens the Company's core business, expands and enhances its strategic scale in pharmaceutical distribution, and expands the Company's support for independent community pharmacies. H.D. Smith has been integrated into the Pharmaceutical Distribution reportable segment.
The purchase price has beenwas allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $1.8 billion,$499.9 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $63.2$163.1 million, $43.1$350.7 million, and $22.8$366.1 million, respectively. The fair value of the intangible assets acquired of $1.1 billion$167.8 million consisted of customer relationships of $882.7 million, trade name of $167.6$156.6 million and software technologya tradename of $52.6$11.2 million. The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively. The Company established a deferred tax liability of $356.1$60.6 million primarily in connection with the intangible assets acquired. The Company is amortizing the fair values of the acquired customer relationships and trade name over their useful lives of 15 years. The fair value of the acquired software technology is being amortized over its estimated useful life of 10 years. Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.
Profarma and Specialty Joint Venture Note 4. Equity Method Investments
In June 2014,As of September 30, 2017, the Company completed the acquisition ofheld a minoritynoncontrolling ownership interest in Profarma, Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), a leading pharmaceutical wholesaler in Brazil. In addition, the CompanyBrazil, and Profarma launchedan ownership interest in a joint venture with Profarma to provide enhanced specialty distribution and services to the Brazilian marketplace.marketplace (the "specialty joint venture"). The Company had accounted for these interests as equity method investments, which were reported in Other Assets on the Company's Consolidated Balance Sheets. In January 2018, the Company invested a total of $117.8an additional $62.5 million to acquire both a minority ownership interest in Profarma of approximately 19.9% and a 50% ownership interestan additional $15.6 million in the specialty joint venture.
venture to increase its ownership interests to 38.2% and 64.5%, respectively. In connection with the additional investment in Profarma, the Company received substantial governance rights, thereby requiring it to begin consolidating the operating results of Profarma as of March 31, 2018 (see Note 3). The Company accounts foralso began to consolidate the operating results of the specialty joint venture as of March 31, 2018 due to its majority ownership interest. In September 2018, the Company made an additional investment of $23.6 million in the specialty joint venture to increase its ownership interest in bothto 89.9%. Profarma and the specialty joint venture as equity method investments,are included within the Pharmaceutical Distribution Services reportable segment and Other, respectively.
The fair value of Profarma, including the noncontrolling interest, was determined based upon an agreed-upon stock price and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $160.1 million, $190.5 million, and $167.7 million, respectively. The Company consolidated short-term debt and long-term debt of $209.9 million and $12.4 million, respectively, cash of $150.8 million, and recorded a noncontrolling interest of $168.0 million. The estimated fair value of the intangible assets consolidated of $84.6 million consisted of customer relationships of $25.9 million and a tradename of $58.7 million. The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years. The Company established a deferred tax liability of $50.1 million primarily in connection with the intangible assets that were recognized. Goodwill and intangible assets resulting from the consolidation are reported innot deductible for income tax purposes.
The fair value of the Other Assets line item onspecialty joint venture was determined based upon the cost of the incremental ownership percentage acquired from the January 2018 investment and was allocated to the underlying assets and liabilities consolidated balance sheet.based upon their fair values at the time of the January 2018 investment. The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $65.0 million, $29.1 million, and $54.3 million, respectively. The Company consolidated short-term debt and cash of $32.7 million and $28.9 million, respectively. The estimated fair value of the intangible assets consolidated of $4.6 million is being amortized over its estimated useful life of 15 years. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.
In fiscal 2015,connection with the incremental January 2018 Brazil investments, the Company recorded an impairment chargeadjusted the carrying values of $30.6 million relating to its 19.9% minority ownership interest in Profarma. The impairment charge was based on the determination by the Company that the decline in Profarma's stock price from the date on which the investment was made to September 30, 2015 was other-than-temporary.
In fiscal 2016, the Company invested an additional $17.2 millionpreviously held equity interests in Profarma and the specialty joint venture. Asventure to equal their fair values, which were determined to be $103.1 million and $31.2 million, respectively. These represent Level 2 nonrecurring fair value measurements. The adjustments resulted in a pretax loss of September 30, 2016,$42.3 million in fiscal 2018 and were comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the Companyremeasurement of Profarma's previously held a minorityequity interest, in Profarmaand an $8.8 million loss on the remeasurement of approximately 24.3% and a 50% ownership interest in the specialty joint venture.venture's previously held equity interest.
Note 3. Variable Interest Entity
As discussed in Note 2, the Company made an additional investment in Profarma in January 2018. In connection with this investment, the Company obtained substantial governance rights, allowing it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidated the operating results of Profarma in its consolidated financial statements as of and for the periods ended September 30, 20162019 and 2015,September 30, 2018. The Company is not obligated to provide future financial support to Profarma.
The following assets and liabilities of Profarma are included in the carrying valueCompany's Consolidated Balance Sheet:
|
| | | | | | | | |
| (in thousands) | | September 30,
2019 | | September 30,
2018 |
| Cash and cash equivalents | | $ | 9,431 |
| | $ | 26,801 |
|
| Accounts receivables, net | | 154,491 |
| | 144,646 |
|
| Inventories | | 185,602 |
| | 168,931 |
|
| Prepaid expenses and other | | 64,119 |
| | 61,924 |
|
| Property and equipment, net | | 30,961 |
| | 32,667 |
|
| Goodwill | | 82,309 |
| | 82,309 |
|
| Other intangible assets | | 74,429 |
| | 80,974 |
|
| Other long-term assets | | 9,169 |
| | 8,912 |
|
| Total assets | | $ | 610,511 |
| | $ | 607,164 |
|
| | | | | |
| Accounts payable | | $ | 165,053 |
| | $ | 150,102 |
|
| Accrued expenses and other | | 49,191 |
| | 37,195 |
|
| Short-term debt | | 106,439 |
| | 115,461 |
|
| Long-term debt | | 60,973 |
| | 39,704 |
|
| Deferred income taxes | | 42,371 |
| | 46,137 |
|
| Other long-term liabilities | | 5,303 |
| | 31,988 |
|
| Total liabilities | | $ | 429,330 |
| | $ | 420,587 |
|
Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.
Note 4. Income Taxes
The following table summarizes the Company's income before income taxes for the periods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Domestic | | $ | 336,150 |
| | $ | 704,935 |
| | $ | 394,721 |
|
| Foreign | | 630,956 |
| | 472,488 |
| | 523,166 |
|
| Total | | $ | 967,106 |
| | $ | 1,177,423 |
| | $ | 917,887 |
|
The components of the Company's equity method investments in Brazil was $56.7 million and $30.5 million, respectively, after adjusting for changes in exchange rates and earnings.
Note 5. Discontinued Operations
In May 2013, the Company completed the divestiture of AmerisourceBergen Canada Corporation ("ABCC"). ABCC's loss beforeconsolidated income taxestax expense (benefit) are summarized in the fiscal year ended September 30, 2014 was $7.5 million, which includesfollowing table for the impact of a final purchase price working capital adjustment.
The Company sold ABCC for $67.9 million, including a C$50.0 million note due from the buyer, with interest accruing at 3% annually, and scheduled monthly payments to be made over a seven-year term that commenced in June 2013. The Company
periods indicated:
63 |
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Current provision: | | |
| | |
| | |
|
| Federal | | $ | (12,801 | ) | | $ | 247,755 |
| | $ | 141,071 |
|
| State and local | | 15,246 |
| | 39,328 |
| | 35,950 |
|
| Foreign | | 81,989 |
| | 69,972 |
| | 57,313 |
|
| Total current provision | | 84,434 |
| | 357,055 |
| | 234,334 |
|
| Deferred provision (benefit): | | |
| | |
| | |
|
| Federal | | 61,819 |
| | (828,023 | ) | | 265,074 |
|
| State and local | | (31,086 | ) | | 33,887 |
| | 54,995 |
|
| Foreign | | (2,196 | ) | | (1,388 | ) | | (1,000 | ) |
| Total deferred provision (benefit) | | 28,537 |
| | (795,524 | ) | | 319,069 |
|
| Provision (benefit) for income taxes | | $ | 112,971 |
| | $ | (438,469 | ) | | $ | 553,403 |
|
entered into a foreign currency denominated contract to hedge the foreign currency exchange risk associated with the Canadian note.
Note 6. Income Taxes
The following illustrates domestic and foreign income from continuing operations before income taxes (in thousands):
|
| | | | | | | | | | | |
| | Fiscal year ended September 30, |
| | 2016 | | 2015 | | 2014 |
| | | | (As Revised) | | (As Revised) |
| Domestic | $ | 906,415 |
| | $ | 55,545 |
| | $ | 588,344 |
|
| Foreign | 484,495 |
| | 213,419 |
| | 81,519 |
|
| Total | $ | 1,390,910 |
| | $ | 268,964 |
| | $ | 669,863 |
|
The income tax (benefit) provision is as follows (in thousands):
|
| | | | | | | | | | | |
| | Fiscal Year Ended September 30, |
| | 2016 | | 2015 | | 2014 |
| | | | (As Revised) | | (As Revised) |
| Current provision: | |
| | |
| | |
|
| Federal | $ | 11,892 |
| | $ | 310,847 |
| | $ | 297,052 |
|
| State and local | 26,741 |
| | 46,240 |
| | 37,301 |
|
| Foreign | 55,275 |
| | 29,216 |
| | 15,733 |
|
| | 93,908 |
| | 386,303 |
| | 350,086 |
|
| Deferred provision: | |
| | |
| | |
|
| Federal | (119,218 | ) | | 1,283 |
| | 15,449 |
|
| State and local | (11,490 | ) | | 18,201 |
| | 22,658 |
|
| Foreign | (219 | ) | | 1,342 |
| | (106 | ) |
| | (130,927 | ) | | 20,826 |
| | 38,001 |
|
| (Benefit) provision for income taxes | $ | (37,019 | ) | | $ | 407,129 |
| | $ | 388,087 |
|
A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows:follows for the periods indicated:
|
| | | | | |
| | Fiscal Year Ended September 30, |
| | 2019 | | 2018 | | 2017 |
| Statutory U.S. federal income tax rate | 21.0% | | 24.5% | | 35.0% |
| State and local income tax rate, net of federal tax benefit | 2.4 | | (0.1) | | 5.4 |
| Foreign tax rate differential | (6.7) | | (6.2) | | (14.6) |
| Valuation allowance | — | | (1.4) | | 2.2 |
| Excess tax benefits related to share-based compensation | (0.8) | | (1.8) | | (3.8) |
| Litigation settlements and accruals (see Note 14) | 0.1 | | (6.3) | | 34.3 |
| Goodwill impairment (see Note 5) | — | | 1.7 | | — |
| Tax reform | (3.6) | | (52.0) | | — |
| Capital gain on distribution | — | | 3.6 | | — |
| Other | (0.7) | | 0.8 | | 1.8 |
| Effective income tax rate | 11.7% | | (37.2)% | | 60.3% |
|
| | | | | |
| | Fiscal Year Ended September 30, |
| | 2016 | | 2015 | | 2014 |
| | | | (As Revised) | | (As Revised) |
| Statutory U.S. federal income tax rate | 35.0% | | 35.0% | | 35.0% |
| State and local income tax rate, net of federal tax benefit | 0.6 | | 10.4 | | 4.1 |
| Foreign | (8.4) | | (20.4) | | (1.9) |
| Warrants | (32.8) | | 109.7 | | 18.4 |
| Valuation allowance | 2.2 | | 9.2 | | 1.7 |
| Other | 0.7 | | 7.5 | | 0.6 |
| Effective income tax rate | (2.7)% | | 151.4% | | 57.9% |
On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "2017 Tax Act") was signed into law. The 2017 Tax Act included a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and new international tax provisions. In March 2013, the Company issued Warrants (as defined in Note 9) in connection with various agreements and arrangements with WBA, as successor in interest to Walgreen Co. ("Walgreens") and Alliance Boots GmbH ("Alliance Boots"). At that time, the Company determined that the Warrants had a fair value of $242.4 million on the date of issuance, which approximated the tax deductible amount that would be deducted ratably on the Company's income tax return over the 10-year term of the various agreements, and that any value in excess of the initial fair value of the Warrants on the date of issuance would not be tax deductible. In November 2015, the Company received a private letter ruling from the Internal Revenue Service ("IRS"), which entitles it to an income tax deduction equalresponse to the fair value of2017 Tax Act, the Warrants onU.S. Securities and Exchange Commission staff issued guidance regarding the date of exercise. Asaccounting for income taxes associated with the 2017 Tax Act to allow companies to record provisional amounts during a result, the Company recorded a deferred tax asset and recognized a tax benefit adjustment of approximately $456 million, which represented the estimated benefit from the tax deduction for the increase in the fair value of the Warrants from the issuance date through September 30, 2015. This tax benefit adjustment had a significant impact to the Company's effective tax rate inone-year measurement period. For the fiscal year ended September 30, 2016. In March 2016 and August 2016,2018, the Warrants were exercised by WBA. InCompany recognized income tax benefits of $612.6 million on the aggregate, the total fair valueCompany's Consolidated Statements of Operations related to effects of the Warrants based on their respective exercise dates was $1,565.9 million. An additional2017 Tax Act, which consisted of a deferred income tax benefit of approximately $52$897.6 million as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 and a one-time transition tax on historical foreign earnings and profits. In the fiscal year ended September 30, 2018, the Company initially recorded a current U.S. income tax expense of $285.0 million on historical foreign earnings and profits through December 31, 2017. The Company completed the accounting for the effects of the 2017 Tax Act in the fiscal quarter ended December 31, 2018 and recognized an income tax benefit of $37.0 million related to a decrease in its foreign earnings and profits through December 31, 2017 (the "transition tax"). The Company expects to pay $182.6 million related to the transition tax, which is net of overpayments and tax credits, over a six-year period commencing in January 2021. There were 0 adjustments recorded to deferred income taxes related to the 2017 Tax Act during the one-year measurement period.
Prior to the 2017 Tax Act, the Company intended to indefinitely reinvest its foreign cash in foreign investments and foreign operations. After further assessment of the impact of the 2017 Tax Act, the Company reevaluated its position and determined that it was no longer reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. Cumulative undistributed earnings of international subsidiaries were $2.4 billion as of
million was recognized primarily relatedSeptember 30, 2019, $1.6 billion of which is considered permanently reinvested. It is not practicable to estimate the changetaxes that would be due if such earnings were to be repatriated in the fair value of the Warrants from September 30, 2015 to their respective exercise dates in fiscal 2016.future.
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows (in thousands):follows:
|
| | | | | | | | |
| | | September 30, |
| (in thousands) | | 2019 | | 2018 |
| Inventories | | $ | 1,293,075 |
| | $ | 1,189,801 |
|
| Property and equipment | | 143,851 |
| | 133,417 |
|
| Goodwill and other intangible assets | | 709,015 |
| | 853,747 |
|
| Other | | 1,892 |
| | 747 |
|
| Gross deferred tax liabilities | | 2,147,833 |
| | 2,177,712 |
|
| | | | | |
| Net operating loss and tax credit carryforwards | | (318,868 | ) | | (421,808 | ) |
| Allowance for doubtful accounts | | (22,544 | ) | | (20,126 | ) |
| Accrued expenses | | (33,312 | ) | | (17,363 | ) |
| Employee and retiree benefits | | (12,420 | ) | | (10,210 | ) |
| Share-based compensation | | (39,961 | ) | | (28,888 | ) |
| Other | | (60,215 | ) | | (49,892 | ) |
| Gross deferred tax assets | | (487,320 | ) | | (548,287 | ) |
| Valuation allowance for deferred tax assets | | 199,682 |
| | 199,985 |
|
| Deferred tax assets, net of valuation allowance | | (287,638 | ) | | (348,302 | ) |
| Net deferred tax liabilities | | $ | 1,860,195 |
| | $ | 1,829,410 |
|
|
| | | | | | | |
| | September 30, |
| | 2016 | | 2015 |
| | | | (As Revised) |
| Merchandise inventories | $ | 1,281,364 |
| | $ | 1,207,356 |
|
| Property and equipment | 123,443 |
| | 106,572 |
|
| Goodwill and other intangible assets | 1,248,297 |
| | 865,316 |
|
| Other | 6,709 |
| | 1,107 |
|
| Gross deferred tax liabilities | 2,659,813 |
| | 2,180,351 |
|
| Net operating loss and tax credit carryforwards | (321,541 | ) | | (73,691 | ) |
| Capital loss carryforwards | (65,535 | ) | | (65,811 | ) |
| Allowance for doubtful accounts | (25,272 | ) | | (30,549 | ) |
| Accrued expenses | (37,842 | ) | | (24,248 | ) |
| Employee and retiree benefits | (17,759 | ) | | (6,165 | ) |
| Stock options | (52,238 | ) | | (41,233 | ) |
| Warrants | — |
| | (59,917 | ) |
| Other | (90,383 | ) | | (66,582 | ) |
| Gross deferred tax assets | (610,570 | ) | | (368,196 | ) |
| Valuation allowance for deferred tax assets | 165,531 |
| | 132,085 |
|
| Deferred tax assets, net of valuation allowance | (445,039 | ) | | (236,111 | ) |
| Net deferred tax liabilities | $ | 2,214,774 |
| | $ | 1,944,240 |
|
The following tax net operating loss and credit carryforward information is presented as of September 30, 2016.2019. The Company had $243.6$12.4 million of potential tax benefits from federal net operating loss carryforwards, expiringwhich expire in 21 to 2018 years, $110.9$171.0 million of potential tax benefits from state net operating loss carryforwards expiring in 1 to 20 years, and $20.9$58.7 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. Included in the federal net operating loss carryforwards is $45.8 million of potential tax benefits that if realized would be an increase to additional paid-in-capital. Included in the state net operating loss carryforwards is $15.1 million of potential tax benefits that if realized would be an increase to additional paid-in-capital. The Company had $65.5 million of potential tax benefits from capital loss carryforwards expiring in 2 to 4 years. The Company had $5.4 million of foreign tax credit carryforwards expiring in 2 to 8 years. The Company had $1.5$6.7 million of state tax credit carryforwards, and $21.1$84.1 million in federal alternative minimum tax credit carryforwards, and $2.1 million in foreign alternative minimum tax credit carryforwards.
InThe Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal 2016,year ended September 30, 2019, the Company increaseddecreased the valuation allowance on deferred tax assets by $33.4$0.3 million primarily due to a legislative change which will enable the addition ofCompany to utilize select net operating losses prospectively. This decrease was offset in part by the additional valuation allowances on certain state and foreign net operating loss carryforwards. In the fiscal 2015,year ended September 30, 2018, the Company increaseddecreased the valuation allowance on deferred tax assets by $26.7$11.1 million primarily due to the additionutilization of certain state net operatingcapital loss carryforwards.and foreign tax credit carryforwards for which a valuation allowance had been recorded.
In the fiscal 2016, there were no tax benefits related to the exercise of employee stock optionsyear ended September 30, 2019, 2018, and lapses of restricted shares. In fiscal 2015 and 2014,2017 tax benefits of $88.1$7.9 million, $22.7 million and $46.3$36.7 million, respectively, related to the exercise of employee stock options and lapses of restricted sharesstock units were recorded as additional paid-in capital.in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2019, 2018, and 2017 are not necessarily indicative of amounts that may arise in future periods.
Income tax payments, net of refunds, were $17.5$117.7 million, in the fiscal year ended September 30, 2016. Income tax payments, net of refunds, were $299.6$104.0 million, and $197.0$105.0 million in the fiscal years ended September 30, 20152019, 2018, and 2014,2017, respectively.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2012.2015.
As of September 30, 20162019 and 2015,2018, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $88.2$124.2 million and $52.8$112.9 million, respectively ($63.195.0 million and $37.2$89.4 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 20162019 and 2015, $48.02018, $76.8 million and $22.2$71.1 million, respectively, of these benefits would have reduced income
tax expense and the effective tax rate. As of September 30, 20162019 and 2015,2018, included in the unrecognized tax benefits are $12.4
$18.6 million and $8.1$14.8 million of interest and penalties, respectively, which the Company records in income tax expense.Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, in fiscal 2016, 2015, and 2014for the periods indicated is as follows (in thousands):follows:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Unrecognized tax benefits at beginning of period | | $ | 98,124 |
| | $ | 323,869 |
| | $ | 75,766 |
|
| Additions of tax positions of the current year | | 18,819 |
| | 2,804 |
| | 252,866 |
|
| Additions to tax positions of the prior years | | 751 |
| | 558 |
| | 1,049 |
|
| Reductions of tax positions of the prior years | | (10,317 | ) | | (224,878 | ) | | (668 | ) |
| Settlements with taxing authorities | | — |
| | (1,847 | ) | | (3,285 | ) |
| Expiration of statutes of limitations | | (1,720 | ) | | (2,382 | ) | | (1,859 | ) |
| Unrecognized tax benefits at end of period | | $ | 105,657 |
| | $ | 98,124 |
| | $ | 323,869 |
|
|
| | | |
| Balance at September 30, 2013 | $ | 46,267 |
|
| Additions of tax positions of the current year | 6,127 |
|
| Additions of tax positions of the prior years | 1,249 |
|
| Reductions of tax positions of the prior years | (4,167 | ) |
| Settlements with taxing authorities | (4,788 | ) |
| Expiration of statutes of limitations | (1,780 | ) |
| Balance at September 30, 2014 | 42,908 |
|
| Additions of tax positions of the current year | 3,616 |
|
| Reductions of tax positions of the prior years | (871 | ) |
| Settlements with taxing authorities | (33 | ) |
| Expiration of statutes of limitations | (898 | ) |
| Balance at September 30, 2015 | 44,722 |
|
| Additions of tax positions of the current year | 24,145 |
|
| Additions to tax positions of the prior years | 11,840 |
|
| Reductions of tax positions of the prior years | (1,407 | ) |
| Settlements with taxing authorities | (2,589 | ) |
| Expiration of statutes of limitations | (945 | ) |
| Balance at September 30, 2016 | $ | 75,766 |
|
Included in the additions of unrecognized tax positions in the fiscal year ended September 30, 2017 is approximately $235.1 million for an uncertain tax position related to the $625.0 million civil litigation reserve recognized during the fiscal year (see Note 13). In the fiscal year ended September 30, 2017, this reserve was considered to be non-deductible. In September 2018, the Company made a payment of $625.0 million, plus interest, to resolve this litigation and it was determined that a portion of the settlement was deductible. Accordingly, the Company reduced its uncertain tax position by $10.3 million and $224.9 million in the fiscal years ended September 30, 2019 and 2018, respectively. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $6.4$12.4 million.
Cumulative undistributed earnings of international subsidiaries were $881.5 million at September 30, 2016. No deferred federal income taxes were provided for the undistributed earnings as they are permanently reinvested in the Company's international operations. It is not practicable to estimate the amount of U.S. tax that would result upon the eventual repatriation of such earnings.
Note 7.5. Goodwill and Other Intangible Assets
FollowingThe following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 20162019 and 2015 (in thousands):2018:
|
| | | | | | | | | | | | |
| (in thousands) | | Pharmaceutical Distribution Services | | Other | | Total |
| Goodwill as of September 30, 2017 | | $ | 4,270,550 |
| | $ | 1,773,731 |
| | $ | 6,044,281 |
|
| Goodwill recognized in connection with acquisitions | | 641,909 |
| | 39,352 |
| | 681,261 |
|
| Goodwill impairment | | (59,684 | ) | | — |
| | (59,684 | ) |
| Foreign currency translation | | — |
| | (1,586 | ) | | (1,586 | ) |
| Goodwill as of September 30, 2018 | | 4,852,775 |
| | 1,811,497 |
| | 6,664,272 |
|
| Goodwill recognized in connection with acquisitions | | — |
| | 43,418 |
| | 43,418 |
|
| Foreign currency translation | | — |
| | (2,183 | ) | | (2,183 | ) |
| Goodwill as of September 30, 2019 | | $ | 4,852,775 |
| | $ | 1,852,732 |
| | $ | 6,705,507 |
|
|
| | | | | | | | | | | |
| | Pharmaceutical Distribution | | Other | | Total |
| Goodwill at September 30, 2014 | $ | 2,400,926 |
| | $ | 547,576 |
| | $ | 2,948,502 |
|
| Goodwill recognized in connection with acquisitions (As Revised) | 35,051 |
| | 1,171,199 |
| | 1,206,250 |
|
| Goodwill disposed in connection with divestitures | (3,605 | ) | | (2,626 | ) | | (6,231 | ) |
| Foreign currency translation | — |
| | (4,130 | ) | | (4,130 | ) |
| Goodwill at September 30, 2015 (As Revised) | 2,432,372 |
| | 1,712,019 |
| | 4,144,391 |
|
| Goodwill recognized in connection with acquisitions | 1,832,113 |
| | 18,196 |
| | 1,850,309 |
|
| Foreign currency translation | — |
| | (3,203 | ) | | (3,203 | ) |
| Goodwill at September 30, 2016 | $ | 4,264,485 |
| | $ | 1,727,012 |
| | $ | 5,991,497 |
|
FollowingThe following is a summary of other intangible assets (in thousands):assets:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | September 30, 2019 | | September 30, 2018 |
| (dollars in thousands) | | Weighted Average Remaining Useful Life | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount |
| Indefinite-lived trade names | | | | $ | 685,324 |
| | $ | — |
| | $ | 685,324 |
| | $ | 685,380 |
| | $ | — |
| | $ | 685,380 |
|
| Finite-lived: | | | | | | | | | | | | | | |
| Customer relationships | | 14 years | | 1,931,212 |
| | (489,471 | ) | | 1,441,741 |
| | 2,549,245 |
| | (555,440 | ) | | 1,993,805 |
|
| Trade names and other | | 13 years | | 271,521 |
| | (103,750 | ) | | 167,771 |
| | 397,946 |
| | (129,303 | ) | | 268,643 |
|
| Total other intangible assets | | | | $ | 2,888,057 |
| | $ | (593,221 | ) | | $ | 2,294,836 |
| | $ | 3,632,571 |
| | $ | (684,743 | ) | | $ | 2,947,828 |
|
|
| | | | | | | | | | | | | | | | | | | | | | | |
| | September 30, 2016 | | September 30, 2015 |
| | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization | | Net Carrying Amount |
Indefinite-lived intangibles — trade names | $ | 684,991 |
| | $ | — |
| | $ | 684,991 |
| | $ | 684,966 |
| | $ | — |
| | $ | 684,966 |
|
Finite-lived intangibles: Customer relationships | 2,322,404 |
| | (273,638 | ) | | 2,048,766 |
| | 1,421,230 |
| | (146,227 | ) | | 1,275,003 |
|
| Trade names and other | 307,234 |
| | (73,142 | ) | | 234,092 |
| | 81,241 |
| | (48,091 | ) | | 33,150 |
|
| Total other intangible assets | $ | 3,314,629 |
| | $ | (346,780 | ) | | $ | 2,967,849 |
| | $ | 2,187,437 |
| | $ | (194,318 | ) | | $ | 1,993,119 |
|
Amortization expense for otherfinite-lived intangible assets was $152.5$167.4 million, $56.5$181.2 million, and $26.0$160.5 million in the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, respectively. Amortization expense for finite-lived intangible assets is estimated to be $158.3 million in fiscal 2017, $156.2 million in fiscal 2018, $153.1 million in fiscal 2019, $149.2$134.1 million in fiscal 2020, $148.4$130.2 million in fiscal 2021, $128.5 million in fiscal 2022, $127.2 million in fiscal 2023, $126.2 million in 2024, and $1,517.5$963.3 million thereafter.
Note 8.6. Debt
Debt consisted of the following (in thousands):following:
|
| | | | | | | | |
| | | September 30, |
| (in thousands) | | 2019 | | 2018 |
| Revolving credit note | | $ | — |
| | $ | — |
|
| Term loans due 2020 | | 399,778 |
| | 398,665 |
|
| Overdraft facility due 2021 (£30,000) | | 32,573 |
| | 13,269 |
|
| Receivables securitization facility due 2022 | | 350,000 |
| | 500,000 |
|
| Multi-currency revolving credit facility due 2024 | | — |
| | — |
|
| $500,000, 3.50% senior notes due 2021 | | 498,908 |
| | 498,392 |
|
| $500,000, 3.40% senior notes due 2024 | | 497,744 |
| | 497,255 |
|
| $500,000, 3.25% senior notes due 2025 | | 496,311 |
| | 495,632 |
|
| $750,000, 3.45% senior notes due 2027 | | 743,099 |
| | 742,258 |
|
| $500,000, 4.25% senior notes due 2045 | | 494,514 |
| | 494,298 |
|
| $500,000, 4.30% senior notes due 2047 | | 492,488 |
| | 492,222 |
|
| Capital lease obligations | | — |
| | 745 |
|
| Nonrecourse debt | | 167,477 |
| | 177,453 |
|
| Total debt | | 4,172,892 |
| | 4,310,189 |
|
| Less AmerisourceBergen Corporation current portion | | 32,573 |
| | 13,976 |
|
| Less nonrecourse current portion | | 106,439 |
| | 137,681 |
|
| Total, net of current portion | | $ | 4,033,880 |
| | $ | 4,158,532 |
|
|
| | | | | | | |
| | September 30, |
| | 2016 | | 2015 |
| Revolving credit note | $ | — |
| | $ | — |
|
| Receivables securitization facility due 2018 | 500,000 |
| | — |
|
| Term loans due in 2020 | 700,000 |
| | 500,000 |
|
| Multi-currency revolving credit facility due 2020 | — |
| | — |
|
| Overdraft facility due in 2021 | 11,275 |
| | — |
|
| $600,000, 1.15% senior notes due 2017 | 599,874 |
| | 599,658 |
|
| $400,000, 4.875% senior notes due 2019 | 398,808 |
| | 398,456 |
|
| $500,000, 3.50% senior notes due 2021 | 499,639 |
| | 499,568 |
|
| $500,000, 3.40% senior notes due 2024 | 498,919 |
| | 498,777 |
|
| $500,000, 3.25% senior notes due 2025 | 497,771 |
| | 497,503 |
|
| $500,000, 4.25% senior notes due 2045 | 499,116 |
| | 499,086 |
|
| Total debt | $ | 4,205,402 |
| | $ | 3,493,048 |
|
| Less current portion | 611,149 |
| | — |
|
| Total, net of current portion | $ | 3,594,253 |
| | $ | 3,493,048 |
|
Multi-Currency Revolving Credit Facility
The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in November 2020 (the "Multi-Currency Revolving Credit Facility"),October 2023, with a syndicate of lenders. In November 2016,September 2019, the Company entered into an amendment with the syndicate of lenders to, among other things, extend the maturity date to November 2021.September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based onupon the Company's debt rating and ranges from 6970 basis points to 110112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee atas of September 30, 2016)2019) and from 0 basis points to 1012.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 65 basis points to 1512.5 basis points, annually, of the total commitment (9 basis points atas of September 30, 2016)2019). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2016.2019.
Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were 0 borrowings outstanding under the commercial paper program as of September 30, 2019 and 2018.
Receivables Securitization Facility
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in November 2018.October 2021. In June 2016,September 2019, the Company amended the Receivables Securitization Facilityentered into an amendment to increase the borrowing capacity from $950 million to $1,450 million and in November 2016, the Company extendedextend the maturity date to November 2019.September 2022. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, ABDCAmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. ABDCAmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2016.
Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest rates, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2016 and 2015.2019.
Revolving Credit Note and Overdraft Facility
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has ana £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI business. In February 2016, the Company amended the overdraft Facility to extend the maturity date from November 2016 to February 2021 and increase the borrowing capacity from £20 million to £30 million.
Term Loans
In February 2015,October 2018, the Company entered intorefinanced $400 million of outstanding Term Loans by issuing a $1.0 billionnew $400 million variable-rate term loan ("February 2015October 2018 Term Loan"), which matures in October 2020. Through September 30, 2016, the Company elected to make principal payments, prior to the scheduled repayment dates, totaling $700 million on the February 2015 Term Loan, and as a result, the Company's next required principal payment is due upon maturity. The February 2015October 2018 Term Loan bears interest at a rate equal either to a base rate or LIBOR, plus a margin or a LIBOR rate, plus a margin.of 65 basis points. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over a LIBOR rate (100 basis points at September 30, 2016) and 0 to 25 basis points over a base rate. The February 2015October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2016.
In November 2015, the Company entered into a $1.0 billion variable-rate term loan ("November 2015 Term Loan"), which matures in 2020. In fiscal 2016, the Company elected to make principal payments, prior to the scheduled repayment dates, of $575 million on the November 2015 Term Loan, and as a result, the Company's next required principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or a LIBOR rate, plus a margin. The margin is based on the public debt ratings of the Company and ranges from 75 basis points to 125 basis points over a LIBOR rate (100 basis points as of September 30, 2016) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2016.
Facility.
Senior Notes
In February 2015,December 2017, the Company issued $500$750 million of 3.25%3.45% senior notes due March 1, 2025December 15, 2027 (the "2025"2027 Notes") and $500 million of 4.25%4.30% senior notes due March 1, 2045December 15, 2047 (the "2045"2047 Notes"). The 20252027 Notes were sold at 99.47%99.76% of the principal amount and have an effective yield of 3.31%3.48%. The 20452047 Notes were sold at 99.81%99.51% of the principal amount and have an effective yield of 4.26%4.33%. Interest on the 20252027 Notes and 2045the 2047 Notes is payable semi-annually in arrears.
In May 2014,arrears and commenced on June 15, 2018. The 2027 and 2047 Notes rank pari passu to the Company issued $600 million of 1.15%Company's other senior notes, due May 15, 2017 (the "2017 Notes")the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and $500 million of 3.40% senior notes due May 15, 2024 (the "2024 Notes"). The 2017 Notes were sold at 99.892% of the principal amount and have an effective yield of 1.187%. The 2024 Notes were sold at 99.715% of the principal amount and have an effective yield of 3.434%. Interest on the 2017 Notes and 2024 Notes is payable semiannually in arrears.October 2018 Term Loan.
The Company used a portion of the net proceeds from the 20172027 Notes and the 20242047 Notes to finance the early retirement of the $500 million, 5.875% senior notes due 2015 (the "2015 Notes"), including the payment of $31.5 million of premiums and other costs. The Company used the remaining amount for general corporate purposes, including the repurchases of shares of its common stock under its special share repurchase program.
The Company has $400 million of 4.875% senior notes that were due November 15,in 2019, (the "2019 Notes")including the payment of a $22.3 million prepayment premium, and $500 millionto finance the acquisition of 3.50%H.D. Smith, which was completed in January 2018 (see Note 2).
The senior notes due November 15, 2021 (the "2021 Notes"). The 2019 Notes and 2021 Notes were sold at 99.2% and 99.858% ofare collectively referred to as the principal amount, respectively, and have effective interest yields of 4.98% and 3.52%, respectively."Notes." Interest on the 2019 and 2021 Notes is payable semiannually in arrears. The 2017 Notes 2019 Notes, 2021 Notes, 2024 Notes, 2025 Notes,were sold at small discounts to the principal amounts and, 2045 Notestherefore, have effective yields that are collectively referred to asgreater than the "Notes."stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes.
The indentures governing the Notes contain restrictions and covenants, which include limitations on
additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test, with which the Company was compliant as of September 30, 2016.2019.
Nonrecourse Debt
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Other Information
Scheduled future principal payments of debt are $611.3 million in fiscal 2017, $500.0 million in fiscal 2019, $700.0$111.2 million in fiscal 2020, $400.0$450.3 million in fiscal 2021, $877.8 million in fiscal 2022, $4.7 million in fiscal 2023, $501.4 million in fiscal 2024, and $2.0$2.3 billion thereafter.
Interest paid on the above indebtedness during the fiscal years ended September 30, 2016, 2015,2019, 2018, and 20142017 was $123.5$167.4 million, $91.5$162.1 million, and $62.9$125.3 million, respectively.
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of interest expense,Interest Expense, Net on the Consolidated Statements of Operations, were $6.3$7.1 million, $5.2$7.7 million, and $3.9$6.2 million, for the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, respectively.
Note 9.7. Stockholders' Equity and Earnings per ShareWeighted Average Common Shares Outstanding
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "Common Stock""common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "Preferred Stock""preferred stock").
The board of directors is authorized to provide for the issuance of shares of Preferred Stockpreferred stock in one or more series with various designations and preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions. Except as required by law, or as otherwise provided by the board of directors of the Company, the holders of Preferred Stockpreferred stock will have no voting rights and will not be entitled to notice of meetings of stockholders. Holders of Preferred Stockpreferred stock will be entitled to receive, when declared by the board of directors, out of legally available funds, dividends at the rates fixed by the board of directors for the respective series of Preferred Stock,preferred stock, and no more, before any dividends will be declared and paid, or set apart for payment, on Common Stockcommon stock with respect to the same dividend period. NoNaN shares of Preferred Stockpreferred stock have been issued as of September 30, 2016.2019.
The holders of the Company's Common Stockcommon stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's Preferred Stock,preferred stock, holders of Common Stockcommon stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company.
The following table illustrates the components of accumulated other comprehensive loss,Accumulated Other Comprehensive Loss, net of income taxes, as of September 30, 2016 and 2015 (in thousands):taxes:
|
| | | | | | | | |
| | | September 30, |
| (in thousands) | | 2019 | | 2018 |
| Pension and postretirement adjustments | | $ | (5,344 | ) | | $ | (5,065 | ) |
| Foreign currency translation | | (107,252 | ) | | (74,811 | ) |
| Other | | 631 |
| | 623 |
|
| Total accumulated other comprehensive loss | | $ | (111,965 | ) | | $ | (79,253 | ) |
|
| | | | | | | |
| | September 30, |
| | 2016 | | 2015 |
| Pension and postretirement adjustments (See Note 11) | $ | (5,843 | ) | | $ | (36,819 | ) |
| Foreign currency translation | (108,704 | ) | | (99,393 | ) |
| Other | 239 |
| | (121 | ) |
| Total accumulated other comprehensive loss | $ | (114,308 | ) | | $ | (136,333 | ) |
In November 2012, the Company's board of directors authorized a program allowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2014, the Company purchased 5.5 million shares of its Common Stock for a total of $363.0 million to complete its authorization under this program.
In August 2013, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. During the fiscal year ended September 30, 2014, the Company purchased 2.4 million shares of its Common Stock for a total of $174.7 million under this program, which included $18.0 million of fiscal 2014 purchases that cash settled in October 2014. During the fiscal year ended September 30, 2015, the Company purchased 3.3 million shares of its Common Stock for a total of $300.8 million under this program. During the six months ended March 31, 2016, the Company purchased 1.1 million shares of its Common Stock for a total of $100.0 million under this program. In May 2016, the Company's board of directors authorized a new share purchase program that, together with availability remaining under the existing August 2013 share repurchase program, permits the Company to purchase up to $750 million of its outstanding shares of Common Stock, subject to market conditions. In September 2016, the Company entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400.0 million for the delivery of 4.5 million shares of its Common Stock.common stock. The initial payment of $400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered an additional 0.5 million shares of the Company's Common Stock.common stock. The number of shares ultimately received was based onupon the volume-weighted average price of the Company's Common Stockcommon stock during the term of the ASR. The Company applied the 4.5 million shares from the ASR to the May 2016 share repurchase program. In addition toDuring the ASR,fiscal year ended September 30, 2017, the Company purchased 2.92.1 million shares of its Common Stockcommon stock (included 0.5 million
shares of common stock received as part of the settlement of the ASR) for a total of $231.2$118.8 million to complete its authorization under the May 2016 program. The Company had $118.8 million of availability remaining under this share repurchase program as of September 30, 2016.
In March 2013, the Company and WBA entered into various agreements and arrangements pursuant to which subsidiaries of WBA were granted the right to purchase a minority equity position in the Company, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of the Company's Common Stock in open market transactions (approximately 7% of the Company's Common Stock on a fully diluted basis as of the date of issuance of the Warrants described below, assuming their exercise in full). In connection with these arrangements, wholly-owned subsidiaries of WBA were issued (a) warrants to purchase up to an aggregate of 22,696,912 shares of the Company's Common Stock at an exercise price of $51.50 per share, exercisable during a six month period beginning in MarchNovember 2016, (the "2016 Warrants"), and (b) warrants to purchase up to an aggregate of 22,696,912 shares of the Company's Common Stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017 (the "2017 Warrants" and, together with the 2016 Warrants, the "Warrants").
In June 2013, the Company commenced a hedging strategy by entering into a contract with a financial institution pursuant to which it executed a series of issuer capped call transactions ("Capped Calls"). The Capped Calls gave the Company the right to buy shares of its Common Stock subject to the Warrants at specified prices at maturity. This hedge transaction was completed in January 2014 and included the purchase of Capped Calls on a total of 27.2 million shares of the Company's Common Stock for a total premium of $368.7 million.
Subsequently, the Company paid a premium of $100.0 million in January 2015 to increase the cap price on certain of the Capped Calls subject to the 2016 Warrants. The Capped Calls allowed the Company to acquire shares of its Common Stock at strike prices of $51.50 and $52.50 and had expiration dates ranging from February 2016 through October 2017. The Capped Calls permitted net share settlement, which was limited by caps on the market price of the Company's Common Stock. The Company accounted for the Capped Calls as equity contracts, and therefore, the above premium was recorded as a reduction to paid-in capital.
In May 2014, the Company's board of directors authorized a specialshare repurchase program allowing the Company to purchase up to $650 million$1.0 billion of its outstanding shares of Common Stock, subject to market conditions, as an opportunity to further mitigate the potentially dilutive effect of the Warrants and supplemented the Company's previously executed warrants hedging strategy. During
the fiscal year ended September 30, 2014, the Company purchased 3.4 million shares of its Common Stock for a total of $252.0 million under this program, which included $18.0 million of purchases that cash settled in October 2014. During the fiscal year ended September 30, 2015, the Company purchased 4.3 million shares (1.6 million under the Call Options for a total of $151.2 million, as defined below) of its Common Stock for a total of $398.0 million under this program, which excluded $18.0 million of purchases that cash settled in October 2014, to complete its authorization under this program.
In March 2015, the Company further supplemented its hedging strategy by entering into a contract with a financial institution pursuant to which it executed a series of issuer call options ("Call Options"). The Call Options gave the Company the right to buy shares of its Common Stock subject to the Warrants at specified prices between April 2015 and October 2015. In total, the Company purchased Call Options on six million shares of its Common Stock for a total premium of $80.0 million. The Company accounted for the Call Options as equity contracts, and therefore, the above premium was recorded as a reduction to paid-in capital.
In April 2015, the Company's board of directors authorized the second special share repurchase program allowing it to repurchase up to $1.0 billion in shares of its Common Stock, subject to market conditions, to further mitigate the potentially dilutive effect of the Warrants as part of its warrants hedging strategy. During the fiscal year ended September 30, 2015, the Company purchased 10.0 million shares (2.9 million under the Call Options for a total of $276.3 million) of its Common Stock for a total of $1.0 billion to complete its authorization under this program.
In September 2015, the Company's board of directors authorized a new special share repurchase program allowing the Company to repurchase up to $2.4 billion in shares of its Common Stock,common stock, subject to market conditions. During the fiscal year ended September 30, 2015,2017, the Company purchased 1.22.7 million shares of its Common Stockcommon stock for a total of $124.1$211.1 million under this program. During the fiscal year ended September 30, 2016,2018, the Company purchased 26.37.7 million shares of its Common Stockcommon stock for a total of $1,535.1$663.1 million, which included $24.0 million of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, the Company purchased 1.4 million shares of its common stock for a total of $125.8 million, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program.
In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program. Theprogram, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had $740.9$461.1 million of availability remaining under this special share repurchase program as of September 30, 2016. However, this availability will not be utilized subsequent to September 30, 2016 as the earnings per share dilution effect of the Warrants was fully mitigated by the Company concurrent with the August 2016 exercise of the 2017 Warrants (see below).program.
In March 2016, the 2016 Warrants were exercised by WBA for $1,168.9 million in cash. The shares issued for the 2016 Warrants were from the Company's treasury stock on a first-in, first-out basis, and were originally purchased for $866.0 million. The Company recognized a reissuance gain in paid-in capital of $302.9 million.
In August 2016, the Company and WBA amended the 2017 Warrants so that they became exercisable in whole or in part during the six month period beginning in August 2016 at an exercise price of $52.50. In August 2016, the 2017 Warrants were exercised by WBA for $1,191.6 million in cash. The shares issued for the 2017 Warrants were from the Company's treasury stock on a first-in, first-out basis, and were originally purchased for $1,157.5 million. The Company recognized a reissuance gain in paid-in capital of $34.1 million.
The earnings per share dilutive effect of the Warrants was fully mitigated by the Company hedging a portion of its obligation to deliver Common Stock with a financial institution and repurchasing additional shares of its Common Stock under the special share repurchase programs, as described above, for the Company's own account over time.Shares Outstanding
Basic earnings per share is computed on the basis ofby dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of Common Stockcommon stock outstanding during the periods presented. Diluted earnings per share is computed on the basis ofby dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of Common Stockcommon stock outstanding, during the periods presented plus the dilutive effect of stock options restricted stock,and restricted stock units during the unsettled ASR transaction, and the Warrants.periods presented.
The following table illustrates the components of diluted weighted average shares outstanding (in thousands):outstanding: |
| | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Weighted average common shares outstanding - basic | | 210,165 |
| | 217,872 |
| | 218,375 |
|
| Effect of dilutive securities - stock options and restricted stock units | | 1,675 |
| | 2,464 |
| | 3,227 |
|
| Weighted average common shares outstanding - diluted | | 211,840 |
| | 220,336 |
| | 221,602 |
|
|
| | | | | | | | |
| | September 30, |
| | 2016 | | 2015 | | 2014 |
| Weighted average common shares outstanding — basic | 212,206 |
| | 217,786 |
| | 227,367 |
|
| Effect of dilutive securities — stock options, restricted stock, restricted stock units, and the unsettled September 2016 ASR transaction | 3,338 |
| | — |
| | 4,787 |
|
| Dilutive effect of the Warrants | 10,415 |
| | — |
| | 3,251 |
|
| Weighted average common shares outstanding — diluted | 225,959 |
| | 217,786 |
| | 235,405 |
|
The potentially dilutive shares from employee stock options restricted stock,and restricted stock units the unsettled September 2016 ASR transaction, and the Warrants that were antidilutive for the fiscal 2016, 2015,years ended September 30, 2019, 2018, and 20142017 were 3.14.6 million, 18.63.2 million, and 2.04.1 million, respectively.
Note 10.8. Related Party Transactions
As a result of WBA's exercise of the Warrants (see Note 9), itWBA owns more than 10% of the Company's Common Stock,outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes branded and generic pharmaceutical products to WBA and an agreement that provides the Company the ability to access genericsfavorable economic pricing and related pharmaceuticalgeneric products through a global sourcinggeneric purchasing services arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026.
Revenue from the various agreements and arrangements with WBA was $43.4$60.3 billion, $40.5$54.7 billion, and $33.1$45.4 billion in the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, respectively. The Company's receivable from WBA, (afternet of incentives, owed to it) was $4.0$6.1 billion and $3.1$5.6 billion atas of September 30, 20162019 and 2015,2018, respectively.
Note 11.9. Retirement and Other Benefit Plans
The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.
The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, composedcomprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.
Defined Benefit Plans
The Company approved the termination, effective August 1, 2014,69
In December 2015, the Company completed the settlement of plan benefits through the combination of lump-sum distributions to participants and the purchase of a nonparticipating annuity contract, which transferred the remaining obligation from the plan. Plan assets were sufficient to satisfy the obligations of the plan. During the fiscal year ended September 30, 2016, the Company recorded a pension settlement charge of $47.6 million, which primarily consisted of the recognition of unrecognized actuarial losses that were included in Accumulated Other Comprehensive Loss, net of the related deferred tax assets.
In June 2016, the Company transferred the surplus plan assets to its defined contribution 401(k) plan and recorded a charge of $17.1 million to Employee Severance, Litigation and Other in the Company's consolidated statements of operations.
Defined Contribution Plans
The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 25%50% of their regular compensation before taxes. ThePrior to January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. Effective January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary. Effective January 1, 2019, the Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. In connection withBased on the termination ofCompany's performance in fiscal 2019 and 2018, the salaried defined benefit plan, as discussed above, $17.1 million was transferredCompany recognized an expense for a discretionary contribution to the 401(k) plan, and the Company has committed to allocating these funds to participants who were activePlan in the 401(k) plan as of December 31, 2015, based upon their eligible calendar 2016 earnings.fiscal years ended September 30, 2019 and 2018. There were no0 discretionary contributions made forrecognized in the fiscal year ended September 30, 2015. A discretionary contribution was made for the fiscal year ended September 30, 2014.2017. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.
The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including all of the Company's executive officers. ThisPrior to January 1, 2017, the Company contributed an amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeded the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2017, this plan providesprovided eligible participants with an annual amount equal to 4%3% of the participant's base salarytotal cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the Internal Revenue Code.IRC. Effective January 1, 2019, this plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.
Costs of the defined contribution plans charged to expense for the fiscal years ended September 30, 2016, 2015,2019, 2018, and 20142017 were $34.4$51.0 million, $23.5$37.9 million, and $22.5$28.3 million, respectively.
Deferred Compensation Plan
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan, under which 2.96 million shares of Common Stockcommon stock are authorized for issuance, allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee to cash, mutual funds, or stock credits. Stock credits, including dividend equivalents, are equal to the full and fractional number of shares of Common Stockcommon stock that could be purchased with the participant's compensation allocated to stock credits based onupon the average of closing prices of Common Stockcommon stock during each month, plus, at the discretion of the board of directors, up to one-half of a share of Common Stockcommon stock for each full share credited. Stock credit distributions are made in shares of Common Stock. Nocommon stock. NaN shares of Common Stockcommon stock have been issued under the deferred compensation plan through September 30, 2016.2019. The Company's liability relating to its deferred compensation plan as of September 30, 20162019 and 20152018 was $23.6$28.0 million and $18.0$27.5 million, respectively.
Note 12.10. Share-Based Compensation
Stock Options
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of Common Stockcommon stock to employees at a price not less than the fair market value of the Common Stockcommon stock on the date the option is granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years (ten years for all grants issued prior to February 2008).years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of Common Stockcommon stock to non-employee directors at the fair market value of the Common Stockcommon stock on the date of the grant. Non-employee director options vest ratably, in equal amounts, over a three-year service period and expire in ten years. Non-employee director options have not been granted since February 2011.
AtAs of September 30, 2016,2019, employee and non-employee director stock options for an additional 22.612.8 million shares may be granted under the AmerisourceBergen Corporation Omnibus Incentive Plan (the "Plan").
The estimated fair valuesvalue of options granted areis expensed as compensation on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based onupon the historical volatility of the Company's Common Stockcommon stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The Company anticipates that the terms of options
granted in the future will be similar to those granted in the past. The risk-free rates during the terms of such options are based onupon the U.S. Treasury yield curve in effect at the time of grant.
The weighted average fair values of the options granted during the fiscal years ended September 30, 2016, 2015,2019, 2018, and 20142017 were $17.43, $14.91,$18.60, $14.16, and $11.22,$13.57, respectively. The following weighted average assumptions were used to estimate the fair values of options granted:
|
| | | | | |
| | Fiscal Year Ended September 30, |
| | 2019 | | 2018 | | 2017 |
| Risk-free interest rate | 2.91% | | 1.89% | | 1.26% |
| Expected dividend yield | 1.79% | | 1.96% | | 1.80% |
| Volatility of common stock | 27.67% | | 26.54% | | 26.78% |
| Expected life of the options | 3.77 years | | 3.76 years | | 3.74 years |
|
| | | | | |
| | Fiscal Year Ended September 30, |
| | 2016 | | 2015 | | 2014 |
| Risk-free interest rate | 1.40% | | 1.23% | | 0.89% |
| Expected dividend yield | 1.38% | | 1.29% | | 1.37% |
| Volatility of Common Stock | 25.05% | | 23.12% | | 23.91% |
| Expected life of the options | 3.72 years | | 3.73 years | | 3.69 years |
Changes to the above valuation assumptions could have a significant impact on share-based compensation expense. During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the Company recordedrecognized stock option expense of $33.1$21.0 million, $30.2$22.6 million, and $21.5$28.6 million, respectively.
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 20162019 is presented below:
|
| | | | | | | | | | | |
| (in thousands, except exercise price and contractual term) | | Options | | Weighted Average Exercise Price | | Weighted Average Remaining Contractual Term | | Aggregate Intrinsic Value |
| Outstanding as of September 30, 2018 | | 8,421 |
| | $77 | | 4 years | | $ | 142,557 |
|
| Granted | | 1,137 |
| | $90 | | | | |
|
| Exercised | | (1,531 | ) | | $50 | | | | |
|
| Forfeited | | (213 | ) | | $84 | | | | |
|
| Expired | | (155 | ) | | $97 | | | | |
| Outstanding as of September 30, 2019 | | 7,659 |
| | $83 | | 4 years | | $ | 35,319 |
|
| Exercisable as of September 30, 2019 | | 4,395 |
| | $83 | | 3 years | | $ | 25,049 |
|
| Expected to vest after September 30, 2019 | | 3,162 |
| | $83 | | 5 years | | $ | 10,010 |
|
|
| | | | | | | | | | |
| | Options (000s) | | Weighted Average Exercise Price | | Weighted Average Remaining Contractual Term | | Aggregate Intrinsic Value (000s) |
| Outstanding at September 30, 2015 | 11,887 |
| | $53 | | 4 years | | |
|
| Granted | 1,892 |
| | $98 | | | | |
|
| Exercised | (2,189 | ) | | $35 | | | | |
|
| Forfeited | (586 | ) | | $77 | | | | |
|
| Outstanding at September 30, 2016 | 11,004 |
| | $63 | | 4 years | | $ | 247,586 |
|
| Exercisable at September 30, 2016 | 5,943 |
| | $47 | | 3 years | | $ | 207,593 |
|
| Expected to vest after September 30, 2016 | 4,896 |
| | $82 | | 5 years | | $ | 39,641 |
|
The intrinsic value of stock option exercises during the fiscal 2016, 2015,years ended September 30, 2019, 2018, and 20142017 was $120.9$51.2 million, $240.2$116.7 million, and $132.4$116.6 million, respectively.
A summary of the status of the Company's nonvested options as of September 30, 20162019 and changes during the fiscal year ended September 30, 20162019 is presented below:
|
| | | | | |
| (in thousands, except grant date fair value) | | Options | | Weighted Average Grant Date Fair Value |
| Nonvested as of September 30, 2018 | | 3,860 |
| | $15 |
| Granted | | 1,137 |
| | $19 |
| Vested | | (1,519 | ) | | $15 |
| Forfeited | | (213 | ) | | $16 |
| Nonvested as of September 30, 2019 | | 3,265 |
| | $16 |
|
| | | | |
| | Options (000s) | | Weighted Average Grant Date Fair Value |
| Nonvested at September 30, 2015 | 6,385 |
| | $11 |
| Granted | 1,892 |
| | $17 |
| Vested | (2,630 | ) | | $9 |
| Forfeited | (586 | ) | | $13 |
| Nonvested at September 30, 2016 | 5,061 |
| | $14 |
During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the total fair values of options vested were $24.4$22.7 million, $20.7$25.8 million, and $19.1$25.2 million, respectively. Expected future compensation expense relating to the 5.13.3 million nonvested options outstanding as of September 30, 20162019 is $35.3$21.6 million, which will be recognized over a weighted average period of 2.0 years.
Restricted Stock and
Restricted Stock Units
Restricted sharesstock units vest in full after three years. The estimated fair value of restricted sharesstock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the grant date market price of the Company's Common Stock.common stock. The estimated fair value of restricted sharesstock units is expensed on a straight-line basis over the requisite service period.period, net of estimated forfeitures. During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the Company recordedrecognized restricted stock unit expense of $19.5$29.2 million, $20.1$26.8 million, and $14.7$25.1 million, respectively.
A summary of the status of the Company's nonvested restricted sharesstock units as of September 30, 20162019 and changes during the fiscal year ended September 30, 20162019 are presented below:
|
| | | | | |
| (in thousands, except grant date fair value) | | Restricted Stock Units | | Weighted Average Grant Date Fair Value |
| Nonvested as of September 30, 2018 | | 1,023 |
| | $80 |
| Granted | | 442 |
| | $89 |
| Vested | | (152 | ) | | $95 |
| Forfeited | | (91 | ) | | $81 |
| Nonvested as of September 30, 2019 | | 1,222 |
| | $81 |
|
| | | | |
| | Restricted Shares (000s) | | Weighted Average Grant Date Fair Value |
| Nonvested at September 30, 2015 | 868 |
| | $63 |
| Granted | 220 |
| | $96 |
| Vested | (406 | ) | | $44 |
| Forfeited | (74 | ) | | $79 |
| Nonvested at September 30, 2016 | 608 |
| | $85 |
During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the total fair values of restricted sharesstock units vested were $17.8$14.5 million, $10.9$15.8 million, and $10.5$13.8 million, respectively. Expected future compensation expense relating to the 0.61.2 million
restricted sharesstock units outstanding as of September 30, 20162019 is $16.0$30.1 million, which will be recognized over a weighted average period of 1.2 years.
Performance Stock Units
Performance stock units are granted to certain executive employees under the Plan whichand represent Common Stockcommon stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based onupon achievement of specific performance goals. Based onupon the extent to which the targets are achieved, vested shares for awards granted prior to fiscal 2018 may range from 0 percent0% to 150 percent150% of the target award amount. For awards granted beginning in fiscal 2018, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's Common Stock, and the compensationcommon stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the Company recognized $12.3performance stock expense of $8.5 million, $10.6$12.8 million, and $6.8$8.4 million, of compensation expense, respectively, related to these performance stock units.respectively.
A summary of the status of the Company's nonvested performance stock units as of September 30, 20162019 and changes during the fiscal year ended September 30, 20162019 is presented below (based onupon target award amounts).
|
| | | | | |
| (in thousands, except grant date fair value) | | Performance Stock Units | | Weighted Average Grant Date Fair Value |
| Nonvested as of September 30, 2018 | | 244 |
| | $77 |
| Granted | | 147 |
| | $90 |
| Vested | | (105 | ) | | $76 |
| Forfeited | | (3 | ) | | $90 |
| Nonvested as of September 30, 2019 | | 283 |
| | $84 |
|
| | | | |
| | Performance Stock Units (000s) | | Weighted Average Grant Date Fair Value |
| Nonvested at September 30, 2015 | 180 |
| | $78 |
| Granted | 90 |
| | $98 |
| Vested | (94 | ) | | $68 |
| Forfeited | (12 | ) | | $94 |
| Nonvested at September 30, 2016 | 164 |
| | $93 |
Shares that vested over the three-year performance period ended September 30, 20162019 were distributed to employees in November 2016.
Employee Stock Purchase Plan
The AmerisourceBergen Corporation Employee Stock Purchase Plan provides for an aggregate of 4,000,000 shares of Common Stock that may be sold to eligible employees (generally defined as employees with at least 30 days of service with the Company). The participants may elect to have the Company withhold up to 25% of base salary to purchase shares of the Company's Common Stock at a price equal to 95% of the fair market value of the stock on the last business day of each six month purchase period. Each participant is limited to $25,000 of purchases during each calendar year. During the fiscal years ended September 30, 2016, 2015, and 2014, the Company acquired 71,016 shares, 53,434 shares, and 68,700 shares, respectively, from the open market for issuance to participants in this plan. As of September 30, 2016, the Company has withheld $1.8 million from eligible employees for the purchase of additional shares of Common Stock.2019.
Note 13. Leases and Other11. Lease Commitments
The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses. TotalDuring the fiscal years ended September 30, 2019, 2018, and 2017, the Company recorded rental expense was $88.8of $108.9 million, $114.9 million, and $80.7 million, respectively, in fiscal 2016, $78.6 millionDistribution, Selling, and Administrative in fiscal 2015, and $75.2 million in fiscal 2014.the Consolidated Statements of Operations.
AtAs of September 30, 2016,2019, future minimum rental payments under noncancelable operating leases and financing obligations were as follows (in thousands):follows:
|
| | | | | | | | | | | | |
| Payments Due by Fiscal Year (in thousands) | | Operating Leases | | Financing Obligations 1 | | Total |
| 2020 | | $ | 94,958 |
| | $ | 22,468 |
| | $ | 117,426 |
|
| 2021 | | 84,002 |
| | 29,790 |
| | 113,792 |
|
| 2022 | | 72,224 |
| | 36,914 |
| | 109,138 |
|
| 2023 | | 63,507 |
| | 35,950 |
| | 99,457 |
|
| 2024 | | 56,377 |
| | 35,276 |
| | 91,653 |
|
| Thereafter | | 177,267 |
| | 270,410 |
| | 447,677 |
|
| Total minimum lease payments | | $ | 548,335 |
| | $ | 430,808 |
| | $ | 979,143 |
|
| | | | | | | |
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation. |
|
| | | | | | | | | | | |
| Fiscal Year | Operating Leases | | Financing Obligations 1 | | Total |
| 2017 | $ | 63,072 |
| | $ | 23,062 |
| | $ | 86,134 |
|
| 2018 | 56,747 |
| | 25,074 |
| | 81,821 |
|
| 2019 | 46,809 |
| | 22,376 |
| | 69,185 |
|
| 2020 | 39,445 |
| | 20,727 |
| | 60,172 |
|
| 2021 | 31,622 |
| | 17,895 |
| | 49,517 |
|
| Thereafter | 77,916 |
| | 72,008 |
| | 149,924 |
|
| Total minimum lease payments | $ | 315,611 |
| | $ | 181,142 |
| | $ | 496,753 |
|
| | | | | | |
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future noncash termination of the financing obligation.
|
The Company outsources to IBM Global Services a significant portion of its corporate and ABDC information technology activities. The remaining commitment under the Company's arrangement, as amended in February 2016, which expires in January 2021, is approximately $112.8 million as of September 30, 2016, of which $45.1 million represents the Company's commitment in fiscal 2017.
Note 14.12. Employee Severance, Litigation, and Other
The following table illustrates the charges incurred by the Company relating to employee severance, litigation,Employee Severance, Litigation, and otherOther for the threeperiods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Employee severance | | $ | 34,147 |
| | $ | 36,694 |
| | $ | 7,767 |
|
| Litigation and opioid-related costs | | 185,145 |
| | 61,527 |
| | 917,573 |
|
| Acquisition-related deal and integration costs | | 43,184 |
| | 33,912 |
| | 16,990 |
|
| Business transformation efforts | | 55,437 |
| | 32,963 |
| | 3,700 |
|
| Other restructuring initiatives | | 12,561 |
| | 18,424 |
| | 13,297 |
|
| Total employee severance, litigation, and other | | $ | 330,474 |
| | $ | 183,520 |
| | $ | 959,327 |
|
Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2018 included costs primarily related to position eliminations resulting from the Company's business transformation efforts and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2017 included costs primarily related to position eliminations as the Company began to reorganize to further align the organization to its customers' needs.
Litigation and opioid-related costs in the fiscal year ended September 30, 2019 consisted of $116.7 million of legal settlements and accruals and $68.5 million of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related costs in the fiscal year ended September 30, 2018 primarily related to opioid lawsuits, investigations, and related initiatives. Litigation and opioid-related costs in the fiscal year ended September 30, 2017 primarily related to litigation settlements and accruals.
Acquisition-related deal and integration costs in the fiscal year ended September 30, 2019 are primarily related to the integration of H.D. Smith. Integration costs primarily include costs to transition servicing legacy H.D. Smith customers to existing company distribution facilities and operating systems. Acquisition-related deal and integration costs in the fiscal year ended September 30, 2018 were primarily related to the acquisition of H.D. Smith.
Business transformation efforts in the fiscal years ended September 30, 2016 (in thousands):
|
| | | | | | | | | | | |
| | 2016 | | 2015 | | 2014 |
| Employee severance and other costs | $ | 53,519 |
| | $ | 5,336 |
| | $ | 1,913 |
|
| Deal-related transaction costs | 19,243 |
| | 32,558 |
| | 6,279 |
|
| Transfer of surplus assets from a settled salaried defined benefit pension plan to a defined contribution 401(k) plan | 17,149 |
| | — |
| | — |
|
| Customer contract dispute settlements | 13,000 |
| | — |
| | — |
|
| Total employee severance, litigation, and other | $ | 102,911 |
| | $ | 37,894 |
| | $ | 8,192 |
|
During fiscal 2014,2019 and 2018 were primarily related to costs associated with reorganizing the Company incurred $6.3 millionto further align the organization to its customers' needs. The majority of deal-related transactionthese costs and $1.9 million of employee severance and other costs. During fiscal 2015, the Company incurred $32.6 million of deal-related transaction costs (primarilywere related to professional fees in connection with the MWI acquisition) and $5.3 million of employee severance and other costs. During fiscal 2016, the Company incurred $53.5 million of employee severance and other costs, $19.2 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from a settled salaried defined benefit pension plan to the Company's defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items). During fiscal 2016, the Company reorganized certain of its business units and corporate functions to improve operating efficiency, and as a result, numerous positions were eliminated.services provided by third-party consultants.
Employees receive their severance benefits over a period of time, generally not in excess of 12 months, or in the form of a lump-sum payment.
Note 15.13. Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, and government investigations, stockholder demands, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties
may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.
For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.
With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.
Government EnforcementOpioid Lawsuits and RelatedInvestigations
A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiaries AmerisourceBergen Drug Corporation ("ABDC") and H.D. Smith, which was acquired in January 2018), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications. Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. The lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. An initial group of cases was consolidated for Multidistrict Litigation Matters("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "Court") in December 2017. Additional cases have been, and will likely continue to be, transferred to the MDL. Further, in June 2018, the Court granted a motion permitting the United States, through the DOJ, to participate in settlement discussions and as a friend of the Court by providing information to facilitate non-monetary remedies.
In April 2018, the Court issued an order creating a litigation track, which includes dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. On December 31, 2018, the Court issued an order selecting two additional cases for a second bellwether discovery and trial track. The timing of discovery, motion practice, and trials for the second set of bellwether cases has not yet been determined.
On October 21, 2019, the Company announced an agreement in principle with two Ohio counties, Cuyahoga and Summit, to settle all claims brought by the two counties against the Company in the first track of the MDL. All claims against the Company were dismissed with prejudice pursuant to the settlement. As a result, the Company recorded a charge of $66.7 million in the fourth quarter of the fiscal year ended September 30, 2019 within Employee Severance, Litigation and Other in its Statement of Operations and in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet.
The Court has continued to oversee court-ordered settlement discussions with attorneys for the plaintiffs and certain states that it instituted at the beginning of the MDL proceedings. On October 21, 2019, the Attorneys General for North Carolina, Pennsylvania, Tennessee, and Texas announced certain proposed settlement terms intended to provide a potential framework for a global resolution of the MDL and other related state court litigation, including cases currently filed and that could be filed. The attorneys general's announcement outlined that the largest U.S. pharmaceutical distributors would be expected to pay an aggregate amount of up to $18.0 billion over 18 years, of which the Company's portion would be 31%, in addition to the development and participation in a program for free or rebated distribution of opioid-abuse medications for a period of 10 years and the implementation of industry-wide changes to be specified to controlled substance anti-diversion programs. The Company is currently engaged in discussions that include the four attorneys general and other parties with the objective of reaching potential terms for a global resolution. The Company is also engaged in related discussions with plaintiffs' lawyers representing local governments and other parties with the same goal of reaching a global resolution with all parties. If agreed, the potential terms for a global resolution would then need to be presented to numerous other states and local governments, and a significant number of such jurisdictions would need to accept the proposed terms in order to achieve an agreement in principle that would provide the finality that the Company requires from a global resolution. Given the large number of parties involved, in government investigationsthe complexity and litigation arising fromdifficulty of the marketing, promotion, saleunderlying issues, and dispensingthe resulting uncertainty of pharmaceutical productsachieving a potential global resolution, the Company continues to litigate and
prepare for trial in the United States. Somecases pending in the MDL as well as in state courts where lawsuits have been filed, and intends to continue to vigorously defend itself in all such cases. A liability associated with a global resolution has not been recognized as of these investigations originate through what are known as qui tam complaintsSeptember 30, 2019, since the Company is unable to predict the outcome of settlement discussions with the states and local governments that will need to participate and, therefore, a global resolution cannot be considered probable. Furthermore, significant uncertainty remains with regard to whether such matters will proceed to trial, and, given the inherent uncertainty related to such litigation, the Company is not in a position to assess the likely outcome, and therefore unable to estimate the range of possible loss.
In June 2019, attorneys for some of the federal False Claims Act.plaintiffs filed a motion proposing a procedure to certify a nationwide "negotiation class" of cities and counties for the purpose of negotiating and settling with defendants engaged in the nationwide manufacturing, sale, or distribution of opioids. The qui tam provisionsattorneys subsequently withdrew the motion and refiled an amended motion on July 9, 2019. The Court granted the motion on September 11, 2019 and certain defendants, including ABDC, are appealing.
On November 6, 2019, a New York state court entered an order accelerating the trial date for cases brought by Nassau and Suffolk Counties and the New York Attorney General against a variety of defendants, including the Company. Pursuant to that order, the trial, which is not part of the federal civil False Claims ActMDL, was scheduled to begin on January 20, 2020, however during a subsequent meeting on November 13, 2019, the court amended the trial date to begin in March 2020.
Aside from those parties that have already filed suit, other entities, including additional attorneys general���s offices, counties, and various state and local civil False Claims Acts permit a private person, known as a "relator" or whistleblower,cities in multiple states, have indicated their intent to file civil actions under these statutes on behalf of the federal, state and local governments. Qui tam complaints are initially filed by the relator under seal (or on a confidential basis) and the filing of the complaint imposes obligations on government authorities to investigate the allegationssue. The Company is vigorously defending itself in the complaintpending lawsuits and intends to determine whethervigorously defend itself against any threatened lawsuits. The Company is not in a position to assess the likely outcome or notits exposure, if any, with respect to intervene in the action. Qui tam complaints remain sealed until the court in which the case was filed orders otherwise.these matters.
Under the federal False Claims Act, the government (or relators who pursue the claims without the participation of the government in the case) may seek to recover up to three times the amount of damages in addition to a civil penalty for each allegedly false claim submitted to the government for payment. Generally speaking, these cases take several years for the investigation to be completed and, ultimately, to be resolved (either through litigation or settlement) after the complaint is unsealed. In addition, some states have pursued investigations under state false claims statutes or consumer protection laws, either in conjunction with a government investigation or separately. There is often collateral litigation that arises from public disclosures of government investigations, including the filing of class action lawsuits by third party payors or by shareholders alleging violations of the securities laws.
The federal Food, Drug and Cosmetic Act (“FDCA”) contains provisions relating to the sale and distribution of pharmaceutical products that are alleged to be adulterated or misbranded. The FDCA includes strict-liability criminal offenses that can be pursued by the government for violations of the FDCA and which can result in the imposition of substantial fines and penalties against corporations and individuals.
The Company has learned that there are filings in one or more federal district courts, including a qui tam complaint filed by one of its former employees, that are under sealalso received subpoenas, civil investigative demands, and may involve allegations against the Company (and/or subsidiaries or businesses of the Company, including its group purchasing organization for oncologists and its oncology distribution business) relating to its distribution of certain pharmaceutical products to providers.
Subpoenas and Ongoing Investigations
From time to time, the Company receives subpoenas orother requests for information, from various government agencies relating torequesting the Company's business or to the business of a customer, supplier or other industry participant. The Company generally responds to such subpoenas and requests in a cooperative manner. These responses often require time and effort and can result in considerable costs being incurred by the Company. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to substantial settlements.
Since fiscal 2012, the Company and AmerisourceBergen Specialty Group ("ABSG") have been responding to subpoenas from the United States Attorney's Office for the Eastern District of New York ("USAO-EDNY") requesting production of documents and information relating to ABSG's oncologyregarding the distribution center and former pharmacyof prescription opioid pain medications from government agencies in Dothan, Alabama (including the practices and procedures of the former pharmacy's pre-filled syringe program), its group purchasing organization for oncologists, and intercompany transfers ofother jurisdictions, including certain oncology products, which the Company believes could be related in whole or in part to one or more of the qui tam actions that remain under seal. The Company has produced documents and has engaged in ongoing dialogue with the USAO-EDNY. The USAO-EDNY has expressed an intention to pursue potential civil and criminal charges based upon
the FDCA and the False Claims Act.states. The Company is engaged in discussions with USAO-EDNY to attempt to reach a negotiated settlement. No conclusion can be drawn at this time as to any likely outcome in this matter.representatives from these government agencies regarding the requests and has been producing responsive documents.
In fiscal 2012,Since July 2017, the Company's subsidiary, AmerisourceBergen Drug Corporation ("ABDC"), received a subpoena from the United States Attorney's Office in New Jersey (the "USAO-NJ") in connection with a grand jury proceeding requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific, and industrial purposes. ABDC also received a subpoena from the Drug Enforcement Administration ("DEA") in connection with the matter. Since fiscal 2012, ABDCCompany has received and responded to a number of subpoenas from bothseveral U.S. Attorney's Offices. Those subpoenas request the USAO-NJ and DEA requesting grand jury testimony and additional information relatedproduction of a broad range of documents pertaining to electronically stored information, documents concerning specific customers' purchasesABDC's distribution of controlled substances and DEA audits. The Company continues to engage in dialogue with the USAO-NJ.
Since fiscal 2013, the Company or ABDC has received subpoenas from the United States Attorney's Office in the District of Kansas and the United States Attorney's Office in the Northern District of Ohio in connection with grand jury proceedings requesting documents concerning ABDC's program for controlling and monitoring diversion of controlled substances into channels other than for legitimate medical, scientific and industrial purposes. As in the New Jersey matter described above, in addition to requesting information on ABDC's diversion control program generally, the subpoenas have also requested documents concerning specific customers' purchases of controlled substances.programs. The Company has responded to the subpoenas and requests for information.
Since fiscal 2016, the Company’s subsidiary U.S. Bioservices has received requests for information from the United States Attorney’s Office for the Southern District of New York (“USAO-SDNY”) relating to its dispensing of one product and its relationship with the manufacturer of the product. The Company isbeen engaged in discussions with the USAO-SDNY.
The Company cannot predictvarious U.S. Attorney’s Offices, including the outcomeHealth Care and Government Fraud Unit of these ongoing investigations, or the impact onCriminal Division of the Company as a resultU.S. Attorney's Office for the District of these matters, which may include settlementsNew Jersey, and has been producing documents in significant amounts that are not currently estimable, limitations onresponse to the Company's conduct, the imposition of corporate integrity obligations and/or other civil and criminal penalties.
State Proceedings
subpoenas.
In June 2012, the Attorney General of the State of West Virginia ("West Virginia"Virginia AG") filed complaints, which have beenwere amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia isAG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of $16.0 million and express denial of the allegations in the complaints and any wrongdoing. During the fiscal year ended September 30, 2017, the Company recognized the $16.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations. The Company paid the $16.0 million settlement in fiscal 2017.
Government Enforcement and Related Litigation Matters
Various government agencies, including the FDA, the Consumer Protection Branch of the Civil Division of the DOJ, and state boards of pharmacy, regulate the compounding of pharmaceutical products. The Company’s subsidiary, PharMEDium, operates Section 503B outsourcing facilities that must comply with current Good Manufacturing Practice ("cGMP") requirements and are inspected by the FDA periodically to determine compliance. The FDA and the DOJ have broad enforcement powers, including the authority to enjoin PharMEDium's Section 503B outsourcing facilities from distributing pharmaceutical products.
On May 17, 2019, PharMEDium reached an agreement on the terms of the Consent Decree with the FDA and the DOJ that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are
acceptable. The Company has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
Additionally, state boards of pharmacy may revoke, limit, or deny approval of licenses required under state law to compound or distribute pharmaceutical products. As a result of reciprocal state actions initiated due to the FDA’s inspectional observations, PharMEDium has suspended shipping of its compounded sterile preparations into several states, either voluntarily, by consent or pursuant to orders of state licensing authorities.
Subpoenas and Ongoing Investigations
From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.
In January 2017, the Company's subsidiary U.S. Bioservices Corporation ("U.S. Bio") received a subpoena for information from the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY") relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. The Company engaged in discussions with the USAO-EDNY and produced documents in response to the subpoena. In April 6, 2015, ABDC2019, the government informed the Company that it had filed a motionnotice with the U.S. District Court for the Eastern District of New York that it was declining to dismiss,intervene in a filed qui tam action related to its investigation. The case was unsealed in April 2019 and counsel for the relator has stated that they intend to file an amended complaint under seal, which was subsequently denied on September 8, 2015. On October 23, 2015, ABDC, together with all other defendants, filed a writ of prohibitionthey intend to submit to the Supreme CourtUSAO-EDNY for further consideration.
The Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") had previously responded to subpoenas from the USAO-EDNY requesting production of Appealsdocuments and information relating to the pre-filled syringe program of West Virginia. On October 30, 2015, ABDC filed an answer to West Virginia's second amended complaint. The writABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of prohibition filed on October 23, 2015 was denied on January 5, 2016. Trial is currently scheduled for January 2017. ABDC anticipates undertaking efforts to try to resolve this matter prior to trial; however, ABDC cannot predict the outcome of this matter.
Other Litigation
certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014.
On September 10, 2014, PharMerica Corp., Pharmacy Corporation27, 2017, pursuant to the terms of Americaa plea agreement, ABSG entered a guilty plea to a one-count strict-liability misdemeanor violation of the Federal Food, Drug, and Chem Rx Pharmacy Services, LLC (collectively, “PMC”), customersCosmetic Act in the United States District Court of ABDC until March 3, 2015, filedthe Eastern District of New York. Under the terms of the agreement, which were approved by the Court, ABSG paid a Complaint in Jefferson Circuit Court in Louisville, Kentucky against ABDC. The original Complaint alleged that ABDC failed to pay in excesstotal criminal fine and forfeiture of $8$260.0 million in rebates pursuantfiscal 2017. The guilty plea resolves the federal criminal investigation related to the failure of Medical Initiatives, Inc. to duly register with the FDA. The Company also entered into a prime vendorCompliance Agreement with the United States Department of Justice for a period of three years. During the fiscal year ended September 30, 2017, the Company recognized the $260.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
The USAO-EDNY also pursued alleged civil claims under the False Claims Act. ABSG reached an agreement between PMC and ABDC underin principle with the USAO-EDNY during the fiscal quarter ended December 31, 2017, which ABDC distributed pharmaceuticals and other products to PMC. PMC subsequently amended its Complaint three times. PMC’s current complaint alleges unpaid-rebatethe Company expected would resolve the alleged civil claims in excess of $33 million and additional breaches and damages for unspecified amounts, which amounts may exceed $100 million.
ABDC answered alltheir entirety. In the fourth quarter of the complaints, denied PMC’s allegations,fiscal year ended September 30, 2018, the Company reached final terms of the settlement agreement with the USAO-EDNY, resolved potential administrative action by the Office of Inspector General of the U.S. Department of Health and filed counterclaims alleging,Human Services by entering into a Corporate Integrity Agreement, and obtained dismissal
with prejudice of the potential civil claims. The Corporate Integrity Agreement has a five-year term, which commenced on September 28, 2018, and requires, among other things, that PMC failedthe maintenance of a compliance program, an independent review organization and a financial recoupment program. Pursuant to pay nearly $50 million in invoices from ABDC. On April 1, 2016, the Jefferson Circuit Court granted ABDC’s motion for partial summary judgmentterms of the settlement agreement with the USAO-EDNY, ABSG made a payment on one counterclaim and entered judgmentSeptember 28, 2018 to resolve the civil litigation without making any admission of liability in the amount of $48.6$625.0 million, against PMC. No trial date is setplus interest from December 1, 2017. As a result of the agreement in principle, the Company had previously accrued a reserve in the amount of $625.0 million in the fiscal year ended September 30, 2017. The reserve was recognized in Employee Severance, Litigation, and Other on the Company's Statement of Operations.
The Company’s subsidiary U.S. Bio settled claims with the U.S. Attorney’s Office for the remaining claims.Southern District of New York ("USAO-SDNY") and with various states arising from the previously disclosed matter involving the dispensing of one product and U.S. Bio’s relationship with the manufacturer of that product. In accordance with the settlement agreements, the United States’ complaint against U.S. Bio was dismissed and the participating states agreed not to bring, and to dismiss with prejudice, any state law claims that they had the authority to bring against U.S. Bio. The Company expectspaid the partiesUnited States $10.7 million in fiscal 2017 and paid the participating states $2.8 million in fiscal 2018. During the year ended September 30, 2017, the Company recognized the $13.4 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
Other Contingencies
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and requires manufacturers, distributors, and importers licensed in NYS to conclude discoveryratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In the fourth quarter of the fiscal year ended September 30, 2018, the Company accrued $22.0 million as an estimate of its liability under the OSA for opioids distributed from January 1, 2017 through September 30, 2018 and recognized this reserve in early 2017. TheCost of Goods Sold on its Consolidated Statement of Operations and in Accrued Expenses and Other on its Consolidated Balance Sheet as of September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, the Company reversed the $22.0 million accrual in the fiscal quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, the Company does not believe a loss contingency is not in a position to assess the likely outcome or its exposure, if any, with respect to this matter.probable.
Note 16.14. Litigation Settlements
Antitrust Settlements
Numerous class action lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these class actions,lawsuits, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the class actionslawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2016, 2015,2019, 2018, and 2014,2017, the Company recognized gains of $133.8$145.9 million, $65.5$35.9 million, and $24.4$1.4 million, respectively, relating to the above-mentioned class actionthese lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's consolidated statementsConsolidated Statements of operations.Operations.
Note 17.15. Business Segment Information
The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and Other. The Pharmaceutical Distribution reportable segment consists of the ABDC and ABSG operating segments. Other consists of the AmerisourceBergen Consulting Services ("ABCS"), World Courier Group, Inc. ("World Courier"), and MWI operating segments.
The Company has aggregated theother operating segments of ABDC and ABSG into one reportable segment, the Pharmaceutical Distribution segment. The results of operations of the ABCS, World Courier, and MWI operating segmentsthat are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation.
Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The Company's ability to aggregate ABDCoperating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and ABSG into one reportable segment was based on the following:
the objective and basic principles of ASC 280;
the aggregation criteria as noted in ASC 280; and
the fact that ABDC and ABSG have similar economic characteristics.World Courier.
The chief operating decision maker ("CODM") forof the Company is the Chairman, President and& Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the ABDC and ABSGCompany's operating segments. ABDC and ABSG each has an executive who functions as an operating segment manager whose role includes reporting directly to the Chairman, President, and Chief Executive Officer of the Company on their respective operating segment's business activities, financial results, and operating plans.
The businesses of the Pharmaceutical Distribution operating segments are similar in that they service both healthcare providers and pharmaceutical manufacturers in the pharmaceutical supply channel. The distribution of pharmaceutical drugs has historically represented more than 95% of the Company's revenues. ABDC and ABSG each operate in a high volume and low margin environment and, as a result, their economic characteristics are similar. Each operatingServices reportable segment warehouses and distributes products in a similar manner. Additionally, each operating segment is subject, in whole or in part, to the same extensive regulatory environment under which the pharmaceutical distribution industry operates.
ABDC distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced CSPs,compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.
ABSG, throughThrough a number of operating businesses, the Pharmaceutical Distribution Services
reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSGthe Pharmaceutical Distribution Services reportable segment provides third party logistics,data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
The Company's use of the terms "specialty" and "specialty pharmaceutical products" refers to drugs used to treat complex diseases, such as cancer, diabetes, and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. The Company believes the terms "specialty"
and "specialty pharmaceutical products" are used consistently by industry participants and its competitors. However, the Company cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as the Company does.
Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG's distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC's distribution centers results in revenue reported under ABDC. Essentially, all of ABSG's sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.
As noted above, Other consists of the ABCS, World Courier, and MWI operating segments. ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers.support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.
The following tables illustrateillustrates reportable and operating segment revenue information for the periods indicated (in thousands):indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Pharmaceutical Distribution Services | | $ | 172,813,537 |
| | $ | 161,699,343 |
| | $ | 147,453,495 |
|
| Other: | | | | | | |
| MWI Animal Health | | 3,975,232 |
| | 3,789,759 |
| | 3,636,305 |
|
| Global Commercialization Services | | 2,893,109 |
| | 2,542,971 |
| | 2,111,558 |
|
| Total Other | | 6,868,341 |
| | 6,332,730 |
| | 5,747,863 |
|
| Intersegment eliminations | | (92,757 | ) | | (92,438 | ) | | (57,532 | ) |
| Revenue | | $ | 179,589,121 |
| | $ | 167,939,635 |
| | $ | 153,143,826 |
|
|
| | | | | | | | | | | | |
| | | Revenue |
| Fiscal year ended September 30, | | 2016 | | 2015 | | 2014 |
| Pharmaceutical Distribution | | $ | 140,731,224 |
| | $ | 131,480,550 |
| | $ | 117,383,967 |
|
| Other | | 6,386,917 |
| | 4,772,178 |
| | 2,449,149 |
|
| Intersegment eliminations | | (268,455 | ) | | (290,925 | ) | | (263,989 | ) |
| Revenue | | $ | 146,849,686 |
| | $ | 135,961,803 |
| | $ | 119,569,127 |
|
Intersegment eliminations primarily represent the elimination of certain ABCSPharmaceutical Distribution Services reportable segment sales to MWI.
The following illustrates reportable segment operating income information for the Pharmaceutical Distribution reportable segment.periods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Pharmaceutical Distribution Services | | $ | 1,671,251 |
| | $ | 1,626,748 |
| | $ | 1,643,629 |
|
| Other | | 380,660 |
| | 355,091 |
| | 373,797 |
|
| Intersegment eliminations | | (659 | ) | | (609 | ) | | (556 | ) |
| Total segment operating income | | $ | 2,051,252 |
| | $ | 1,981,230 |
| | $ | 2,016,870 |
|
|
| | | | | | | | | | | | |
| | | Segment Operating Income |
| Fiscal year ended September 30, | | 2016 | | 2015 | | 2014 |
| | | | | (As Revised) | | (As Revised) |
| Pharmaceutical Distribution | | $ | 1,688,055 |
| | $ | 1,649,741 |
| | $ | 1,409,199 |
|
| Other | | 342,416 |
| | 254,506 |
| | 150,617 |
|
| Intersegment eliminations | | (103 | ) | | — |
| | — |
|
| Total segment operating income | | $ | 2,030,368 |
| | $ | 1,904,247 |
| | $ | 1,559,816 |
|
The following table reconciles total segment operating income to income from continuing operations before income taxes (in thousands):for the periods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Total segment operating income | | $ | 2,051,252 |
| | $ | 1,981,230 |
| | $ | 2,016,870 |
|
| Gain from antitrust litigation settlements | | 145,872 |
| | 35,938 |
| | 1,395 |
|
| LIFO credit (expense) | | 22,544 |
| | (67,324 | ) | | 157,782 |
|
| PharMEDium remediation costs | | (69,423 | ) | | (66,204 | ) | | — |
|
| New York State Opioid Stewardship Act | | 22,000 |
| | (22,000 | ) | | — |
|
| Acquisition-related intangibles amortization | | (159,848 | ) | | (174,751 | ) | | (156,378 | ) |
| Employee severance, litigation, and other | | (330,474 | ) | | (183,520 | ) | | (959,327 | ) |
| Goodwill impairment | | — |
| | (59,684 | ) | | — |
|
| Impairment of long-lived assets | | (570,000 | ) | | — |
| | — |
|
| Operating income | | 1,111,923 |
| | 1,443,685 |
| | 1,060,342 |
|
| Other (income) loss | | (12,952 | ) | | 25,469 |
| | (2,730 | ) |
| Interest expense, net | | 157,769 |
| | 174,699 |
| | 145,185 |
|
| Loss on consolidation of equity investments | | — |
| | 42,328 |
| | — |
|
| Loss on early retirement of debt | | — |
| | 23,766 |
| | — |
|
| Income before income taxes | | $ | 967,106 |
| | $ | 1,177,423 |
| | $ | 917,887 |
|
|
| | | | | | | | | | | | |
| | | Income From Continuing Operations Before Income Taxes |
| Fiscal year ended September 30, | | 2016 | | 2015 | | 2014 |
| | | | | (As Revised) | | (As Revised) |
| Total segment operating income | | $ | 2,030,368 |
| | $ | 1,904,247 |
| | $ | 1,559,816 |
|
| Gain from antitrust litigation settlements | | 133,758 |
| | 65,493 |
| | 24,436 |
|
| LIFO expense | | (200,230 | ) | | (542,807 | ) | | (348,063 | ) |
| Acquisition-related intangibles amortization | | (147,262 | ) | | (54,095 | ) | | (23,167 | ) |
| Warrants expense | | (140,342 | ) | | (912,724 | ) | | (422,739 | ) |
| Employee severance, litigation, and other | | (102,911 | ) | | (37,894 | ) | | (8,192 | ) |
| Pension settlement | | (47,607 | ) | | — |
| | — |
|
| Operating income | | 1,525,774 |
| | 422,220 |
| | 782,091 |
|
| Other (income) loss | | (5,048 | ) | | 13,598 |
| | (4,360 | ) |
| Impairment charge on equity investment | | — |
| | 30,622 |
| | — |
|
| Interest expense, net | | 139,912 |
| | 109,036 |
| | 83,634 |
|
| Loss on early retirement of debt | | — |
| | — |
| | 32,954 |
|
| Income from continuing operations before income taxes | | $ | 1,390,910 |
| | $ | 268,964 |
| | $ | 669,863 |
|
Segment operating income is evaluated by the CODM of the Company beforeand excludes gain from antitrust litigation settlements; LIFO expense;credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; Warrants expense; employee severance, litigation, and other; pension settlement; other (income) loss;goodwill impairment; and impairment charge on equity investment; interest expense, net; and loss on early retirement of debt.long-lived assets. Segment measures were adjusted in fiscal 2019 to exclude impairment of long-lived assets as the CODM excludes these costs in the measurement of segment performance. All corporate office expenses are allocated to eachthe operating segment.segment level.
The Company incurred remediation costs in connection with the suspended production activities at PharMEDium (see Notes 1 and 13). These remediation costs are primarily classified in Cost of Goods sold in the Consolidated Statements of Operations. Future remediation costs will also include costs related to remediation activities responsive to FDA inspectional observations generally applicable to all of PharMEDium’s 503B outsourcing facilities, including product stability studies.
The Company recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2019.
The Company recorded a $30.0 million impairment of a non-customer note receivable related to a start-up venture in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2018.
The following illustrates total assets by reportable segment for the periods indicated:
|
| | | | | | | | | | | | |
| | | September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Pharmaceutical Distribution Services | | $ | 33,160,529 |
| | $ | 31,892,621 |
| | $ | 29,691,127 |
|
| Other | | 6,011,451 |
| | 5,777,217 |
| | 5,625,343 |
|
| Total assets | | $ | 39,171,980 |
| | $ | 37,669,838 |
| | $ | 35,316,470 |
|
|
| | | | | | | | |
| | | Assets |
| At September 30, | | 2016 | | 2015 |
| | | | | (As Revised) |
| Pharmaceutical Distribution | | $ | 28,233,214 |
| | $ | 22,696,383 |
|
| Other | | 5,422,986 |
| | 5,266,599 |
|
| Total assets | | $ | 33,656,200 |
| | $ | 27,962,982 |
|
The CODM does not review assets by operating segment for purposesthe purpose of assessing performance or allocating resources.
|
| | | | | | | | | | | | |
| | | Depreciation & Amortization |
| Fiscal year ended September 30, | | 2016 | | 2015 | | 2014 |
| | | | | (As Revised) | | (As Revised) |
| Pharmaceutical Distribution | | $ | 173,293 |
| | $ | 155,553 |
| | $ | 135,173 |
|
| Other | | 44,180 |
| | 38,987 |
| | 30,340 |
|
| Acquisition-related intangibles amortization | | 147,262 |
| | 54,095 |
| | 23,167 |
|
| Total depreciation and amortization | | $ | 364,735 |
| | $ | 248,635 |
| | $ | 188,680 |
|
The following illustrates depreciation and amortization by reportable segment for the periods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Pharmaceutical Distribution Services | | $ | 232,735 |
| | $ | 225,608 |
| | $ | 188,065 |
|
| Other | | 69,824 |
| | 64,768 |
| | 53,160 |
|
| Acquisition-related intangibles amortization | | 159,848 |
| | 174,751 |
| | 156,378 |
|
| Total depreciation and amortization | | $ | 462,407 |
| | $ | 465,127 |
| | $ | 397,603 |
|
Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense.expense, net.
The following illustrates capital expenditures by reportable segment for the periods indicated:
|
| | | | | | | | | | | | |
| | | Fiscal Year Ended September 30, |
| (in thousands) | | 2019 | | 2018 | | 2017 |
| Pharmaceutical Distribution Services | | $ | 210,161 |
| | $ | 190,191 |
| | $ | 339,478 |
|
| Other | | 100,061 |
| | 146,220 |
| | 126,919 |
|
| Total capital expenditures | | $ | 310,222 |
| | $ | 336,411 |
| | $ | 466,397 |
|
|
| | | | | | | | | | | | |
| | | Capital Expenditures |
| Fiscal year ended September 30, | | 2016 | | 2015 | | 2014 |
| Pharmaceutical Distribution | | $ | 359,356 |
| | $ | 179,870 |
| | $ | 222,985 |
|
| Other | | 105,260 |
| | 51,715 |
| | 41,472 |
|
| Total capital expenditures | | $ | 464,616 |
| | $ | 231,585 |
| | $ | 264,457 |
|
Note 18.16. Fair Value of Financial Instruments
The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable atas of September 30, 20162019 and 20152018 approximate fair value based upon the relatively short-term nature of these financial instruments. Within cashCash and cash equivalents,Cash Equivalents, the Company had $650.0$1,552.0 million and $1,050.0 million of investments in money market accounts as of September 30, 2016. The Company had no investments in money market accounts as of September 30, 2015.2019 and 2018. The fair value of the money market accounts was determined based onupon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
The Company had $39.1 million of investment securities available-for-sale, $13.0 million of which were within cash and cash equivalents, at September 30, 2016. The amortized cost of the investments was $39.1 million at September 30, 2016. The Company had $213.1 million of investment securities available-for-sale, $126.9 million of which were within cash and cash equivalents, at September 30, 2015. The amortized cost of the investments was $213.1 million at September 30, 2015. The fair value of the investments was based on inputs other than quoted prices, otherwise known as Level 2 inputs. The investments consist of fixed-income securities with maturities ranging from October 2016 to July 2017.
The recorded amount of long-term debt (see Note 8)6) and the corresponding fair value as of September 30, 20162019 were $3,594.3$4,033.9 million and $3,750.9$4,158.4 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 20152018 were $3,493.0$4,158.5 million and $3,515.1$4,000.1 million, respectively. The fair value of long-term debt was determined based onupon inputs other than quoted market prices, otherwise known as Level 2 inputs.
Note 19.17. Quarterly Financial Information (Unaudited)
| | | | | Fiscal Year Ended September 30, 2016 | | Fiscal Year Ended September 30, 2019 |
| (in thousands, except per share amounts) | | First Quarter | | Second Quarter | | Third Quarter | | Fourth Quarter | | Fiscal Year | | First Quarter | | Second Quarter | | Third Quarter | | Fourth Quarter | | Fiscal Year |
| | | (As Revised) | | (As Revised) | | (As Revised) | | | | | |
| Revenue | | $ | 36,709,046 |
| | $ | 35,698,357 |
| | $ | 36,881,680 |
| | $ | 37,560,603 |
| | $ | 146,849,686 |
| | $ | 45,392,452 |
| | $ | 43,319,602 |
| | $ | 45,239,265 |
| | $ | 45,637,802 |
| | $ | 179,589,121 |
|
| Gross profit (a) | | $ | 964,877 |
| | $ | 1,075,331 |
| | $ | 1,107,863 |
| | $ | 1,124,535 |
| | $ | 4,272,606 |
| | $ | 1,297,580 |
| | $ | 1,424,756 |
| | $ | 1,231,239 |
| | $ | 1,184,737 |
| | $ | 5,138,312 |
|
| Distribution, selling, and administrative expenses; depreciation; and amortization | | 608,039 |
| | 612,302 |
| | 610,706 |
| | 624,925 |
| | 2,455,972 |
| | 779,085 |
| | 751,802 |
| | 764,539 |
| | 830,489 |
| | 3,125,915 |
|
| Warrants expense (income) | | 467,375 |
| | (503,946 | ) | | (83,704 | ) | | 260,617 |
| | 140,342 |
| |
| Employee severance, litigation, and other and pension settlement | | 67,599 |
| | 16,493 |
| | 52,234 |
| | 14,192 |
| | 150,518 |
| |
| Operating (loss) income | | $ | (178,136 | ) | | $ | 950,482 |
| | $ | 528,627 |
| | $ | 224,801 |
| | $ | 1,525,774 |
| |
| Net income | | $ | 329,639 |
| | $ | 603,450 |
| | $ | 349,155 |
| | $ | 145,685 |
| | $ | 1,427,929 |
| |
| Employee severance, litigation, and other | | | 40,672 |
| | 55,389 |
| | 60,006 |
| | 174,407 |
| | 330,474 |
|
| Impairment of long-lived assets | | | — |
| | 570,000 |
| | — |
| | — |
| | 570,000 |
|
| Operating income | | | $ | 477,823 |
| | $ | 47,565 |
| | $ | 406,694 |
| | $ | 179,841 |
| | $ | 1,111,923 |
|
| Net income (b) | | | $ | 391,753 |
| | $ | 28,073 |
| | $ | 302,002 |
| | $ | 132,307 |
| | $ | 854,135 |
|
| Net income attributable to AmerisourceBergen Corporation (b) | | | $ | 393,652 |
| | $ | 27,135 |
| | $ | 301,959 |
| | $ | 132,619 |
| | $ | 855,365 |
|
| Earnings per share operations: | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|
| Basic | | $ | 1.60 |
| | $ | 2.90 |
| | $ | 1.62 |
| | $ | 0.66 |
| | $ | 6.73 |
| | $ | 1.86 |
| | $ | 0.13 |
| | $ | 1.44 |
| | $ | 0.64 |
| | $ | 4.07 |
|
| Diluted | | $ | 1.45 |
| | $ | 2.68 |
| | $ | 1.55 |
| | $ | 0.64 |
| | $ | 6.32 |
| | $ | 1.84 |
| | $ | 0.13 |
| | $ | 1.43 |
| | $ | 0.63 |
| | $ | 4.04 |
|
| |
| (a) | The first, second, third, and thirdfourth quarters of the fiscal 2016year ended September 30, 2019 include gains of $12.8 million and $121.0 million, respectively, from antitrust litigation settlements.settlements of $87.3 million, $52.0 million, $3.5 million, and $3.1 million, respectively. The first, second, and third quartersquarter of the fiscal 2016year ended September 30, 2019 include LIFO chargescredits of $101.6$3.0 million, $92.4$66.8 million, and $80.4$9.9 million, respectively. The fourth quarter of the fiscal 2016year ended September 30, 2019 includes LIFO expense of $57.2 million. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of $17.9 million, $12.3 million, $11.7 million, and $6.7 million, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a LIFO credit$22.0 million reversal of $74.1 million.a previous estimate of our liability under the New York State Opioid Stewardship Act. |
| |
| (b) | The Company revised its previously reported quarterly financial informationfirst quarter of the fiscal year ended September 30, 2019 includes a $37.0 million income tax benefit adjustment to correct its accounting for certain leases (see Note 2).the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of $13.7 million. |
| | | | | Fiscal Year Ended September 30, 2015 | | Fiscal Year Ended September 30, 2018 |
| (in thousands, except per share amounts) | | First Quarter | | Second Quarter | | Third Quarter | | Fourth Quarter | | Fiscal Year | | First Quarter | | Second Quarter | | Third Quarter | | Fourth Quarter | | Fiscal Year |
| | | (As Revised) | | (As Revised) | | (As Revised) | | (As Revised) | | (As Revised) | |
| Revenue | | $ | 33,588,602 |
| | $ | 32,669,267 |
| | $ | 34,233,556 |
| | $ | 35,470,378 |
| | $ | 135,961,803 |
| | $ | 40,466,332 |
| | $ | 41,033,858 |
| | $ | 43,142,309 |
| | $ | 43,297,136 |
| | $ | 167,939,635 |
|
| Gross profit (a) | | $ | 752,299 |
| | $ | 911,976 |
| | $ | 891,464 |
| | $ | 973,574 |
| | $ | 3,529,313 |
| | $ | 1,112,652 |
| | $ | 1,255,683 |
| | $ | 1,211,341 |
| | $ | 1,032,641 |
| | $ | 4,612,317 |
|
| Distribution, selling, and administrative expenses; depreciation; and amortization | | 464,761 |
| | 497,461 |
| | 569,563 |
| | 624,690 |
| | 2,156,475 |
| | 663,658 |
| | 736,814 |
| | 746,593 |
| | 778,363 |
| | 2,925,428 |
|
| Warrants expense (income) | | 371,405 |
| | 752,706 |
| | (14,900 | ) | | (196,487 | ) | | 912,724 |
| |
| Employee severance, litigation, and other | | 3,503 |
| | 24,871 |
| | 2,625 |
| | 6,895 |
| | 37,894 |
| | 30,021 |
| | 37,449 |
| | 75,553 |
| | 40,497 |
| | 183,520 |
|
| Operating (loss) income | | $ | (87,370 | ) | | $ | (363,062 | ) | | $ | 334,176 |
| | $ | 538,476 |
| | $ | 422,220 |
| |
| Net (loss) income | | $ | (200,542 | ) | | $ | (514,105 | ) | | $ | 213,362 |
| | $ | 363,120 |
| | $ | (138,165 | ) | |
| Goodwill impairment | | | — |
| | — |
| | — |
| | 59,684 |
| | 59,684 |
|
| Operating income | | | $ | 418,973 |
| | $ | 481,420 |
| | $ | 389,195 |
| | $ | 154,097 |
| | $ | 1,443,685 |
|
| Net income (b) | | | $ | 861,853 |
| | $ | 282,160 |
| | $ | 277,875 |
| | $ | 194,004 |
| | $ | 1,615,892 |
|
| Net income attributable to AmerisourceBergen Corporation (b) | | | $ | 861,853 |
| | $ | 287,455 |
| | $ | 275,809 |
| | $ | 233,288 |
| | $ | 1,658,405 |
|
| Earnings per share operations: | | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
|
| Basic | | $ | (0.91 | ) | | $ | (2.33 | ) | | $ | 0.97 |
| | $ | 1.71 |
| | $ | (0.63 | ) | | $ | 3.95 |
| | $ | 1.31 |
| | $ | 1.26 |
| | $ | 1.08 |
| | $ | 7.61 |
|
| Diluted | | $ | (0.91 | ) | | $ | (2.33 | ) | | $ | 0.89 |
| | $ | 1.56 |
| | $ | (0.63 | ) | | $ | 3.90 |
| | $ | 1.29 |
| | $ | 1.25 |
| | $ | 1.07 |
| | $ | 7.53 |
|
| |
| (a) | The second third, and fourththird quarters of the fiscal 2015year ended September 30, 2018 include gains of $21.5 million, $43.6 million, and $0.4 million, respectively, from antitrust litigation settlements.settlements of $0.3 million and $35.6 million, respectively. The first,third quarter of the fiscal year ended September 30, 2018 includes a LIFO credit of $16.1 million. The fourth quarter of the fiscal year ended September 30, 2018 includes LIFO expense of $83.5 million. The second, third, and fourth quarters of the fiscal 2015year ended September 30, 2018 include LIFO chargesPharMEDium remediation costs of $144.0$22.5 million, $151.1 million, $158.7$12.0 million, and $88.9$26.6 million, respectively. The fourth quarter of the fiscal year ended September 30, 2018 includes a $22.0 million estimate of our liability under the New York State Opioid Stewardship Act. |
| |
| (b) | The Company revised its previously reported quarterly financial information to correct its accounting for certain leases (see Note 2).first quarter of the fiscal year ended September 30, 2018 includes a loss on early retirement of debt of $23.8 million. The second quarter of the fiscal year ended September 30, 2018 includes a $42.3 million loss on consolidation of equity investments and a $30.0 million impairment of a non-customer note receivable. The first and fourth quarters of the fiscal year ended September 30, 2018 included discrete income tax benefits recognized in connection with the 2017 Tax Act of $587.6 million and $25.0 million, respectively. |
Note 20. Subsequent Events
Dividend Increase
In November 2016, the Company's board of directors increased the quarterly dividend paid on Common Stock by 7% and declared a regular quarterly cash dividend of $0.365 payable on December 5, 2016 to shareholders of record on November 21, 2016.
Share Repurchase Program
In November 2016, the Company's board of directors authorized a new share repurchase program allowing the Company to repurchase up to $1.0 billion in shares of its Common Stock, subject to market conditions.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company's reports submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
The Company's Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company's management, have evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company's disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There were no changes during the fiscal quarter ended September 30, 20162019 in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, those controls.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The management of AmerisourceBergen Corporation ("AmerisourceBergen" or the "Company") is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that:
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
AmerisourceBergen's management assessed the effectiveness of AmerisourceBergen's internal control over financial reporting as of September 30, 2015.2019. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on management's assessment and those criteria, management has concluded that AmerisourceBergen's internal control over financial reporting was effective as of September 30, 2016.
During the first quarter of fiscal 2016, the Company acquired PharMEDium Healthcare Holdings, Inc. ("PharMEDium"). As permitted by related SEC staff interpretive guidance for newly acquired businesses, the Company excluded PharMEDium from management's assessment of the effectiveness of the Company's internal control over financial reporting as of September 30, 2016. In the aggregate, PharMEDium represented 8% of the total assets and less than 1% of total revenue of the Company as of and for the fiscal year ended September 30, 2016.2019.
AmerisourceBergen's independent registered public accounting firm, Ernst & Young LLP, has issued an attestation report on the effectiveness of AmerisourceBergen's internal control over financial reporting. This report is set forth below.
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ON INTERNAL
CONTROL OVER FINANCIAL REPORTING
TheTo the Stockholders and the Board of Directors and Stockholders of AmerisourceBergen Corporation
Opinion on Internal Control over Financial Reporting
We have audited AmerisourceBergen Corporation and subsidiaries’subsidiaries' internal control over financial reporting of as of September 30, 2016,2019, based on criteria established in Internal Control — IntegratedControl-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AmerisourceBergen Corporation and subsidiaries’subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of September 30, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of the Company and our report dated November 19, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the company’sCompany’s internal control over financial reporting based on our audit.
We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’scompany's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’scompany's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
As indicated in the accompanying Management’s Report on Internal Control Over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of PharMEDium Healthcare Holdings, Inc., which is included in the 2016 consolidated financial statements of AmerisourceBergen Corporation and subsidiaries and constituted 8% of total assets as of September 30, 2016 and less than 1% of revenues and net income, respectively for the year then ended. Our audit of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries also did not include an evaluation of the internal control over financial reporting of PharMEDium Healthcare Holdings, Inc.
In our opinion, AmerisourceBergen Corporation and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of September 30, 2016, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of AmerisourceBergen Corporation and subsidiaries as of September 30, 2016 and 2015, and the related consolidated statements of operations, comprehensive income, changes in stockholders’ equity, and cash flows for each of the three years in the period ended September 30, 2016 of AmerisourceBergen Corporation and subsidiaries and our report dated November 22, 2016 expressed an unqualified opinion thereon.
Philadelphia, Pennsylvania
November 22, 201619, 2019
ITEM 9B. OTHER INFORMATION
None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information appearing in our Notice of Annual Meeting of Stockholders and Proxy Statement for the 20172020 Annual Meeting of stockholdersStockholders (the "2017"2020 Proxy Statement"), including information appearing under "Election of Directors,"Proxy Statement Highlights - Director Nominees and Board Summary," "Codes of Ethics,"Corporate Governance and Related Matters," "Audit Committee Matters," and "Section 16 (a) Beneficial Reporting Compliance,"Delinquent Section 16(a) Reports," is incorporated herein by reference. We will file the 20172020 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.
Information with respect to Executive Officers of the Company appears in Part I of this report.
We adopted a Code of Ethics for Designated Senior Officers that applies to our Chief Executive Officer, Chief Financial Officer, and Corporate Controller. A copy of this Code of Ethics is filed as an exhibit to this report and is posted on our Internet website, which is www.amerisourcebergen.cominvestor.amerisourcebergen.com. Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.
ITEM 11. EXECUTIVE COMPENSATION
Information contained in the 20172020 Proxy Statement, including information appearing under "Additional Information about the Directors, the Board"Corporate Governance and the Board Committees," "Compensation Committee Matters,"Related Matters" and "Executive Compensation"Compensation and Related Matters" in the 20172020 Proxy Statement, is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information contained in the 20172020 Proxy Statement, including information appearing under "Beneficial Ownership of Common Stock" and "Equity Compensation Plan Information" in the 20172020 Proxy Statement, is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information contained in the 20172020 Proxy Statement, including information appearing under "Additional Information about the Directors, the Board,"Corporate Governance and the Board Committees," "Corporate Governance," "Employment Agreements"Related Matters" and "Certain"Related Person Transactions" in the 20172020 Proxy Statement, is incorporated herein by reference.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information contained in the 20172020 Proxy Statement, including information appearing under "Audit Committee Matters" in the 20172020 Proxy Statement, is incorporated herein by reference.
PART IV
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) (1) and (2) List of Financial Statements and Schedules.
Financial Statements: The following consolidated financial statements are submitted in response to Item 15(a)(1):
|
| |
| | Page |
| |
| |
| |
| |
| |
| |
| |
| |
Financial Statement Schedule: The following financial statement schedule is submitted in response to Item 15(a)(2): | |
| |
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.
(a) (3) List of Exhibits.*
|
| |
Exhibit Number | Description |
2.13.1 | Agreement and Plan of Merger, dated as of October 5, 2015, by and among PharMEDium Healthcare Holdings, Inc., the Registrant, Paris Acquisition Corp. and Clayton, Dubilier & Rice LLC (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed on October 7, 2015).
|
3.1 | Amended and Restated Certificate of Incorporation of the Registrant, dated as of March 4, 2010, as amended by the Certificate of Amendment dated as of February 17, 2011, and the Certificate of Amendment dated as of March 6, 2014 and the Certificate of Amendment dated as of March 2, 2017 (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2014)2017). |
| 3.2 | |
| 4.1 | |
| 4.2 | First Supplemental Indenture, dated as of November 19, 2009, between the Registrant and U.S. Bank National Association, as trustee, related to the Registrant's 4.875% Senior Notes due 2019 (incorporated by reference to Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on November 23, 2009). |
4.3 | Form of 4.875% Senior Notes due 2019 (incorporated by reference to Exhibit A to First Supplemental Indenture, dated as of November 19, 2009, between the Registrant and U.S. Bank National Association, as trustee, related to the Registrant's 4.875% Senior Notes due 2019, which is filed as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed on November 23, 2009). |
4.4 | |
4.54.3 | |
4.64.4 | Third Supplemental Indenture, dated as of May 22, 2014, between the Registrant and U.S. Bank National Association, as trustee, related to Registrant's 1.150% Senior Notes due 2017 (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on May 22, 2014). |
4.7 | Form of 1.150% Senior Notes due 2017 (incorporated by reference to Exhibit A to Third Supplemental Indenture, dated as of May 22, 2014, between the Registrant and U.S. Bank National Association, as trustee, related to Registrant's 1.150% Senior Notes due 2017, which is filed as Exhibit 4.1 to the Registrant's Current Report on 8-K filed on May 22, 2014). |
4.8 | |
4.94.5 | |
4.104.6 | |
4.114.7 | |
4.124.8 | |
4.134.9 | |
|
| 4.10 | |
| 4.11 | Number A to Seventh Supplemental Indenture, dated as of December 4, 2017 between the Registrant and U.S. Bank National Association, as trustee, related to the Registrant's 3.450% Senior Notes due 2027, which is filed as Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on December 5, 2017).
|
| 4.12 | |
| 4.13 | |
| 4.14 | |
| 10.1 | |
|
| |
Exhibit Number | Description |
| 10.2 | |
| ‡10.3 | AmeriSource Master Pension Plan (incorporated by reference to Exhibit 10.9 to Registration Statement on Form S-1 of AmeriSource Health Corporation, Registration No. 33-27835, filed March 29, 1989). |
‡10.4 | AmerisourceBergen Drug Corporation Supplemental Retirement Plan, as amended and restated as of November 24, 2008 (incorporated by reference to Exhibit 10.2 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2008). |
‡10.5 | |
‡10.610.4 | AmerisourceBergen Corporation 2001 Restricted Stock Plan, as amended and restated as of November 12, 2008 (incorporated by reference to Exhibit 10.18 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2008). |
‡10.7 | |
‡10.810.5 | |
‡10.910.6 | |
‡10.1010.7 | Form of Restricted Stock Award Agreement to Employee under the |
‡10.11 | Form of Restricted Stock Unit Award Agreement to Employee under the AmerisourceBergen Corporation Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2013). |
‡10.12 | Form of Performance-Based Restricted Stock Unit Award Agreement to Employee under the AmerisourceBergen Corporation Equity Incentive Plan (incorporated by reference to Exhibit 10.13 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2013). |
‡10.13 | AmerisourceBergen Corporation 2011Amended and Restated Employee Stock Purchase Plan, as amended and restated on May 14, 2015March 2, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2015)March 31, 2018). |
‡10.1410.8 | |
‡10.1510.9 | |
‡10.1610.10 | |
‡10.1710.11 | Form of Restricted Stock Award Agreement to Non-Employee Director under the AmerisourceBergen Corporation Omnibus Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on March 10, 2014). |
‡10.18 | |
‡10.1910.12 | |
|
| |
Exhibit
Number
| Description |
‡10.2010.13 | |
‡10.2110.14 | |
‡10.2210.15 | Amended and Restated Employment |
‡10.2310.16 | Letter |
‡10.2410.17 | Employment |
‡10.2510.18 | Second Amendment and Restatement of Employment Agreement, dated as of November 11, 2010, between the Registrant and Steven H. Collis |
‡10.26 | Stock Option Award to Steven H. Collis, dated as of August 7, 2013 (incorporated by reference to Exhibit 10.1 to Registrant's Current Report on Form 8-K filed on August 9, 2013). |
‡10.27 | Restricted Stock Award to Steven H. Collis, dated as of August 7, 2013 (incorporated by reference to Exhibit 10.2 to Registrant's Current Report on Form 8-K filed on August 9, 2013). |
‡10.28 | Employment Agreement, dated as of June 4, 2012, between the Registrant and Dale B. Danilewitz (incorporated by reference to Exhibit 10.29 to Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2015). |
‡10.29 | Employment Agreement, dated as of April 8, 2010, between the Registrant and James D. Frary (incorporated by reference to Exhibit 10.21 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2011). |
‡10.30 | Employment Agreement, dated as of May 20, 2016, between the Registrant and Kathy H. Gaddes (incorporated by reference to Exhibit 10.310.10 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016)December 31, 2018).
|
‡10.3110.19 | |
| ‡10.20 | |
| ‡10.21 | |
|
| |
Exhibit Number | Description |
| ‡10.22 | |
‡10.32 | Employment Agreement, dated as of November 26, 2010, between the Registrant and Peyton R. Howell (incorporated by reference to Exhibit 10.20 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2011). |
‡10.33 | Employment Agreement, dated July 15, 2015, between the Registrant and Robert P. Mauch (incorporated by reference to Exhibit 10.34 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2015). |
‡10.34 | Employment Agreement, dated as of May 20, 2016, between the Registrant and Sun Park (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016).
|
10.3510.23 | |
10.3610.24 | |
10.3710.25 | |
10.3810.26 | |
|
| |
Exhibit
Number
| Description |
10.3910.27 | Omnibus Amendment, dated November 4, 2015 to (i) the Amended and Restated Receivables Purchase Agreement, dated as of April 29, 2010, as amended, among AmeriSource Receivables Financial Corporation, as Seller, AmerisourceBergen Drug Corporation, as Servicer, the Purchaser Agents and Purchasers party thereto and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as Administrator and (ii) the Receivables Sale Agreement, dated as of July 10, 2003, as amended, among AmeriSource Receivables Financial Corporation as Buyer, and AmerisourceBergen Drug Corporation, as originator (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 4, 2015).
|
10.4010.28 |
|
10.4110.29 | Amended and Restated Receivables Purchase Agreement, dated as of April 29, 2010, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the various purchaser groups party thereto, and Bank of America, National Association, as administrator (incorporated by reference to Exhibit 99.1 to the Registrant's Current Report on Form 8-K filed on May 5, 2010). |
10.4210.30 | First Amendment to Amended and Restated Receivables Purchase Agreement, dated as of April 28, 2011, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, and Bank of America, National Association, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on May 4, 2011). |
10.4310.31 | Second Amendment to Amended and Restated Receivables Purchase Agreement, dated as of October 28, 2011, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, servicer, the purchaser agents and purchasers party thereto, and Bank of America, National Association, as administrator (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on October 28, 2011). |
10.4410.32 | Third Amendment to Amended and Restated Receivables Purchase Agreement, dated as of November 16, 2012, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, and Bank of America, National Association, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on November 21, 2012). |
10.4510.33 | Fourth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of January 16, 2013, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, and the Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on form 8-K filed on January 17, 2013). |
10.4610.34 | Fifth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of June 28, 2013, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, and the Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on July 3, 2013). |
10.4710.35 | Sixth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of October 7, 2013, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, Market Street Funding LLC, as assignor, PNC Bank, National Association, as assignee, and the Bank of Tokyo-Mitsubishi UFJ, LTD., New York Branch, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on October 10, 2013). |
|
10.48 | |
Exhibit Number | Description |
| 10.36 | Seventh Amendment to Amended and Restated Receivables Purchase Agreement, dated as of July 17, 2014, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto and the Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as Administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on July 22, 2014). |
10.4910.37 | Eighth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of December 5, 2014, by and among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the purchaser agents and purchasers party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on December 8, 2014). |
10.5010.38 | Tenth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of June 21, 2016, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto,Working Capital Management Co., LP, as assignor, Advantage Asset Securitization Corp., Mizuho Bank, Ltd., as assignee, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 23, 2016).
|
|
| 10.39 | Eleventh Amendment to Amended and Restated Receivables Purchase Agreement, dated as of November 18, 2016, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed on November 22, 2016). |
Exhibit
Number
10.40 | DescriptionTwelfth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of December 18, 2017, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrator (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2017). |
10.5110.41 | Thirteenth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of October 31, 2018, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd. (f/k/a The Bank of Tokyo-Mitsubishi UFJ, Ltd.), as administrator (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed on November 6, 2018). |
| 10.42 | Fourteenth Amendment to Amended and Restated Receivables Purchase Agreement, dated as of September 18, 2019, among AmeriSource Receivables Financial Corporation, as seller, AmerisourceBergen Drug Corporation, as servicer, the Purchaser Agents and Purchasers party thereto, and MUFG Bank, Ltd., as administrator (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed on September 23, 2019). |
| 10.43 | |
10.5210.44 | |
10.5310.45 | |
| 10.46 | |
| 10.47 | Eighth Amendment and Restatement Agreement, dated as of November 13, 2015,September 18, 2019, among the Registrant,AmerisourceBergen Corporation, the borrowing subsidiaries party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.210.1 to the Registrant’s Current Report on Form 8-K filed on November 13, 2015)September 23, 2019).
|
10.5410.48 | Amendment No. 1 to Fifth Amendment and Restated Credit Agreement, dated as of April 1, 2016, among the Registrant, the borrowing subsidiaries party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 99.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016).
|
10.55 | Revolving Credit Note, dated as of March 8, 2013, between the Registrant and Citizens Bank of Pennsylvania (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2013). |
10.5610.49 | |
|
10.57 | |
Exhibit Number | Description |
| 10.50 | Term Loan Credit Agreement, dated as of February 9, 2015,October 31, 2018, among the Registrant,AmerisourceBergen Corporation, the lenders party thereto and Wells Fargo Bank, of America, N.A., as administrative agentAdministrative Agent (incorporated by reference to Exhibit 10.110.2 to the Registrant's Current Report on Form 8-K filed on February 9, 2015)November 6, 2018). |
10.5810.51 | First Amendment No. 1 to the Term Loan Credit Agreement, dated as of November 25, 2015,September 18, 2019, among the Registrant,AmerisourceBergen Corporation, the lenders party thereto and Wells Fargo Bank, of America, N.A.,National Association, as Administrative Agent (incorporated by reference to Exhibit 10.110.2 to the Registrant’s Current Report on Form 8-K filed on December 2, 2015).
|
10.59 | Amendment No. 2 to Term Loan Credit Agreement, dated as of April 1, 2016, among the Registrant, the lenders party thereto and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 99.3 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016).
|
10.60 | Term Loan Credit Agreement, dated as of November 13, 2015, among the Registrant, the lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on November 13, 2015).
|
10.61 | Amendment No. 1 to Term Loan Credit Agreement, dated as of April 1, 2016, among the Registrant, the lenders party thereto and JPMorgan Chase Bank, N.A., as Administrative Agent (incorporated by reference to Exhibit 99.2 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016).
|
12 | Computation of Ratio of Earnings to Fixed Charges. |
14 | AmerisourceBergen Corporation Code of Ethics for Designated Senior Officers (incorporated by reference to Exhibit 14 to the Registrant's Annual Report on Form 10-K for the fiscal year ended September 30, 2003)23, 2019). |
| 21 | |
| 23 | |
| 31.1 | |
| 31.2 | |
| 32 | |
| 101 | Financial statements from the Annual Report on Form 10-K of AmerisourceBergen Corporation for the fiscal year ended September 30, 2016,2019, formatted in Inline Extensible Business Reporting Language (XBRL)(iXBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders' Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). |
| |
| * | Copies of the exhibits will be furnished to any security holder of the Registrant upon payment of the reasonable cost of reproduction. |
| |
| ‡ | Each marked exhibit is a management contract or a compensatory plan, contract or arrangement in which a director or executive officer of the Registrant participates or has participated. |
ITEM 16. FORM 10-K SUMMARY
Not applicable.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| | | | |
| | | AMERISOURCEBERGEN CORPORATION |
Date: November 22, 201619, 2019 | | By: | | /s/ STEVEN H. COLLIS Steven H. Collis Chairman, President and Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below as of November 22, 201619, 2019 by the following persons on behalf of the Registrant and in the capacities indicated.
|
| | |
| Signature | | Title |
| | | |
/s/ STEVEN H. COLLIS___________________________ Steven H. Collis | | Chairman, President and Chief Executive Officer (Principal Executive Officer) |
| | | |
/s/ TIM G. GUTTMAN____________________________JAMES F. CLEARY____________________________ Tim G. GuttmanJames F. Cleary
| | Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
| | | |
/s/ LAZARUS KRIKORIAN________________________ Lazarus Krikorian | | Senior Vice President and Corporate ControllerChief Accounting Officer (Principal Accounting Officer) |
| | | |
/s/ ORNELLA BARRA_________________________________________________________________________ Ornella Barra | | Director |
| | |
/s/ DOUGLAS R. CONANT________________________
Douglas R. Conant
| | Director |
| | | |
/s/ D. MARK DURCAN____________________________ D. Mark Durcan | | Director |
| | | |
/s/ RICHARD W. GOCHNAUER____________________ Richard W. Gochnauer | | Director |
| | | |
/s/ LON R. GREENBERG__________________________ Lon R. Greenberg | | Director |
|
| | |
| Signature | | Title |
| | | |
/s/ JANE E. HENNEY, M.D.________________________ Jane E. Henney, M.D. | | Lead Independent Director |
| | | |
/s/ KATHLEEN W. HYLE__________________________ Kathleen W. Hyle | | Director |
| | | |
/s/ MICHAEL J. LONG____________________________ Michael J. Long | | Director |
| | | |
/s/ HENRY W. MCGEE____________________________ Henry W. McGee | | Director |
AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
| | | (In thousands) | | Balance at Beginning of Period | | Charged to Costs and Expenses (1) | | Deductions- Describe (2) | | Balance at End of Period (3) | | Balance at Beginning of Period | | Charged to Costs and Expenses (1) | | Deductions- Describe (2) | | Balance at End of Period (3) |
| Year Ended September 30, 2016 | | |
| | |
| | |
| | |
| |
| Year Ended September 30, 2019 | | | |
| | |
| | |
| | |
|
| Allowances for returns and doubtful accounts | | $ | 923,755 |
| | $ | 2,882,914 |
| | $ | (2,880,635 | ) | | $ | 926,034 |
| | $ | 1,049,901 |
| | $ | 3,720,642 |
| | $ | (3,546,656 | ) | | $ | 1,223,887 |
|
| | | | | | | | | | | | | | | | | |
| Year Ended September 30, 2015 | | |
| | |
| | |
| | |
| |
| Year Ended September 30, 2018 | | | |
| | |
| | |
| | |
|
| Allowances for returns and doubtful accounts | | $ | 1,022,052 |
| | $ | 2,721,263 |
| | $ | (2,819,560 | ) | | $ | 923,755 |
| | $ | 1,068,251 |
| | $ | 3,397,562 |
| | $ | (3,415,912 | ) | | $ | 1,049,901 |
|
| | | | | | | | | | | | | | | | | |
| Year Ended September 30, 2014 | | |
| | |
| | |
| | |
| |
| Year Ended September 30, 2017 | | | |
| | |
| | |
| | |
|
| Allowances for returns and doubtful accounts | | $ | 358,161 |
| | $ | 3,643,663 |
| | $ | (2,979,772 | ) | | $ | 1,022,052 |
| | $ | 926,034 |
| | $ | 3,157,960 |
| | $ | (3,015,743 | ) | | $ | 1,068,251 |
|
| |
| (1) | Represents the provision for returns and doubtful accounts. |
| |
| (2) | Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries and reductions to the returns allowance.recoveries. |
| |
| (3) | Includes an allowance for doubtful accounts for long-term accounts receivable within Other Assets on the consolidated balance sheetsConsolidated Balance Sheets of $20,689$981 thousand, $23,991and $23,668,$13,568 thousand and $17,890 thousand as of September 30, 2016, 20152019, 2018, and 2014,2017, respectively. |
